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The importance of interactions between the host and gut microbiota in the 
pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly 
apparent. Probiotics offer a potential new therapy for the treatment of IBS, 
but current results with these products are conflicting, largely as a result of 
poorly designed trials and non-standardisation of outcome measures.   
Aims 
The objective of this study was to assess the efficacy and safety of a liquid, 
multi-strain probiotic in the treatment of IBS. 
Methods 
A single-centre, randomised, double-blind, placebo-controlled trial of adult 
patients with symptomatic IBS. Patients received 12 weeks of treatment with 
the probiotic or placebo (1ml/kg/day). The primary efficacy measure was a 
change in the IBS symptom severity score (IBS-SSS) from baseline to week 








A total of 186 patients were randomised and 152 patients completed the 
study. The mean difference in change in IBS symptom severity scores 
between the two groups was statistically significant (-35.0 (95% CI; -62.03, -
7.87); p=0.01). Adverse events were mild and transient and no serious 
adverse events were reported. 
Conclusion 
The multi-strain probiotic is associated with an improvement in overall 
symptom severity in patients with IBS, is well tolerated and has a good safety 
profile. 
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Irritable bowel syndrome (IBS) is a common diagnosis given to 
patients with a variety of gastrointestinal symptoms and is one of the major 
recognised functional gastro-intestinal disorders. IBS is the term to describe 
or categorise a cluster of relapsing and remitting gastrointestinal symptoms 
that encompass a variety of interrelated heterogenic conditions grouped 
together under one ‘umbrella’ term.  It is this heterogenic clustering of 
symptoms, including diffuse or localised abdominal pain often relieved by 
defecation, abdominal bloating, change in bowel openings, tiredness and 
passing of mucus amongst others; coupled with absence of conventional 
organic disease that essentially characterises the condition and makes the 
diagnosis clinically.  Although  often thought of as a ‘modern disease’ it was 
first noted in 1871, in The American Journal of Medical Sciences by JM Da 
Costa who first described ‘a painful affliction of the colon, membranous 
enteritis, a condition which is but very incompletely known and scarcely 
recognized as a separate disease by the profession’.[1]  It was several 
decades until the terms ‘spastic colon’ or ‘the irritable colon syndrome’ were  
widely used or recognised; but Da Costa’s work is frequently cited by later 
authors as one of the first descriptive scripts of the condition that is now 





In 1931, Edmund Spriggs in his substantial work ‘functional disorders of the 
colon’ gives a full description of ‘the functional disorder of the colon’ akin to 
IBS. Interestingly,  in this work he alludes to several aetiological and 
pathogenic concepts in IBS namely; the association of the disorder with the 
aftermath of infective tropical dysentery, pyorrhoea and other septic 
infections of the mouth and throat, the acquirement or inheritance of an 
‘unstable nervous system’ as a predisposing risk factor and the response of 
symptoms to a simpler diet than the ‘modern civilised diet [2] and other 
concepts that remain a significant focus in research literature and study 
today. Later, in 1962, Chaudhary and Truelove further described the ‘irritable 
colon syndrome in an authoritative and influential publication. They included 
the recognition of possible sub-groups according to bowel habit (constipation 
or diarrhoeal predominance) and the apparent efficacy of early treatment 
with phenobarbitone or codeine.[3] 
 
 The features of IBS often differ markedly between patients both in 
terms of abdominal symptoms and severity, bowel habit and associated 
extra-intestinal symptoms. Response to treatment and natural history of the 
disease often varies markedly and as such it is difficult to consider IBS as a 
single entity. Several attempts have been made to develop a standard of 
nomenclature and diagnosis for all functional gastro-intestinal disorders 
including IBS. The most recent and widely used of these is the so called 




international consensus opinion of IBS researchers in an attempt to 
standardise clinical trials and practice to allow for a meaningful comparison 
of studies. The ROME III criteria sub divides IBS according to the 
predominant pattern of bowel habit into constipation (C-IBS), diarrhoea (D-
IBS), both diarrhoea and constipation – mixed (M-IBS) and unclassified (U-
IBS) where there is little or no change in bowel habit (table 2).[5] Whilst it is 
not necessarily the convention, it may be useful in both research and clinical 
practice to consider IBS as a group of interrelated but different disorders that 
share the common symptom of abdominal discomfort/pain.  Differing 
aetiology, prevalence, treatment strategies and responses of the individual 
sub types should also not be overlooked, but unfortunately high quality data 
on these aspects of the disease is often lacking. 
 
Today patients frequently consult their physician and 
gastroenterologist with a variety of abdominal symptoms akin to IBS. 
However, over a century since its first description and despite significant 
advances in our understanding of the epidemiology and pathogenesis of IBS 








1.2 The epidemiology of irritable bowel syndrome. 
 
Many studies can be found in the literature that estimate the 
prevalence of IBS in differing communities, with estimates ranging from 2.5% 
-22%.[6-34] These studies are summarised in table 3. The reasons for the 
significant differences in prevalence estimates are numerous and complex. 
One of the principle reasons is the heterogenic nature of the condition and 
the lack of a definitive diagnostic test. As such clinicians and research 
groups are reliant on a combination of negative tests to exclude other 
organic diagnoses and the application of certain diagnostic criteria to make a 
considered if not definitive diagnosis of IBS.  
 
There has been much evolution in the diagnostic criteria since the 
original Manning criteria were first published in 1978.[35] The original 
Manning criteria comprised a simple list of symptoms in keeping with a 
diagnosis of IBS (table 1).  The presence of greater than two, greater than 
three or greater than four symptoms from this list gave rise to the ‘Manning 
2’, ‘Manning 3’ and ‘Manning 4’ criteria respectively. In the study by Talley et 
al. in 1991 a postal survey of 1021 members of the general population in 
America, 835 respondents reported a prevalence of 17.0%, 12.8% and 8.7% 
using the Manning 2 ,3 and 4 criteria respectively.[13] Jones et al. 1992, in a 




the United Kingdom, using the Manning 3 criteria reported a somewhat 
higher prevalence of 22%.  Whilst both of the studies utilised a postal survey 
for data collection they were looking at different populations (USA and UK).  
In addition, Jones et al. used a single questionnaire designed by the study 
group based on previous published works whereas Talley et al. garnered the 
information from a general health questionnaire. Neither questionnaire was 
validated specifically to identify patients with IBS although Jones et al.  
amalgamated questions from several previously published, validated 
questionnaires. The Jones et al. study is perhaps more likely to suffer from a 
response bias as it was aimed at identifying a particular condition from within 
the target population and hence subjects with the condition may be more 
likely to respond.[9] Further studies using the Manning criteria return 
prevalence estimates of between 8.7% and 22%.[8, 9, 13, 17, 18, 22]   The 
Manning criteria are the least specific of the criteria and as such give rise to 
the highest prevalence estimates and are likely to overestimate the true 
prevalence of the condition.   
 
The Manning criteria were later superseded by the Rome criteria in 
1989. The concept for the Rome criteria was first discussed at the 12th 
International Congress of Gastroenterology in Lisbon 1984 due to the 
growing need for a standardised, robust set of diagnostic criteria that could 
be used comparatively in both research and clinical practice. Subsequently, 




first published in 1989.[36] Since this time the Rome criteria have undergone 
several reviews and revisions and now include a full classification based on 
international consensus opinion of experts in the field, of all the functional 
gastrointestinal disorders including IBS. This has led to several criteria 
namely;  the Rome (1989) [36], Rome 1990, first revision [37], Rome I (1994) 
[38], Rome II (1999) [39], and the latest Rome criteria, The Rome III (2006). 
[5] The Rome criteria apply more specific and stringent diagnostic criteria to 
the diagnosis of IBS as well as including a temporal component (Table 2). 
These more stringent criteria have ultimately led to lower prevalence 
estimates than given in studies using the Manning criteria.  
 
Several authors have compared the differing diagnostic criteria on the 
same population. Hahn et al. (1997) compared Manning 2 and Rome (1989) 
using data from 42,392 face-to-face interviews of the National Health 
interview survey (NHIS) in America. They reported a prevalence of 8% and 
3% respectively.[17] The Rome criteria returns a much lower prevalence 
than the Manning criteria, which is consistent with other studies although the 
overall prevalence in this study was significantly lower than the majority of 
studies in similar populations. This disparity may be a result of the  direct 
face-to-face interviews used in the study. Mearin et al. in 2001 also used 
face-to-face interviews of 2000 subjects in Spain to compare the Manning 
and Rome I and Rome II criteria. This study unusually, reported a higher 




but went on to report a markedly lower prevalence of 3.3% when the Rome II 
criteria were applied.[11] Saito et al. in (2000) in a study of 892 subjects in a 
postal survey of the American general population, reported a prevalence of 
20.4%, 15,7% and 13.1% for the Manning 2, Manning 3 and Rome criteria 
respectively.[18] These results are similar in scale to those shown by both 
Talley et al. (1991) and Jones et al. (1992).[9, 13]  
 
Later studies using the Rome II standard consistently returned a lower 
estimate of prevalence when applying the Rome II criteria compared to any 
of the preceding criteria. Saito et al. (2003) is  an example of this, in their 
study that compared  892 (643 respondents)  subjects of the general 
population in the USA via a postal survey using Rome (1989), Rome (1990), 
Rome I and Rome II and finds a prevalence of  27.6%, 5.1%, 6.8%, and 
5.1% respectively.[12]  One exception to this is Thompson et al who in 2002 
reported a higher prevalence of 13.1% with Rome II compared to 10.3% with 
Rome I criteria. The most recent Rome III criteria were first published in 2006 
and to date their use for prevalence studies has been limited to populations 
other than the USA or UK. As such it is not possible to confidently state how 
the prevalence estimates in these populations would be affected by the 
application of the new criteria. Studies using the Rome II criteria have been 
performed but in differing populations. The reported prevalence using Rome 
III  in these populations is 7.85% (2126 ,North China university students)[28], 




general population of India).[33] We found only one study that directly 
compared the Rome III criteria with previous classifications. This paper, 
conducted by Sperber et al. compared the Rome II and Rome III criteria in a 
sample of 1221 subjects (1000 respondents) of the general population of 
Israel and reported a prevalence of 2.9% and 11.4 % respectively.[34]   
 
It is clear that prevalence estimates vary dramatically between 
different studies and populations. As previously stated the heterogenic 
nature of the condition, differences in cultural expectations and the lack of a 
specific diagnostic test contribute significantly to this.  The application of 
differing diagnostic classification systems also has a dramatic impact upon 
the reported prevalence estimates. On one side, the Manning criteria is likely 
to overestimate the true prevalence by being too non-specific and not 
applying a temporal component to the criteria. On the other side, the Rome II 
and III criteria undoubtedly exclude a significant amount of IBS at least in 
part from the application of strict temporal and frequency criteria.  What is not 
apparent from the published studies is why the comparative data when 
applying the different classification criteria does not result in differences of a 
similar magnitude. For example, Mearin et al. (2001) compared Rome I and 
Rome II; finding a difference between the two criteria in the order of more 
than three times lower prevalence with the older criteria  (12.1% and 3.3%). 
Saito et al. (2003) however, compared the same criteria and found little 




implication from this is simple, as although the criteria themselves may be 
robust their application in prevalence studies is open to individual 
interpretation resulting in quite different results between study groups. The 
latest Rome criteria (Rome III) are too restrictive and as a result may actually 
exclude a substantial number of patients that experienced clinicians would 
likely  accept as having a clinical diagnosis of IBS.  This may be of no 
significant consequence to clinical practice but in the research environment 
may substantially bias the results of clinical trials by excluding patients who 
do have IBS.  Given the significant heterogeneity of IBS and the current lack 
of established biological markers it is unlikely that any diagnostic criteria will 
be completely accurate. However, a balance between usability and 
application both in research and clinical practice are essential if criteria are to 
be widely adopted. The Rome IV criteria, when agreed and published will 
hopefully go a step further to addressing some of these issues. 
 
Differing methodological approaches using retrospective patient data, 
medical insurance data and diagnostic coding or prospective data with postal 
survey, face-to face interviews, telephone interviews and self-reporting 
symptom questionnaires are also likely to have a significant influence on the 
estimated prevalence. The specific influence these factors may have is likely 
to be complex and not enough data is available in the literature to give a 
considered opinion. Caution should therefore always be exercised when 




symptoms themselves are also often transient in nature and as such the 
phrasing of questions that ask ‘have you ever’ or ‘are you currently’ suffering 
from will clearly affect the results. One such study looked at this  transient 
characteristic of symptoms and found that 38% of the study cohort who 
reported IBS symptoms did not meet diagnostic criteria in a self-reported 
questionnaire one year later.[40] 
 
The majority of epidemiological report a female predominance of IBS 
although gender differences show considerable variability ranging from as 
high as 1.0: 4.3 (male: female) to equal prevalence in some studies (table 3). 
The majority of studies  however report ratios in the order of 1:1 to 2:1 (male 
: female) in studies of western populations.[41]  India appears to differ with a 
male predominance of 4.2:1.0 in young adults.[42] The overall trend in the 
incidence of IBS is that it decreases with increasing age; 4.2% of the age 
group 30-39 compared to 2.7%  in those aged 60-69 in one study (overall 
prevalence 4.7%).[12] Symptomology may also change with gender and age 
with constipation being more prevalent in females and older individuals.[13, 
43] There is also a marked difference in the reported prevalence between 
different populations. The incidence seems to be generally higher in 
America, Canada, USA and Europe with intermediate rates in eastern 
countries such as China, Korea and Singapore and the lowest rates in 
developing countries like India. The reasons for these differences, in addition 




genetic factors as well as differing urbanisation, socioeconomic and health 
care.[44-46] 
 
There is no consensus opinion on the prevalence of IBS for any 
specific population. In developed countries it is likely to be in the order of 
around 7-10% of the general population and may be significantly higher. 
Regardless of the particular diagnostic criteria, IBS is associated with 
significantly increased healthcare costs [47-51] and absenteeism.[52] 
However, of those people who report symptoms that meet criteria for IBS 
only 9%-33% consult their physician about their symptoms.[9, 51]   
Healthcare costs for patients with IBS were significantly higher (by a factor of 
1.1-6.0) when compared with non-matched non-IBS controls in two studies; 
one in America and one in the UK.[52, 53] In addition to the diagnostic and 
therapeutic costs of treating IBS, the indirect healthcare costs are also 
significantly higher.[54] In trying to rationalise and understand these costs, 
research has focused on understanding the characteristics or circumstances 
which result in an IBS patient consulting their physician or accessing 
healthcare in other ways.   
 
It is widely reported in the literature, and a commonly held belief 
amongst clinicians and specialists, that patients with IBS have a higher 




component in the aetiology of IBS symptoms.[55-64] In fact, Chaudhury and 
Truelove (1962) report that 80% of their 130 cases had contributing 
psychological factors. These factors consisted of diagnosable psychiatric 
illnesses such as depression, personality traits such as increased anxiety 
and  environmental stress such as marital or family problems.[3] A 
retrospective review of this early work has resulted in the opinion that 
inappropriate methodology may have led to an overestimation of the 
prevalence of psychiatric illness in IBS and in my opinion this is probably 
inappropriately quoted as evidence for its role in the aetiology of the 
condition.[55] The role of psychological factors in the aetiology and 
management of IBS is discussed in more detail later and needs to be viewed 
in the different context of aggravating the condition.  
 
It is important to consider the influence that the methodological factors 
have on the reported prevalence of the disease. The methodologies used for 
data collection in the epidemiological studies for IBS vary greatly with many 
relying on self-reported questionnaires about abdominal symptoms. Such 
questionnaires will undoubtedly be influenced by any psychological factors 
affecting the cohort studied. The environment from which the data is 
collected may further compound this effect. For example, IBS cases can be 
over represented within the patient group; this is likely to be the case in a 
primary care setting as IBS sufferers are known to be more frequent users of 




cohort and should not be extrapolated as representative of IBS cohorts in 
general. [65] Psychological factors may also introduce response bias into 
large scale population studies, as cases with underlying psychological 
problems may be more or less likely to respond depending on their state of 
mind.  
 
In Summary, the heterogenic nature of IBS, associated psychological 
factors, differing classifications and methodology and the lack of a specific 
diagnostic test has undoubtedly led to significant variation and inaccuracies.  
Consequently any  reported prevalence must be considered with caution. 
 
1.3 The aetiology of irritable bowel syndrome 
 
To date the understanding of the aetiology of IBS is limited and whilst 
in recent years there have been significant advances in attempts to 
understand the underlying possible pathogenic mechanisms of IBS, there is 
still no single accepted theoretical model of IBS. If we accept the idea that 
IBS is not likely to be a single entity, but to consist of a group of inter-related 
but differing conditions with similar symptomology, then logically we should 
also expect differing pathogenic / pathophysiologic mechanisms and 
aetiologies.  IBS is likely to be the result of a complex interaction of  a 




physical and psychosocial elements and principles.     
    
1.3.1 Post infectious irritable bowel syndrome  
 
  Post-infectious irritable bowel syndrome (PI-IBS) is the term 
used to define a sub-group of patients, where there is a clear temporal 
relationship between an acute gastro-intestinal infection and the subsequent 
persistence of symptoms akin to IBS. PI-IBS tends to predominantly but not 
exclusively lead to IBS-D. Chaudhary and Truelove reported that 25% of 
their patient group had a clear episode of infective gastroenteritis prior to 
developing IBS; but do not give further details of the temporal relationship 
between the infective insult and the development of symptoms.[3] Since this 
work, multiple retrospective and prospective studies have re-examined the 
possible link between enteric infection and the development of IBS. 
 
 A retrospective study of 124 patients and 120 controls reported an 
increased incidence of PI-IBS at three years post-infection with a strain of 
Shigella sp. (14.9%) compared to controls (4.5%) with an odds ratio of 3.93. 
They also showed that the recovery rate for PI-IBS was lower in patients with 
a previous history of functional bowel disorders other than IBS.[66] Similarly, 
a prospective study of 72 patients with confirmed Trichinella Britovi infection 




following year (13.9%) compared to the 27 controls, none of whom 
developed IBS.[67] A prospective study of 194 conference delegates after an 
outbreak of norovirus showed that 23.6% of those affected had IBS like 
symptoms at three months, compared to 3.4% in delegates who were 
unaffected by the original outbreak (odds ratio 6.9). At six and twelve months 
from follow up the prevalence in the two groups was similar, indicating a 
more rapid recovery than is perhaps associated with PI-IBS after non-viral 
gastro-enteritis.[68] Both the patient and control groups in this prospective 
study of 109 subjects before and after a period of ‘foreign travel’ are small 
and the study did not find any association between traveller’s diarrhoea and 
the development of IBS. However, as this study was small it is likely to be 
significantly under powered.[69] 
 
A recent study of the aetiology of IBS in patients from three different 
recruitment sources, put the prevalence of PI-IBS as between 6% and 17% 
of total IBS cases depending on the data source used. It is also noted that 
this study unintentionally consisted of almost entirely female respondents 
and was conducted forty years after the Chauhury & Truelove publication. 
[70] The number of individual studies investigating PI-IBS are too numerous 
to mention individually. It is interesting to note however, that the majority of 
studies that show a clear temporal relationship between an acute gastro-
enteritis and PI-IBS come from the UK, with only limited evidence in similar 




India and other developing countries, have failed to show any correlation 
between previous or current acute gastro-intestinal infections and the 
development of PI-IBS.[71, 72, 79] This raises the possibility that PI-IBS may 
be a phenomenon unique to the developed world. 
 
 Gwee et al. suggested a ‘hygiene hypothesis’ as a potential 
explanation for this idea.[45] They proposed that infants in a developing 
country are exposed to a large number of gastro-intestinal infections in early 
life. Accordingly it is suggested that this leads to early development of an 
immunological state that is both able to respond efficiently and effectively to 
antigenic challenges and be equally tolerant of normal, non-pathogenic gut 
microbes. A corresponding relative lack of, or reduced exposure to microbes 
in the relatively ‘sterile’ developed world; leads to a naive immune system 
that may be less effective at dealing with potential pathogens and at the 
same time have exaggerated immune mediated inflammatory responses to 
both pathogenic and commensal gut microbes later in life.[45] This theory is 
at least in part supported by the findings of increased inflammatory 
enteroendocrine (Ec) cells and altered levels of the pro- and anti-
inflammatory mediators observed in subjects with PI-IBS [73-75, 80], which 
is discussed in more detail in the section on pathogenic mechanisms. The 
theory is also noticeable for its striking similarity with suggestions that the 
high prevalence of childhood asthma in developed as opposed to developing 




hypothesis, if not conclusive, does re-emphasise the increasing interest in 
the interaction of the gastrointestinal microbiota and other antigenic material 
with the host and the subsequent possible consequence in disease 
pathogenesis. 
 
1.3.2 Food allergy and intolerance. 
 
 The acquirement of nutrients requires that food components cross the 
gastro-intestinal barrier and once in the systemic circulation, (in some 
subjects) these components may have antigenic properties that result in 
allergenic stimulation, immune responses and the development of allergy; 
which can be confirmed by challenges of the offending foodstuff and 
characteristic laboratory findings.[83] Intolerances on the other hand are less 
well understood, but much more common and consist of a clustering of 
symptoms that result from challenge to offending foods, but without any 
specific laboratory findings or evidence of a true allergenic response.  
 
 Food allergy and intolerance is frequently reported by individuals in 
the general population but there is poor correlation between the reported 
incidence and actual positive tests for food allergy. In one study with over 
7000 respondents from an unselected population, 20% reported food allergy 




testing with only 19.4% having a positive result.[84] In patients with IBS, the 
reported incidence was even higher but a similar discrepancy and problems 
of interpretation is evident. In  one study of  patients with IBS food 
intolerance/allergy was reported in 32% of subjects, but of these only 14% 
were suspected to have allergy/intolerance based on clinical criteria; 
including total and specific serum IgE, provocation testing and or elimination 
re-challenge diets.[85] In a separate study, rates of food intolerance/allergy 
were as high as 63% but of these only 52% had positive ‘skin-prick’ tests. 
There was also little correlation between the positive test results and the 
reported food intolerance.[86] Interestingly, a systematic review that included 
over 4200 subjects from fourteen studies, found that those who met 
diagnostic criteria for IBS were four times more likely to have diagnosis of 
coeliac disease than the general population. [87] This is a curious finding as 
coeliac disease is usually the main differential diagnosis in patients with 
diarrhoea. A separate study also showed increased serum IgG but not IgA 
coeliac related antibodies (anti-gliadin and anti-tissue transglutaminase 
(TTG)) in 37% and HLA-DQ2 genotype in 39% of patients with D-IBS 
(diarrhoea predominant).[88] These findings suggest that some patients with 
D-IBS not only show an immunological response to dietary gluten but also 
that this reaction can predict their response to a gluten free diet.  
Furthermore, this provides direct evidence of a possible dietary trigger for 
low level inflammation and altered motility in a sub-group of patients with IBS 
and raises the possibility that similar triggers and immunological response to, 





The two most commonly reported food intolerances in patients with 
IBS are dairy (40.7%) intolerance; which is usually related to an intolerance 
to the disaccharide lactose; and wheat/grains (39.4%), commonly felt to be to 
the gluten component.[89] These often result in the severe bloating and 
diarrhoeal symptoms that are often predominant in IBS patients. Dietary 
fructose, and sorbitol malabsorption are also implicated in the 
symptomatology of IBS, as higher rates of malabsorption can be 
demonstrated in patients with IBS compared to controls.[90] The symptoms 
are presumably caused by a combination of osmotic retention of fluids 
resulting in loosening of stool and perhaps by providing additional substrate 
for fermentation by the colonic microbiome. In the hands of certain 
individuals symptom improvement with elimination diets fairs much better 
than allergy testing. In one, non-randomised, study of 189 patients with IBS, 
48% showed symptomatic improvement after elimination diets for commonly 
reported intolerances and remained well throughout follow up. Of these 50% 
identified intolerances to two-five food groups. [89] In a separate study, the 
presence of HLA-DQ2 and increased levels of coeliac related IgG antibodies 
were found to predict response to gluten free diet in IBS patients.[88] 
Conversely in a separate study of 4622 subjects, no correlation was found 
between reported food intolerance, or improvement in symptoms on 
elimination diets with the results of food allergy testing.[91] In recent years 




monosaccharaides and polyols’ has received considerable interest. 
FODMAPs elimination diets have been shown in several observational 
studies to improve the global symptoms of IBS. [92-94] To date there have 
been no true randomised-controlled trials and the methodology of the 
published data is unacceptable to draw any firm conclusions.   
 
The effect of fibre intake on symptoms in IBS has been re-examined 
repeatedly with a variety of changing messages. There is no significant data 
in the published literature examining the role of variations in dietary fibre 
intake in the aetiology of IBS. The use of dietary fibre as a treatment strategy 
is discussed later.  
 
The evidence for dietary intolerances and food allergy in the context of 
the aetiology and pathogenesis of IBS is inconclusive with conflicting results 
from different studies. Clearly, as is often the case, there are proponents and 
opponents to dietary interventions as a therapeutic target for IBS and this 
may have some merit. However, the evidence that specific food intolerance 
and allergy play a role in the pathogenesis of IBS is unconvincing.  This does 
not necessarily preclude the use of elimination diets in the treatment of IBS, 
where perhaps there is at least some evidence, but even then there is a lack 
of randomised controlled trial data.  The complex physiological changes that 




within the GI tract are a normal phenomenon. There is also a multitude of 
evidence to suggest disordered physiological response and visceral 
hypersensitivity in patients with IBS.  If these physiological changes are 
exaggerated or result in symptoms in IBS it is not, in my opinion and based 
on the evidence available, appropriate to define this in the vast majority of 
patients with IBS as food allergy or intolerance. Dietary manipulation and 
elimination diets remain an important part of current treatments for IBS but 
perhaps as our understanding of the pathophysiology and pathogenesis of  
the disease increase, so too will our understanding of the impact of dietary 
components. 
  
1.3.3 Psychosocial factors in the aetiology of irritable bowel syndrome 
 
Psychological factors are thought to play both an important role in the 
development of IBS and possibly may even play a direct contributory role in 
the disease pathogenesis. Certainly it is clearly established that patients with 
IBS who consult their doctor have an increased incidence of psychological 
co-morbidities and traits than either the general population, or patients with 





  The aetiology and natural history of IBS as well as the response to 
treatment is significantly influenced by psychological factors in most if not all 
patients. However, this interaction may have been misrepresented or over 
interpreted in the literature and may contribute to the misunderstanding of 
the disease in the clinical setting resulting in poor treatment outcomes.  
Chaudhury and Truelove identified  psychological factors  in 80% of 130 
patients and subdivided these factors into; diagnosable psychiatric illness, 
anxious personality type and those suffering from environmental stress such 
as family, marital or work related.[3] This high prevalence of psychiatric 
conditions led the authors and others to conclude that psychological factors 
were a key component in the aetiology of IBS. Creed and Guthrie 1987 on 
the other hand highlight that there was a high likelihood that poor 
methodology in this and other earlier studies might lead to erroneous 
interpretation. These include significant selection biases of patients, failure to 
use standardised diagnostic classifications and failure to use, or 
inappropriate use of, reliable psychological instruments which predisposes to 
significant overestimation of the incidence of psychological abnormalities 
associated with IBS.[55] Furthermore, and much more importantly, the study 
does not address whether there is a temporal or causal relationship between 
IBS and the psychiatric parameters. The high prevalence reported in what is 
often referred to as a ‘landmark’ study is still used to support the theory of a 





 Some studies have shown a higher incidence of divorce/separation, 
alcoholism, childhood deprivation, unsatisfactory relationships in childhood 
with / between parents [95]  and a higher prevalence of sexual abuse in 
subjects with IBS compared to non-neoplastic organic disease.[96, 97] 
Hislop et al. in an observational study of 333 consecutive patients with IBS 
noted 31% had either lost a parent through death, divorce or separation, 
19% were exposed to parental alcoholism and 61% felt that relationships 
with or between parents were unsatisfactory before the age of 15.[95]  This 
study did not include a control group.  A multi-centre, prospective, case 
control study of 196 patients (200 controls) with IBS who attended 
outpatients in a teaching hospital found that patients with IBS reported a 
significantly higher rate of sexual abuse (31.6%),  than controls (14.0%).[96] 
However, the patient group was selected from teaching hospital outpatient 
clinics only. As psychological abnormalities are more common in IBS 
patients who seek medical consultation,[56] it is possible the population 
studied are not representative of patients with IBS as a whole. These studies 
are invariably retrospective as they ask the individuals to recall past 
experience and do not therefore adequately demonstrate either a causal or 
direct temporal relationship. 
 
 Patients who develop IBS after an acute GI infection have not been 
thought to have a particular premorbid personality. However, Spence et al. 




gastroenteritis, that those patients who go on to develop post infectious IBS 
(PI-IBS) have significantly higher levels of stress and anxiety at the time of 
the primary infection than patients who do not.[98] A second similar 
prospective study of 75 patients by Gwee et al. also shows higher scores for 
anxiety, depression, somatisation and neurotic traits on psychometric testing, 
at the time of the infective illness in those patients who go on to develop PI-
IBS.[99] The authors of both studies suggest that this reflects a causative 
role of the identified characteristics. However, whilst these studies are 
interesting and suggest a causative and temporal relationship between 
psychological factors and the development of IBS, they utilise questionnaires 
to report the psychiatric traits and the IBS like symptoms. Due to the semi-
subjective nature of these questionnaires, self-reporting and response bias 
(25% non-response in one study), these results should be viewed with some 
caution.  Drossman et al. 1998 studied a cohort of 238 subjects, 72 patients 
with IBS who regularly consulted their physician, 82 IBS ‘non-patients’ 
(patients who met the diagnostic criteria for IBS but did not regularly consult 
a physician) and 84 healthy controls without IBS. They demonstrated a 
higher incidence of psychological factors including abnormal personality 
traits, disruptive illness behaviour and lower positive stressful life event 
scores in the IBS patient group than either the ‘non patients’ or controls. IBS 
‘non-patients’ were intermediate between the two groups but tended to have 
a higher coping ability, and less disruptive illness behaviour or psychological 
denial [57]. This study suggests that the abnormal psychological traits are a 




itself. Similarly, Akehurst et al. 2002 showed increased healthcare utilisation 
and costs in a cohort of  patients with IBS compared with 213 age matched 
healthy controls. This also corresponded  with lower health related quality of 
life scores (HR-QOL) reported in the IBS patient group.[65] Hershbach et al. 
1999 further supported this view with similar findings, that people with IBS do 
not differ from controls but patients with IBS  have more psychopathology, 
fear of illness and are more markedly affected by stress concluding that the 
psychopathology is a not a characteristic of the disorder but a sampling 
bias.[60] Conflictingly, Heaton 1992 demonstrated that the number and 
severity of IBS symptoms predicted health seeking behaviour independently 
of psychological factors.[7] 
 
 It is apparent from the literature that the interaction between the 
psychological factors (which are undoubtedly associated with IBS) and the 
physical symptoms in patients with IBS is complex. It appears that they are 
both important in the pathophysiology and health seeking behaviour of IBS 
patients. Whether they are truly part of the disease aetiology or simply a trait 
that leads to consultation continues to divide opinion. Some patients with 
quite severe IBS have no apparent underlying psychological problems and 
the disparity between the frequency of psychological problems in patients 
seen in secondary and tertiary care settings compared to those in the 
community or primary care setting would suggest that it is a feature of 




observed between psychological symptoms and development of PI-IBS 
suggest at least some role in pathogenesis. 
 
1.4 Pathogenesis and underlying mechanisms. 
 
The causes for IBS are unknown and speculative. The genetic and 
psychosocial influences have been discussed previously. Historically IBS has 
been regarded as a condition in which altered gut motility, visceral 
hypersensitivity and psychological factors are the key pathogenic 
mechanisms. More recent research now suggests that autonomic, enteric 
and central nervous system dysfunction, altered immune function and 
disordered inflammatory responses are also key pathogenic mechanisms in 
IBS.  These pathogenic mechanisms are the result of a combination of 
various genetic and environmental influences with each, if not all, of the 
mechanistic components interacting and contributing to a varying degree, 
depending on the aetiology and sub-type of IBS encountered. 
 
An understanding of the complex physiology and function of the 
organs that are collectively referred to as the gastro-intestinal (GI) tract is 
essential when considering the pathogenic mechanisms of IBS.  The GI tract 
does not merely function as an organ to facilitate transfer of nutrients from 




non-specific defence mechanisms as well innate and adaptive immunological 
components that protect against invasion of microbes and other luminal 
antigens.  
 
1.4.1 Brain-Gut Axis: Visceral hypersensitivity, hyperalgesia and 
central pain perception. 
 
 The gastrointestinal tract is innervated both by intrinsic and extrinsic 
nervous systems. The brain-gut axis commences with signals arising from 
the intrinsic enteric nervous system within the gut wall being transmitted to 
via various visceral afferent pathways, including the enteric, spinal and vagal 
pathways to the central nervous system.[100] The brain-gut axis within the 
CNS involves complex communications between a variety of structures, 
including the limbic sensory and motor cortex, hypothalamus, mesencephalic 
and medullary systems.[101] This complex system allows for physiological 
and homeostatic reflex to occur directly within the ENS, as well as through 
more complex interactions and reflexes originating in and/or under the 
influence of the central nervous system.[102] It is through these mechanisms 
that regulation of basic GI physiology such as blood flow and secretion are 
regulated, as well as the much more complex integration and co-ordination of 
gut physiology within the wider homeostatic requirements and mechanisms 




a role in the satiety, pain and emotional and immune responses, [103] as 
well as adjusting the sensitivity of these reflexes and visceral pain 
sensation.[104] Whilst the vast majority of the reflex interactions and control 
of gut physiology and function are not consciously either perceived or 
controlled in normal subjects, there are central and peripheral adaptive 
mechanisms that alter the perception of visceral stimuli.[101] These include 
inflammation, tissue injury, food and luminal antigenic material as well as 
emotional stressors; all of which can directly and indirectly influence gut-
physiology and perception of stimuli via the gut-brain axis.[100, 105-108] 
 
 The term visceral hypersensitivity describes a state in which a subject 
reports a painful or uncomfortable sensation to a physiological or other 
stimulus that would not usually be considered painful by a healthy subject.   It 
was first described by Richie et al. who demonstrated a hyperalgesic 
response to balloon distension within the pelvic colon in subjects with IBS 
compared to controls.[109] Over the last decade or so the underlying 
mechanisms of visceral hypersensitivity are becoming increasingly 
understood; as a result it is becoming clear that it is one of the key 
mechanisms that underpins the abdominal pain and discomfort that is 
reported in IBS patients. The exact underlying mechanisms and the degree 
of involvement of the brain-gut axis in the development of IBS is still being 
unearthed. Structural and functional abnormalities of anterior mid-singulate 




Further differences are proposed in terms of regional changes in grey matter 
density [111] but as yet it is not known whether these changes are 
predisposing to; part of the pathophysiology of, or a result of repetitive 
visceral stimulation in the context of IBS.[112] Further disturbance in the 
interaction between the CNS and the autonomic nervous system (ANS) 
mediated in principle via corticotrophin releasing factor (CRF) and the CRF-1 
and CRF-2 receptors, may also result in increased perception of both 
gastrointestinal and non-gastrointestinal symptoms in IBS patients. [113, 
114]   
 
 The exact pathogenesis and mechanisms of visceral hypersensitivity 
itself are not known, although there are several theories such as increased 
sensitisation as a result of repeated mucosal injury and/or inflammation.[105] 
The visceral afferent fibres of the gut lumen are polymodal  and triggered by 
local luminal chemical, thermal and mechanical stimuli.[115] The sensitivity 
of so called ‘silent’ mechanoreceptors can be increased by mucosal injury 
such as the instillation of deoxycolic acid in a rat model and may persist long 
after the removal of the initial insult and resultant inflammation.[116] Injury to 
the enteric mucosa leads to the production and release of a host of chemical 
(potassium, adenosine triphosphate (ATP) and bradykinin) and inflammatory 
(prostaglandin E2 (PGE2)) mediators. [117] In addition, to direct afferent 
nerve stimulation these substances can also induce the release of  




further amplification of the stimulus resultant in visceral pain.[118] Serotonin 
appears to play a particularly important role in stimulating primary afferent 
nerve endings and perpetuating the visceral pain response. [119].  In 
addition to local mediators of pain, significant central sensitisation to visceral 
pain response is also implicated.  This takes place both at the level of the 
spinal cord mediated via substance P, neurokinin 1,  and N-methyl-D-
aspartate (NMDA) receptors; and centrally via gamma-aminobutyric acid 
GABA and serotonergic pathways.[120] Information from animal models is 
vital to the understanding of the pathophysiological mechanisms underlying 
the development of visceral hyperalgesic states. Abnormal somatic pain in 
IBS is equally essential to elucidate, but hampered by technical difficulties. 
Nevertheless information from clinical studies is progressing our knowledge 
of pain albeit slowly. One way forward in these respects is the use of 
objective assessment such as functional MRI in the investigation of the 
consequence of a physiological and painful stimuli, such as thermal skin 
exposure and rectal distension. 
 
A study of twenty patients with IBS and fourteen healthy controls 
looked at responses to rectal balloon distension on five occasions over a 
period of twelve months. In the IBS group positron emission tomography 
mapping showed increased limbic, paralimbic and pontine stimulation 
consistent with central up regulation/arousal of response that corresponded 




to visceral stimuli that was not present in normal controls.[121] Abnormal 
pain sensitisation to somatic stimulation is also a feature of IBS, although 
whether this is due to central pain sensitisation of viscera-somatic 
convergence sensitisation as a result of the visceral insult is not clear.[122]  
A possible mechanism for the somatic sensitisation could be the same as 
that seen in chronic neuropathic pain; where persistent afferent nerve 
stimulation of the spinal cord leads to hyperalgesia, pain and allodynia.[105] 
A further clinical study demonstrated the phenomenon of temporal 
summation of pain in patients with IBS compared to controls, where repeat 
exposure to the same noxious, thermal stimulus resulted in exaggerated 
somatic pain response that could be blocked by dextromethorphan, an 
NMDA receptor antagonist.[123] 
 
Clearly, our understanding of the central and peripheral components 
that lead to visceral hypersensitivity and hyperalgesia is relatively poor, but 
the combination of central arousal and habitualisation, together with 









1.4.2 Genetic Factors. 
 
 The possibility of one or more genetic factors that directly or indirectly, 
through increased susceptibility, are involved in the pathogenesis of IBS is 
raised by the observation of familial aggregation of IBS.[124, 125] In a 
prospective study of 355 patients with IBS, 17% had one or more family 
members with IBS like symptoms compared to 7% in the family of the 
spouse.[124] However, familial aggregation alone is insufficient evidence to 
suggest a genetic component, as it may simply be representative of a 
common exposure to environmental factors.   
  
 Several twin studies have been conducted in patients with IBS, but the 
results are conflicting both with each other and the familial aggregation 
studies.  Two twin studies conducted by Bengston et al. and Levy et al. of 
12,700 and 10,609 twins, respectively, reported greater concordance of IBS 
in monozygotic (22.4% and 17.2%) than dizygotic twins (9.1% and 8.4%) 
respectively.[126, 127] Bengston et al. also reported 48.4% concordance in 
female monozygotic twins which is very suggestive of a genetic component. 
But then goes to report a higher incidence of IBS in low birth weight twins 
suggesting an intra-uterine environmental factor may also be of significant 
importance.[126] Levy et al. reported a higher proportion of dizygotic twins 
with a mother (15.2%) with IBS than a co-twin (6.7%) This raises further 




offspring and co-twin (dizygotic) is equal and as such the proportions should 
be similar.[127] A further study from Mohammed et al. of 5,032 twins 
reported equal concordance, but with a much higher concordance than either 
Bengsten et al. or Levy et al., in monozygotic and dizygotic twins (28% and 
27%) with similar prevalence suggesting that a genetic factor is unlikely 
[128]. All three studies rely on self-reporting of IBS by answering yes/no to a 
simple question and do not employ any recognised diagnostic criteria to 
confirm the diagnosis, which limits the relevance of the results. These 
genetic studies perhaps raise more questions than they answer. 
 
 The importance of adrenoceptors and serotonin in the pathogenesis of 
IBS is discussed later, but it is essential to note that over 95% of serotonin is 
located in the enteric nervous system. Within the enteric nervous system 
there are two distinct seritonergic pathways; the intrinsic and extrinsic 
pathway, which are mediated principally through 5-HT4 and 5-HT3 receptors 
respectively. The intrinsic pathway relates mainly to peristaltic reflexes, 
motility and secretory functions, whereas the extrinsic pathway relates to 
visceral sensation and nociceptive pathways[129]. Genetic polymorphisms in 
alpha2-adrenoceptor and the serotonin transporter (SERT) have been linked 
to different subtypes of IBS and as such perhaps give the strongest evidence 





A study of 230 patients with IBS and 430 healthy controls, found that there 
was a significantly lower frequency of the high producer interleukin 10 (IL-10) 
and tumour necrosis factor alpha (TNFα) genotypes (21% versus 32% (P = 
0.003)) in patients with IBS.[74] A further study confirms this result, reporting 
significantly more patients with IBS (9%) than controls (3%)(P = 0.035) with a 
high TNFα, low IL-10 genotype. Genetic polymorphisms in TNFα  and IL-10 
polymorphisms linked with IBS provide further evidence and may contribute 
to some of the disordered or exaggerated inflammatory to luminal antigens 
seen in IBS.[74, 132] 
 
 An ever increasing body of evidence seems to support the presence 
of several genetic factors implicated directly in the pathogenesis and/or 
susceptibility to the development of IBS. However, the degree of influence of 
these genetics components, although not clear, is likely to be modest and 
further large population based studies are required. 
 
1.4.3 Infection, Inflammation and mucosal injury. 
 
 The role of infection in the cause of PI-IBS has already been 
discussed and whilst there is some inconsistency in results from different 
populations and with different types of infection, it would appear that there is, 




IBS) in a sub-group of patients.  What is less clear is the role of enteric 
infections and commensal bacteria in the underlying pathophysiology of all 
IBS cases.  The development and maintenance of a functioning and 
immune-competent gut mucosa is dependent on the complex interactions 
between the luminal microbiome and the host, but this is discussed in more 
detail later.  
 
The host mucosal and immune-response to an enteric infection may 
result in changes that persist long after the original infection in IBS patients.  
In a prospective study by Spiller et al. serial rectal biopsies following infection 
with Campylobacter enteritis were performed in patients with PI-IBS and a 
healthy control group.  The PI-IBS group had significantly increased small 
intestinal permeability, higher numbers of enteroendocrine cells, 
intraepithelial lymphocytes and CD3, CD4 and CD8 within the lamina propria 
of the gastrointestinal mucosa than the healthy controls in the first three 
months after the infection and some changes persisted one year later.[80] A 
further study by Dunlop et al. also reported higher numbers of 
enterochromaffin cells and T-lymphocytes in patients three months after 
Campylobacter enteritis in patients who developed PI-IBS compared to those 
who did not have persisting symptoms.[73] Gwee et al. also noted 
significantly greater expression of the pro-inflammatory cytokine IL-1β three 
months after acute gastroenteritis in patients with PI-IBS than in normal 




in PI-IBS patients may also serve to drive the inflammatory response by 
exposing the intra- and sub-mucosal elements to luminal antigenic 
material.[80] Goral et al. identified higher serum levels of the pro-
inflammatory cytokine Il-2 and an increased number of mast cells in colonic 
biopsies in D-IBS compared to C-IBD and normal controls.[133] Han et al. 
have also shown that soluble factors taken from colonic biopsies of PI-IBS 
patients can activate peritoneal mast cells in vitro and significantly increase 
protein-activated receptor (PAR(2)) mRNA (a mediator of hyperalgesia) 
expression.[134] Genetic factors that influence the immune-inflammatory 
response to enteric infections are also likely to be important. Villani et al 
describe four specific genetic variants associated with PI- IBS, two located in 
TLR9 encoding for a ‘pattern recognition’ receptor; one at CDH1 encoding a 
tight junction protein and one in IL6 encoding a cytokine. IL-10 and TNFα 
polyporhisms are also both associated with IBS.[132]  
 
Pro-inflammatory genetic variants and persisting inflammatory 
mucosal changes in response to acute enteric infections in patients with IBS, 
certainly point towards an infective or inflammatory mediated disease in PI-
IBS. However, whether the mucosal injury and persisting inflammation is the 
result of a pre-existing abnormal pro-inflammatory state of the host or an 
infection mediated phenomenon is not clear. It has also been shown in 
animal models that inflicted stress by either early maternal separation or 




permeability.[135, 136] Furthermore, it is probably a reasonable assumption 
to state that all adults at some time in the past will have experienced at least 
one, and likely more, enteric infections.  
 
Therefore, in my opinion, even when a direct temporal relationship 
between the infective insult on the gut mucosa and the development of IBS 
symptoms is not evident, it would be wrong to conclude the IBS as non-
infective. It is entirely possible that accumulative previous infective enteric 
and perhaps even non-enteric events may be contributory in the 
pathogenesis of all IBS symptoms. Again the lack of animal models for IBS 
and scarcity of data in man hampers interpretation. 
 
1.5 Clinical Practice: Classification and Diagnosis   
     
 The importance of the initial consultation in the diagnosis cannot be 
overstated, as the lack of a specific diagnostic test(s) for IBS means that the 
skill of the physician in acquiring a comprehensive medical and psychosocial 
history together with a full physical examination is vital. Allowing sufficient 
time during the initial consultation to establishment a good rapport, obtain the 
history and explore the patient thoughts and ideas is equally as important 
and is perhaps the key to a successful working ‘doctor-patient’ relationship.  




considerable amount of time before seeking advice, or may even have had 
several unrewarding consultations or unsuccessful treatments in the past. 
Patients are further frustrated by the fact that many gastroenterologists and 
some general physicians are content to reach the diagnosis without providing 
much in the way of treatment as this is so often a laborious process. 
 
 
1.5.1  Clinical definition and classification  
 
In clinical practice the term ‘IBS’ if often loosely applied to any patient 
that has a functional gastro-intestinal disorder (FGID). Inappropriate and 
inaccurate application of the diagnosis ‘IBS’ may result in confusion for 
clinicians and patients alike and result in insufficient or ineffective treatment. 
The Rome Foundation was created in order to address this and other issues 
around the treatment/management and classification of FGIDs. The most 
recent Rome criteria (ROME III) were published in 2006.[4] For research 
purposes it is essential to use defined diagnostic criteria to ensure the 
validity and comparability of research findings. The most commonly used are 
the Rome II or Rome III criteria (Table 1).  Further classification of IBS based 
on predominant stool consistency according to the Bristol Stool Form Scale 
[137] results in four subtypes: C-IBS (constipation), D-IBS (diarrhoea),  M-







 The belief that IBS is a diagnosis of exclusion should be confined to 
the history books and yet, despite recent guidelines repeatedly emphasising 
the need for a positive clinical diagnosis, [138] up to 72% of non-expert 
clinicians compared to 8% of experts uphold the idea of a diagnosis of 
exclusion. [139] A clinician with an interest in IBS, who is knowledgeable 
about functional gastro-intestinal disorders, can be reasonably confident of 
making a diagnosis of IBS based on history and examination alone.  
However, in clinical practice it is usual to include some baseline non-invasive 
laboratory investigations to support the clinician’s diagnosis of IBS and 
exclude other disorders. These investigations should be limited to simple 
non-invasive laboratory based investigations which are sensitive for 
excluding organic intestinal disease. Invasive investigations including 
colonoscopy should be recommended only in the presence of ‘red flag’ 
symptoms, abnormal laboratory tests or if the clinician strongly suspects an 
alternative diagnosis.  
 
 Occasionally, it can be extremely difficult to reassure a patient about 
the absence of organic disease without undertaking a colonoscopy. In such 




most appropriate option, it should not be undertaken lightly and may increase 
patient anxieties about diagnostic uncertainty. Colonoscopy is not without 
well recognised clinical risks and particularly in  patients with IBS, as a result 
of the inherent visceral hypersensitivity, it can often be a very painful and 
unpleasant procedure. Furthermore, if an IBS patient experiences a painful 
colonoscopy and has psychological co-morbidities, it  may ultimately result in 
worsening psychological and physical symptoms as well as a worsening 
belief that something ‘more serious’ has been missed due to the pain 
experienced. If a colonoscopy is undertaken, it is essential that the patients’ 
expectations are managed appropriately and they are informed prior to the 
procedure that a normal result is expected. 
 
 The presenting history of IBS will vary considerably between cases, 
but to satisfy diagnostic criteria the symptoms need to have started at least  
two months previously and include abdominal pain/discomfort (a sensation 
that is not comfortable but falls short of pain) occurring on at least one day of 
each week (Rome III criteria: table 1). The abdominal discomfort/pain is 
associated with a change in the frequency and consistency of bowel 
movements and is relieved by defecation at least some of the time. The 
disordered bowel habit may change over time but commonly includes either 
or both diarrhoea and constipation in varying proportions. The symptoms of 
urgency of bowel movement (common in patients with ulcerative colitis); 




bloating; prominent gastro-colic reflex (sensation to defecate shortly after 
meals); increased flatulence and passage of mucus per rectum are all 
associated with IBS, but are not essential features nor are they sufficient 
alone to make a diagnosis. Extra-intestinal manifestations are also a frequent 
but non-essential feature in many patients and include; lethargy, poor 
concentration, poor appetite, anxiety, joint and muscular pain, headaches’ 
urinary symptoms, menstrual irregularity and difficulty sleeping.  
 
 The ‘red flag’ symptoms of passing blood per rectum, iron deficiency 
anaemia, weight loss and nocturnal bowel movements all raise the possibility 
of an alternative diagnosis including inflammatory bowel disease and gasto-
intestinal malignancy. 
 
1.6 Treatment options for IBS in clinical practice.  
 
 The currently available treatment for IBS is centred on symptom 
control. There is no conclusive evidence to suggest that if left untreated the 
symptoms of IBS will deteriorate and IBS alone is never directly fatal. 
However, the long term psychological effects of untreated IBS are not 
known. Furthermore, the long-term consequences of disordered gut 
physiology as well as repeated painful stimuli themselves, although not 




choosing a treatment for IBS with safety and side effects of any treatment 
arguably remaining the highest priority.[138] Many different treatments are 
available for IBS but the efficacy is limited and in some cases there is lack of 
proof to the efficacy by appropriately designed trials. In general, treatment 
strategies include conventional medicines, dietary manipulation, 
psychological therapy and alternative treatments. 
 
1.6.1 Dietary Treatments. 
 
1.6.1.1 Dietary Fibre Intake 
 
An increase in dietary fibre intake has frequently been advocated to improve 
the symptoms of IBS, (especially in constipation predominant IBS) but the 
evidence to support this is limited.  Fibre exists in two principle forms; soluble 
fibre (including psyllium (ispaghula) and pectins) and insoluble (bran and 
cereal husks). Insoluble fibre, is a chemically inert substance and passes 
through the GI tract largely unchanged, It retains water within the gut lumen 
by osmosis and in theory acts as a stool bulking agent. Soluble fibre 
dissolves in the luminal contents and provides a fermentation substrate that 
releases short chain fatty acids and gas to be used and as such may 





 The use of all types of dietary fibre is controversial but still advocated 
by many clinicians in the treatment of IBS. However, the evidence for this is 
limited and some studies suggest that it may even worsen symptoms.  
Francis et al., in a study of 100 consecutive IBS patients from their outpatient 
unit, found that 55% reported a worsening of all symptoms but especially 
bowel disturbance followed by distension and pain associated with bran 
supplements and only 10% found any improvement.[140] A systematic 
review of the use of psyllium in IBS patients identified twelve studies met 
their inclusion criteria, but that the methodology and study designs were 
heterogeneous. The results of the study were conflicting with only half 
showing improvement in global symptoms scores and one showing an 
improvement in pain. Quality of life and flatulence scores did not 
improve.[141] A second systematic-review including seventeen studies of 
both soluble an insoluble fibre found that fibre was efficacious in improving 
global symptoms in 60% of patients but not abdominal pain, which may be 
worsened in some patients and that overall there was no significant 
difference from placebo. [142] The authors of both studies concluded that 
there was insufficient evidence to support the recommendation of fibre as a 
treatment for IBS.[141, 142] 
 





 Food intolerance and food allergies are frequently self-reported with 
up to 20% of the general population [84] and 32-63% of IBS patients,[85, 86] 
reporting one or more food intolerances. However, in these studies there was 
significant disparity in self-reporting intolerances, the results of IgG allergy 
testing and response to elimination diets.[84-86] The principle of IgG testing 
in IBS patients is to establish the presence of the ‘true’ immune mediated 
allergic response to antigenic food components rather than a physiological 
intolerance as in lactose intolerance. In doing so it is hoped that IgG testing 
results will provide a basis for food elimination diets.   The use of elimination 
diets in the treatment of IBS is common in clinical practice; whether this is 
evidence based practice is not clear. Drisko et al. studied twenty patients 
who had not responded to conventional treatments for IBS with elimination 
diets based on the results of IgG food allergy testing and found significant 
improvement in abdominal pain, stool frequency and IBS-quality of life (QOL) 
scores.[143] A second study by Zat et al, of 25 patients with IBS, also found 
improvements in pain, bloating, bowel habit satisfaction and overall QOL 
after treatment, with elimination diets based on IgG food allergy testing.[144] 
However, both studies were small, non-randomised and did not include a 
placebo arm. 
 
 Lactose and fructose intolerance are one of the more common 




prevalence of fructose/lactose intolerance of 33% in both IBS patients and 
healthy controls, based on hydrogen/methane breath testing in response to 
an oral carbohydrate challenge. They also found that whilst the IBS patients 
were more likely to report symptoms associated with the food intolerance, 
only 47% had improvement in symptom compared to 77% of controls.[145] A 
second study by Goldstein et al. looked at combined lactose, fructose and 
sorbitol intolerance in 94 patients with IBS and 145 patients with IBS like 
symptoms, that did not fulfil the Rome criteria and found that 56% and 60% 
of patients reported symptom improvement on elimination of the offending 
sugar(s). [146] Again, neither study was randomised nor placebo controlled, 
in addition the method for diagnosing lactose/fructose intolerance is 
frequently criticised.   
 
 Wheat intolerance is also frequently encountered in IBS patients with 
one large systematic-review finding that patients who met diagnostic criteria 
for IBS were four times more likely to have biopsy proven coeliac 
disease.[87]  Such patients are effectively irrelevant in the context of 
treatment of IBS and have been wrongly diagnosed. However, those that 
remain (and who do not have coeliac disease) often appear to show some 
improvement on a wheat free diet. Wanschaffe et al. found that in D-IBS 
patients who were positive for coeliac IgG but not IgA antibody and thus not 
consistent with true coeliac disease; and had HLA-DQ2 expression, had 




negative (12%) on wheat exclusion diets.[88] Unsurprisingly, this study was 
not placebo controlled but does appear to demonstrate that response to 
wheat free diet can be predicted on the basis of serum parameters.  
 
 A randomised controlled trial in which 160 patients with IBS received 
either a ‘sham-diet’ or an elimination diet, based on the positive IgG 
responses to food allergy testing also reported a positive outcome. This 
study found that symptom improvement, rated by a global rating scale was 
10% higher in the ‘true’ diet compared to the ‘sham’ diet.[147] Whilst, this 
study did attempt to have a control/placebo arm by introducing the ‘sham’ 
diet, it was heavily criticised as the diets were markedly different; and the 
true diet, when compared to the ‘sham’ diet excluded substantially more 
foodstuffs that are  commonly reported as food intolerances in IBS patients. 
The level of reported IgG positive food allergy was also exceptionally high 
when compared to other studies. 
 
 Perhaps the most extreme elimination diet is the so-called low 
FODMAP diet (fermentable oligo- di- and monosaccharides and polyols) in 
which patients eliminate a large variety of different foods. The evidence for 
this diet is limited to a few studies, including the original study of 62 
consecutive non-randomised patients in a double-blind, placebo controlled, 




of patients who received fructose and fructans respectively reported that the 
symptoms were not adequately controlled.[148] The methodology of this 
study is extremely limited both by its size, lack of randomisation and 
crossover design. In addition, there is no discussion of whether a validated 
instrument is used to assess outcome measures and the result compares 
diet adherent and non-adherent patient outcomes. A recent study of 82 
patients in a UK institution comparing low FODMAP with standard dietetic 
therapy diet reported a significant improvement in composite symptoms 
scores of 86% vs. 49% respectively (P = <0.001) and satisfaction with 
symptom improvement 76% vs. 54% (P = 0.038).[92] This study compares 
retrospective data on standard dietary therapy with data from patients 
prospectively treated with low FODMAP diet and whilst it demonstrates 
superiority over standard therapy the study design has significant 
methodological limitations. The study was not blinded or randomised; 
contained no placebo or sham arm, combined retrospective and prospective 
data, the outcome measure was not validated and the research group failed 
to classify IBS patients according to any recognised classification. The 
results must therefore be viewed with marked caution. 
 
 Dieticians frequently play a major role in the treatment of patients with 
IBS and are usually a member the clinical multi-disciplinary team for patients 
with IBS. Whilst their role in IBS treatment is clinically important, the 




inherent methodological limitations of dietary interventional studies make it 
difficult to come to any firm conclusions about diet as a treatment for IBS.  
However, the same can also be said about many other commonly used 
interventions in IBS, many of which lack conclusive evidence of efficacy.  
 
1.6.2 Conventional medicines for the treatment of IBS. 
 
 There are a multitude of available conventional medications available 
as both ‘over the counter’ remedies and those that require a medical 
prescription. The evidence of efficacy for individual medications is often 
variable and for some agents the side effect profile may limit the use in a 
substantial number of patients. The following section reviews the evidence 
for medical therapies commonly used but is not intended to be an exhaustive 











 Antispasmodic medications are commonly used in both primary and 
secondary care for the treatment of IBS and as such have remained one of 
the key prescribed medications for some time.  Those available in the United 
Kingdom (UK) include alverine, dicyloverine, mebeverine, peppermint oil and 
hyoscine butylbromide (a scopolamine derivative). Other antispasmodics not 
available or not licensed for the treatment of IBS in the UK include pinavrium, 
pirenzepine, propinox and trimebutine. 
 
 Mebeverine, arguably the most commonly prescribed antispasmodic 
in the UK has not been shown to be efficacious in the improvement of global 
symptom severity in patients with IBS.  Kruis et al. in an RCT of 80 patients 
did not show any difference in improvement in global symptom severity score 
of mebeverine over placebo, (RR 0.83; 85% CI: 0.31 to 2.23). [149] 
Moreover, a recent meta-analysis with a total of 555 patients did not find any 
benefit of mebeverine over placebo in controlling global symptom severity 
(RR 1.13 95% CI: 0.59-2.16, P = 0.71).[150] A further study of 712 IBS 
patients using hyoscine butylbromide and hyoscine butylbromide in 
combination with paracetamol demonstrated superiority in both arms over 
placebo.[151] A systematic review of the use of smooth muscle relaxants in 
IBS which included 23 studies and 1888 patients in total, concluded that they 
were superior to placebo in the treatment of IBS (OR 1.65; 95% CI: 1.30-




using several different smooth muscle relaxants/antispasmodics and 
therefore the results may not be applicable to the individual drugs.  Lastly, it 
is important to consider that side effects, whilst usually not severe, are not 
uncommon in patients using these medications which in the context of 




 The role and mechanisms of action of anti-depressants and drugs that 
act via serotonin pathways in the treatment of IBS is complex.  Anti-
depressants are frequently used in clinical practice and have been shown to 
be useful in the management of IBS and other chronic pain conditions via 
their peripheral neuromodulatory and analgesic as well as central effects on 
pain modulation and perception.[153-156] There is evidence from clinical 
trials for the use of individual agents including imipramine (desipramine) 
amitriptyline, paroxetine, fluoxetine and citalopram for the treatment of IBS. 
 
 Rajagopalan et al. in 1998 studied 40 patients with IBS, defined by the 
Rome criteria, in a randomised controlled trial of placebo versus 
amytriptylline (at incremental doses of 25mg for one week, 50mg for one 
week and 75mg thereafter for twelve weeks). 22 patients completed the 




scores at twelve weeks in the treatment group (63.6%) compared to placebo 
(25.9%).[157] Greenbaum et al. studied 41 patients with a clinical but 
unclassified (no diagnostic criteria given) IBS in a double blind crossover 
study with desipramine, atropine and placebo. 28 patients completed three, 
six week periods of treatment and reported a significant improvement in the 
global symptom severity score during treatment with desipramine.[158]  Both 
studies have significant methodological limitations and do not use 
standardised outcomes measures, although these were unlikely to be 
available at the time the studies were conducted. Both studies suffer from 
high dropout rates with little explanation as to the reasons and subsequent 
exclusion of these patients from the efficacy analysis, as was standard 
practice at the time. These methodological limitations and the sizes of the 
studies significantly limit the application and validity of the results. A later 
randomised, double-blind study of  imipramine versus placebo by Abdul-Baki 
et al. included 107 Rome II, IBS patients but significant drop outs during the 
sixteen week study resulted in only 56 (31 treatment, 25 placebo) completing 
the study. The study was closed early and only a retrospective ad-hoc power 
calculation was performed. Patients on imipramine showed a greater 
improvement in both QOL and symptoms severity scores but failed to reach 
significance, perhaps due to the very high dropout rate in both the placebo 
and treatment group and the small study cohort. [159]  Vahedi et al. 
undertook a study of amitriptyline in 54 patients with D-IBS showing a 




versus placebo (28%)(p = 0.001) but did not use a validated outcome 
measure and simply relied on binary outcomes to symptom reporting.[160]  
 
 A double blind placebo controlled crossover trial of 23 patients 
demonstrated superiority of citalopram over placebo in global symptom 
score, abdominal pain, and severity of impact of symptoms on daily life, (P < 
0.05)[161] but has been criticised for its size of cohort and crossover design . 
A further study of citalopram versus imipramine and placebo in 51 patients 
failed to show superiority of either citalopram or imipramine over placebo in 
improvement in global symptom severity score, but did show an 
improvement in severity of interference of symptoms(P = 0.05), distress (P = 
0.02) for imipramine. [162] 
 
 Several meta-analysis of tricyclic antidepressants have also been 
conducted. One identifies seven eligible randomised control trials, including 
some of the aforementioned studies, of reasonable quality. It reports a 
pooled relative risk (RR) of 1.93 for an improvement in symptoms with tri-
cyclic antidepressants compared to placebo (p <0.0001)[163]. A further 
systemic review and meta-analysis including nine RCTs for tri-cyclic anti-
depressants and five for serotonin re-uptake inhibitors (SSRIs) found an RR 




0.006) respectively and an overall effect RR of 0.66 (CI: 0.57 – 0.78)(p < 
0.00001) favouring treatment with anti-depressants. [164] 
 
 Whilst the results of some of the trials for anti-depressant usage in 
IBS are conflicting and often the size of said studies methodologies are 
limiting; the meta-analyses are favourable and in clinical practice they are 
often used to reasonably good effect. However, the side effects of 
drowsiness, sleep disturbance, daytime somnolence, increased anxiety and 
reduced concentration are not infrequent. Whilst these side effects often 
reduce after a short time period, in practice they often limit the tolerability and 
acceptability of the treatment. 
 
1.6.2.3 Serotonin receptor agonists and antagonists. 
 
 Serotonin has a key role in the physiological mechanisms over and 
above those related to pain and visceral hypersensitivity.  As a result the 
5HT3 and 5HT4 have been utilised as therapeutic targets for the treatment of 
IBS.  The 5HT4 agonist tergaserod was shown to be superior to placebo in 
several clinical trials at improving abdominal pain and global symptom 
severity in patients with C-IBS, but not quality of life.[165, 166] A subsequent 
systematic review of 11RCTS including 9242 subjects also concluded that it 




it was withdrawn because of concerns over increased risk of ischaemic 
cerebrovascular, cardiovascular events and severe diarrhoea. 
 
 The 5HT3 agonist, Alosetron has been evaluated in several studies 
and shown to be efficacious in treating some symptoms of IBS. A systematic 
review of the data, including eight RCTS and a total of 4987 patients 
comparing Alosetron with placebo concluded that it may be effective in 
controlling abdominal pain and improving global symptom severity (RR 0.79 
95% CI: 0.69 – 0.90; P < 0.00001). [167] However, it is also of note that two 
of the included studies only evaluated D-IBS and four included cohorts with 
at least 70% D-IBS. Furthermore, five excluded males and  two included 
predominantly females without excluding males. The results are therefore 
only applicable to D-IBS in females. There have also been concerns about 
the association of Alosetron with ischaemic colitis and severe constipation 
which previously led to its withdrawal although it has now been re-





 Abdominal pain is widely accepted as one of the principle symptoms 




patient consultation. [168] The role of both localised mucosal injury and 
inflammatory mediators and centrally mediated changes in pain perception in 
IBS has been discussed previously. In common with other chronic conditions 
in which pain is a significant feature such as osteoarthritis, it is important to 
consider the effects and side effects of both centrally and peripherally acting 
analgesic agents. Whilst many medications including antidepressants and 
anti-spasmodics may have an effect on pain they are not considered 
analgesics and are discussed separately. 
 
 Despite the fact that centrally and locally acting analgesics are 
frequently used in the management of patients with IBS, the evidence of 
efficacy is limited.  Pregabalin has been shown to increase sensation 
thresholds in IBS patients with rectal hypersensitivity [169].  Asimadoline, a 
kappa-opioid agonist was also shown to improve pain in patients with IBS-D, 
but only in the overall cohort of IBS patients studied[170].  As such further 
evaluation is required and this compound is not currently used in clinical 
practice. Centrally acting opioid analgesia is often prescribed for pain in IBS 
with codeine, tramadol and morphine salts all used with little if any evidence 
of safety or efficacy in this patient group.  The narcotic induced bowel 
syndrome, an under-diagnosed condition of increasing functional abdominal 
pain, as a result of inappropriate long-term opiate analgesia in patients with 
IBS remains a potential significant entity that clinicians need to be mindful of 




in some studies the long term use of analgesics have been associated with 
an increased risk of IBS, but this is complicated by the increased incidence 
of somatic pain also associated with the condition. [172]  
  
1.6.2.5 Other conventional medicines used in the treatment of IBS.  
 
 Two further drugs have recently been evaluated for efficacy in the 
treatment of IBS- C.  
 
 Linaclotide is a 14 amino acid, minimally absorbed peptide guanylate 
cyclase-C agonist that works by activation of the cystic fibrosis 
transmembrane conductance regulator to stimulate chloride secretion and 
thus increases gastrointestinal fluid secretion and colonic transit. Chey et al. 
in a study of 804 patients with IBS-C reported a responder rate of 33.7% vs. 
13.9%  
(p = <0.0001) in the treatment and placebo groups respectively. [173] A 
responder was defined in accordance with the FDA, (Federal Drug 
Administration, USA) as a patient with an improvement of ≥ 30% from 
baseline in the average of worst daily abdominal pain score and an increase 
of ≥1 complete spontaneous bowel movement from baseline per week. A 




patients with IBS-C using the same FDA approved outcome measure 
showed a pooled RR of 1.95 and NNT of 7. [174]  
 
 Lubiprostone is an orally active prostone that stimulates type-2 
chloride channels (CIC-2) also increasing luminal fluid secretion and colonic 
transit.  Drossman et al. in a combined analysis of two randomised controlled 
trials of lubiprostone with a total patient number of 1174 using the same FDA 
primary end-point reported a 17.9% vs. 10.1% (p = 0.001) in the treatment 
and placebo groups respectively. [175] 
 
 
1.6.2.6 Antibiotics in the treatment of IBS.  
 
 The use of non-absorbable antibiotics in the treatment of IBS perhaps 
remains controversial.  Several different systemic antibiotics were previously 
trialled including oxytetracycline and metronidazole, but the unwanted 
systemic affects and side effects have limited there use.  Neomycin, and 
more recently rifaximin, are a more favourable option as they both are non-
absorbable and as such should be less likely to produce any unwanted 
systemic effects.  Pimental et al. found that  neomycin in a randomised, 
double-blind controlled trial of 111 patients with IBS was significantly more 




and at normalising bowel habit, 35.3% vs. 13.9% (p = <0.001) than 
placebo.[176] However, it must be noted that 84% of patients in this study 
had positive lactulose breath tests (LBT) and that normalisation of the LBT 
after treatment predicted the clinical response in 75% of patients, hence 
these patients may have simply had SIBO without IBS and that treatment of 
the SIBO resulted in the symptom improvement. In a further study by Yang et 
al. they also found that normalisation of abnormal baseline LBT predicted 
clinical response in patients treated with rifaximin. They also found that 
repeated treatments with rifaximin remained efficacious whereas retreatment 
with neomycin was only effective in 25% of cases. 
 
A further, landmark study by Pimental et al. of 1260 IBS patients treated with 
fourteen days of oral rifaximin versus placebo reported significant 
improvement in daily symptom severity (40.7% vs. 31.7%, p = <0.001), 
bloating (40.2% vs. 30.3%, p = <0.001) and average daily symptom scores 
(40.2% vs. 29.9%, p = <0.001). [177] However, whilst this study appears 
robust it does not report the frequency of abnormal baseline LBT or whether 
its normalisation predicts outcome. Although this could quite conceivably be 
a difference in study protocol, the principle author has utilised this argument 
for the presence of SIBO and improvement in LBT as a predictor of response 







1.6.3 Psychological therapies in the treatment of IBS. 
 
 Multiple different psychological therapies are proposed as efficacious 
in IBS including psychoeducational support, mindfulness therapy and 
cognitive behavioural therapy (CBT). Of these the most widely used and 
researched is CBT which can take the form of a one-to-one clinician or nurse 
therapy, group therapy, distance or self-directed therapy. The cognitive 
behavioural model is based on the concept that events, emotions, thoughts, 
actions and physiological responses are all interlinked and in relation to IBS, 
the thoughts and interpretation of internal sensations and external events are 
of particular importance.  The idea that ‘this unpleasant sensation must mean 
that something is wrong’ is thus interpreted as a potential threat leading to 
increased physical arousal anxiety and awareness of bodily sensations, 
which ultimately result in the original discomfort being experienced as more 
noxious and severe. [178] Multiple studies, of various design and quality 
report improvements in both physical symptoms and general well-being as a 
result of CBT, but as with other studies of medical interventions in IBS they 
suffer from significant methodological limitations. [179-183] However, a 
meta-analysis by Lachner et al including seventeen controlled studies 






1.6.4 Complementary medicine in the treatment of IBS. 
 
 A variety of alternative therapies are used for the treatment of patients 
with IBS including acupuncture, acupressure, ocular acupressure, various 
massage therapies, colonic irrigation, herbal medicine, Chinese herbal 
medicine, homeopathy and hypnotherapy.  The evidence base for alternative 
medicines in the treatment of IBS is extremely limited. Both acupuncture and 
hypnotherapy have been the subject of Cochrane reviews and in both cases 
the reviewers concluded that there were insufficient studies of acceptable 
quality to draw any conclusions.[184, 185]  Often, in clinical practice, patients 
report beneficial effects of a variety of alternative and complementary 
treatments but this may simply reflect a placebo response. The relative lack 
of efficacious conventional treatment may result in desperation in some 
patients who are ‘willing to try anything’ and ultimately, sometimes in 
desperation, turn to alternative/complementary treatments. Whilst, the vast 
majority of complementary treatments involve no risk to the patient, 
reasonable caution should be recommended with any ingested or invasive 
procedures. Conventional medicine endeavours to practice evidence based 
medicine but this is sometimes not the case. It may not be considered 




complementary therapies but to disregard or undermine them with a lack of 
an efficacious conventional alternative may do patients a disservice.  
 
 It is not the intention of the author to give a comprehensive or 
exhaustive review of differing treatment modalities and the associated 
evidence of efficacy for them and this does not fall within the scope of this 
thesis. It is worth noting that a large proportion of the clinical studies for IBS 
treatments are limited not only by the heterogeneity of the condition itself but 
also the lack of use or availability of standardised or validated instruments or 
measures of outcome. In addition, this lack of good scientific practice and 
methodological approach serves only to compound these problems. The vast 
majority of therapies available either lack sufficient efficacy or have too 






Table 1: Diagnostic classification systems for the diagnosis of IBS. 
i, Manning Criteria 
Increased frequency of defecation with the onset of pain 
Stools more ‘loose’ with the onset of pain 
Abdominal pain eased by defecation 
Abdominal Distension 
Passage of Mucus 
Feeling of incomplete evacuation 
 
ii, Rome I Criteria 
Minimum of 3 months continuous or recurrent symptoms: 
Abdominal pain/discomfort* which is: 
Relieved by defecation (and/or) 
Associated with a change in stool frequency  and/or consistency 
And 2 or more of the following (occurring at least 1 day in 4 on average) 
Altered stool frequency 
Altered stool consistency (lumpy/hard/watery/mushy/loose) 
Difficulty defecating (straining/urgency or feeling of incomplete 
evacuation) 











iii, Rome II Criteria 
12 weeks or greater of abdominal pain/discomfort* in the last 12 
months 
(does not need to be consecutive) 
and 2 of the following: 
Pain/discomfort  relieved by defecation 
Onset of pain/discomfort* associated with change in stool frequency 
Onset of pain/discomfort* associated with a change in consistency of 
stool 
Other symptoms not required but supportive of a diagnosis of IBS 
Abnormal frequency of stool 
Abnormal stool consistency (lumpy/hard/mushy/loose/watery) 
Difficulty passing stool (straining/urgency or feeling of incomplete 
evacuation 
Passage of mucus 
Abdominal bloating/distension 
 
iv, Rome III Criteria 
3 months or greater of abdominal pain/discomfort in the last 6 months 
(does not need to be consecutive) 
 Associated with 2 or more of the following for at least 25% of the time: 
Pain/discomfort*  relieved by defecation 
Onset of pain/discomfort *associated with change in stool frequency 
Onset of pain/discomfort* associated with a change in consistency of 
stool 
No Evidence of any inflammatory anatomic, metabolic or neoplastic 
process that explains the symptoms  
*’discomfort’ is defined as an uncomfortable sensation not described as pain 
Description of the various diagnostic classification systems used in the idetifiaction 
and diagnosis of patients with IBS. (adapted from): Adapted with permission for 
reuse from; Saito et al. 2003 [12] and Romecriteria.org 









IBS – C 
(constipation) 
Hard or lumpy stools > 25% of the time and 
Loose (mushy) or watery stools < 25% of the time 
IBS – D 
(diarrhoea) 
Loose (mushy) or watery stools > 25% of the time and 
Hard or lumpy stools < 25% of the time 
IBS –M 
(mixed) 
Hard or lumpy stools > 25% of the time and 
Loose (mushy) or watery stools > 25% of the time  
IBS – U 
(un-subtyped) 
Insufficient abnormality of stool consistency to meet the 
criteria for IBS- C/D/M 
 
In the absence of anti-diarrheals or laxatives. 
 
Hard or lumpy stools: Bristol Stool Form Scale 1-2 
Loose (mushy) or watery stools: Bristol Stool Form Scale 6-7 
 
Description of IBS subtype classification according to predominant stool type. 























Gwee KA et al [22] 
2004 (1998-
2002) 
Face-to-face survey of random 








Hillila MT et al [8] 2004 (2001) Postal Survey (Finland) 









Wilson S et al [15] 2004 
Postal survey of patients from 
group 4 local GP practices (UK) 
Rome II 4807/8386 (57.3%) 2.1:1 10.5 




Internet/ e-survey of general 
population sample (USA) 
Rome II 25986/31829 (82%) 1:1.8 6.6 
Okeke EN et al [24] 2005 
Questionnaire to sample of 
university students (abstract 
only) (Nigeria) 
Rome II 330 1:1.8 26.1 
Vandvik PO et al 
[25] 
2006 (2001) 
Questionnaire administered to 
sample of general population at 
local mobile unit and by post 
(Norway 
Rome II 4622/11078 (42%) 1:1.9 8.4 
Sherber AD et al 
[34] 






























Questionnaire from a primary 
care clinician for ’non-patients’ 
attending a community hospital 
(Greece) 
Rome II 2397/3112 (67.1%) 1:3 15.7 
Perveen I et al [27] 
2009 
(2004/5) 
Door step survey of  general 
population sample (Bangladesh) 
Rome II 1503/- (97.2%) 1:1.36 7.7 
Valerio-Urena J et al 
[29] 
2010 
Face-to-face interview of 
random general population 
sample (Mexico) 
Rome II 459 1:2.5 16.9 




of general population sample 
(completed at home or in 






et al [32] 
2011 (2004) Postal Survey (Iran) Rome II 1978/3600 (54.9%) 1:1.7 10.9 
Gulewitsch MD et al 
[31] 
2011 (2009) 
Internet/ e-survey of university 
students (Germany) 
Rome III 2196/2399 (91.6%) 1:1.4 19.4 
Makharia GK [33] 
2011 
(2008/9) 
Door to door Survey (India) Rome III 4767 1:1.5 4 
Dong YY et al [28] 2010 (2009) Survey of university students 
(North China) 
Rome III 2126/2500 (85%) 1:1.8 7.9 
Nam et al [29] 2010 (2007) Questionnaire given to 
participants in health screening 
programme (Korea) 





















Valerio-Urena J et al 
[29] 
2010 Face-to-face interview of 
random general population 
sample (Mexico) 
Rome II 459 1:2.5 16.9 
Zhao Y et al [30] 2010 
(2007/8) 
Self-administered questionnaire 
of general population sample 
(completed at home or in 
regional office) (China) 




et al [32] 
2011 (2004) Postal Survey (Iran) Rome II 1978/3600 (54.9%) 1:1.7 10.9 
Gulewitsch MD et al 
[31] 
2011 (2009) Internet/ e-survey of university 
students (Germany) 
Rome III 2196/2399 (91.6%) 1:1.4 19.4 
Makharia GK [33] 2011 
(2008/9) 
Door to door Survey (India) Rome III 4767 1:1.5 4 
 
 
Summary of previous studies of prevalence of IBS in different population groups. Specific information given about methodology 















The Intestinal mucosa, luminal microbiota, 






2.1  The intestinal mucosa 
 The human gut has a mucosa that is comprised of a variety of 
different cellular and non-cellular components  with a surface area that is 
approximately 400 m2.[186] In its simplest form it can be considered a simple 
physical barrier between the gut lumen and the host.  However, this 
oversimplified description fails woefully to do justice the complex integrated 
functions of both the gastrointestinal mucosa and its interaction with the 
luminal contents.  Whilst the mucosa itself acts as a physical barrier it must 
also facilitate the passive and active transfer for nutrients from the luminal 
contents to the host. In addition it has a vital role in the prevention of 
microbial invasion and the development of immunocompetance and 
tolerance. [187-189]  
 
The mucosa itself consists of a single layer of columnar cells whose 
apical surface are covered in microvilli and a glycocalyx mucous layer which 
together form the ‘brush border’.[186]  Interspersed between the columnar 
cells are follicle associated epithelium (FAE), a highly specialise epithelium  
which plays a key role in the mucosal immune function.[190] The FAE is 
found overlying areas of the mucosa associated lymphoid tissue (MALT) 
throughout the GI tract.[190] The FAE and Peyer’s patches contain important 
antigen presenting cells including M-cells and immunoregulatory cells and 
phagocytic cells. [190] Within the mucosa itself intra-epithelial lymphocytes 




terminally differentiated B-cells, T-cells and dendritic cells.[191]  In certain 
areas of the distal small bowel, where the luminal content contains high 
numbers of micro-organisms, the FAE is found in more organised structures 
caller ‘Peyer’s patches’. Together the FAE, MALT, Peyer’s patches, lymphoid 
follicles, intra-epithelial lymphocytes, mesenteric lymph nodes and lamina 
propria contain the largest aggregation of immune-competent immune cells 
within the human body, and is collectively known as the gut associated 
lymphoid tissue (GALT).[191, 192] 
 
 The antigen presenting phagocytic and immunoregulatory cells of the 
mucosal immune system allow the production of a rapid, selective and potent 
immune response to the threat of invasion by harmful pathogenic bacteria 
from within the gut lumen.[190, 193] These complex interactions also serve 
to develop the ability of the immune system to differentiate between harmful 
and commensal bacteria, nutrients and food antigens. In addition, the 
interactions between T-cells and MHC-II expressing antigen presenting cells, 
leads to modulation of particular anti-inflammatory pathways to down 
regulate the immune response and favour tolerance. [194]These processes 
are vital so that the powerful immunogenicity to harmful microbiota does not 
result in inappropriate immune activation to commensal bacteria or food 
antigens. [187, 193] The symbiosis that results between the host and the 
luminal microbiota as well as being regulated by a complex network of 




host factors including age, antibiotic use, established immune competency 
and the gut flora itself. [195] Throughout the life of the host, the commensal 
bacteria of the bowel are involved in instructing the immune system and are 
ultimately responsible for the presence of inflammatory and immune cells 
within the healthy gut. This so-called physiological, or controlled 
inflammation,  refers to the described presence of inflammatory and immune 
cells within the mucosa and sub-mucosa of the gastrointestinal tract, 
reflecting the degree of mucosal immune accommodation that is a 
requirement to normal, healthy gut function.[196] At the same time it must 
also be noted that the healthy commensal bacteria, whilst living in symbiosis 
with the host when contained with the gut lumen, can if they gain access to 
another body cavity (e.g by perforation of the viscera or by entry into the 
vascular compartment) become potentially fatal to the host. 
 
2.2 The intestinal microbiota and its role in the development and 
function of the gastro-intestinal tract. 
 
The human gastrointestinal microbiota is a complex ecosystem; 
containing between 300-500 different known species of microorganism [197] 
and likely many more uncharacterised or unknown species, more than ten 
times the number of eukaryotic cells of the host[198] and makes up 




intestinal microbiota is technically difficult with between 40 and 80% of the 
observed microbial count being unrecoverable through conventional culture 
techniques.[200, 201] In addition, differing regions of the GI tract have 
markedly different environmental conditions resulting in differing microbial 
populations and as such stool cultures may only reflect the microbial 
population of the very distal colon and rectum. Recent advanced gene 
amplification techniques using 16s rRNA and rDNA sequences are 
increasingly used to investigate the composition of the human microbiota. 
These techniques have shown that there are at least 82 different microbial 
species and 284 individual clones present in the adult-male faecal sample. 
Furthermore, of the 284 clones identified 76% did not correspond to genetic 
sequences available in public library resources and are potentially hitherto 
unknown species, that may be unique to the human intestinal microbiome. 
[200]  
 
The gastro-intestinal microbiota are not simply the fortunate 
beneficiaries of the complex and tolerant mucosal immune system of the 
host, but rather an integral part of the development and function of the  
mucosa, physiology and immune system of the human gut. Evidence for 
these interactions and the role of the microbiota in normal gut function and 
disease, comes from work in animal models and particularly work in germ-




Germ-free rodents are instrumental in our understanding of mucosal 
microbibiota interaction.  However they seem to have an enlarged caecum 
which resolves on the introduction of normal commensal flora suggesting 
that the gut microbiota influence the motility of the large bowel. [202] Further 
evidence of the role of the microbiome in gut motility is suggested  by the 
failure of differentiation of the serotonin (5-HT, 5 hydroxytryptamine) 
secreting enteroendocrine cells of the bowel in a germ-free environment, 
leading to reduced colonic motility.[203, 204] This abnormal motility is likely 
to be a result of these and perhaps other yet unknown factors.   Short chain 
fatty acids (SCFA) are produced as a result of microbial fermentation and are 
essential for the proliferation and differentiation of gut epithelial cells.[205, 
206] In germ-free mice, the absence of the trophic effect of the SCFAs leads 
to a decreased turnover of cells with the mucosal crypts and less total 
number of crypts.[205] There is also evidence to suggest that these SCFAs 
are also the principle source of energy for the colonic enterocytes and thus 
the microbial fermentation is essential for the absorption of water, sodium 
and other essential minerals including calcium and magnesium.[207, 208] 
Further potential support for the importance of the microbiota in nutrition is 
seen in the clinical phenonoma of the development of a mild coagulopathy, 
that can result from the use of broad spectrum antibiotics suggesting the 
importance of bacterial synthesis of vitamin K2 (menaquinone).[209]  
The role of the gut microbiota in the development of the host immune 




between these microorganisms and the gut immune cells are essential in the 
development of both immune competence, memory and tolerance of the 
complicated immunoregulatory systems of the gut.[210] In germ free rodents 
the GALT is developmentally deficient. However, this can be reversed by 
early introduction of microbes into the gut lumen in the neonatal period, but 
not in adult life.[210]   The microbiota continue to interact both local and 
systemically with the host immune system and can lead to both an 
immunoregulatory effect, resulting in inflammation refractory states, or 
propagate an immune response’ resulting in an exaggerated immune 
response.[211]  Some species of luminal commensal bacteria, such as 
lactobacillus acidophyllus, are also known to directly  inhibit the adhesion of 
pathogenic bacteria such as salmonella Typhimurium and Escherica 
coli.[212] The interactions of the microbiota within the host immune system 
promote an immune-tolerance that provides a considerable advantage to the 
micro-organism in a food rich environment with optimal living conditions.  In 
addition, they can have a more direct influence on the luminal environment, 
with some organisms producing enyzmes that regulate the production of 
essential  nutrients by the host enterocytes and in so doing so produce an 







2.3 The Role of intestinal microbiota in pathogenesis of IBS and 
other disease. 
 
 The scale and complexity of interactions of the commensal and 
pathogenic microbiota of the human GI tract and the mucosa and immune 
system of the host alone, would implicate the potential for their involvement 
in the development of disease of GI tract.   The role of the gut microbiota in 
IBD is not fully established, however, in experimental genetic models of 
inflammatory disease colonisation of the gut lumen is required for the 
experimental colitis to develop.[214] Human studies show differences in the 
composition of the gut microbiome in patients with active ulcerative colitis 
and active and inactive Crohn’s disease when compared to controls.[215] 
The importance of this finding and the nature of the relationship (cause or 
effect) however is yet unclear. Furthermore, the microbiota of relatives of 
Crohn’s patients has also been shown to be different from controls.[216] In 
paediatric coeliac disease there is again a differing profile of gut bacteria 
compared to normal subjects.[217]The role of the gut microbiota in disease 
pathogenesis is not limited to those that affect the GI tract.   
 
In experimental autoimmune encephalomyelitis, the animal model of 
multiple sclerosis, the gut microbiota are important in the disease induction 




responses.[218] In neonates, differences in the gut microbiota and 
colonisation with Bacteriodes fragilis correlates with a high asthma predictive 
index and the development of asthma and atopy.[219] In non-alcoholic fatty 
liver disease, (NAFLD)  small bowel bacterial overgrowth with gram negative 
organisms in animal models is linked to increased endogenous alcohol 
production, choline deficiency and insulin resistance, all factors that have 
been implicated in its pathogenesis. The potential of specific functions of the 
gut microbiome in the development and pathogenesis of various diseases is 
keenly explored but its discussion is outside the scope of this thesis.  
 
Knowledge of the pathogenic mechanisms that lead to the 
development of IBS is still expanding, but it is becoming clear that the gut 
microbiota potentially are a key player in its development and in the on-going 
temporal variability of symptoms.  Key quantitative and qualitative differences 
in the gut microbiome of IBS patients have been demonstrated using gene 
cloning and sequencing techniques.  The faecal microbiota of patients with 
IBS has been shown both to differ from that of healthy controls [220, 221] 
and to have an increased temporal instability.[221] Specific differences in the 
predominant species of commensal microorganisms in  IBS patients is 
reported, but the importance is not clearly understood and some of the 
results are conflicting with both increased [222] and decreased [223] 
microbiotal diversity reported.  Increased numbers of firmicutes and 




and faecalibacterium groups are reported.[223]  Lower levels of Lactobacilli 
sp. are found in IBS-D,[224] and differences in the proportions of the 
predominant Clostridium coccoides –E rectal species in both IBS-D and IBS-
C.[221] Further differences with decreased levels of clostiridum coccoides 
and bifidobacterium catenulatum group together with increased levels of 
ruminococcus productus-C coccoides in all IBS sub-groups has also been 
described.[224] Many other observed differences have been noted but the 
relevance of these findings has not been established.  
 
 Small intestinal bacterial overgrowth (SIBO) has been long 
proposed as a potential pathological mechanism for IBS but this remains 
controversial.  Hydrogen and methane gases are both a bi-product of 
bacterial fermentation and higher levels of these are reported in patients with 
IBS. [225] In research and clinical practice the hydrogen breath test using 
either lactulose or sucrose as an orally delivered substrate are used to 
diagnose SIBO. However, whilst some authors report high levels of up to 
78% of SIBO prevalence within IBS patient cohorts, [226] others report no 
significant difference in SIBO between IBS patients and healthy controls. 
[227] Further support for the SIBO hypothesis is levied at the improvement 
seen in IBS symptoms in trials using broad spectrum non-absorbable 
antibiotics, [176, 177, 226] although much of this work comes from the same 
research group and again has been criticised for its methodology.  The 




colonic bacteria is fairly universally accepted, but the presence of SIBO in 
the context of IBS continues to split opinion.   
 
 The effects of bacterial fermentation on the gut motility and the 
potential role for abnormal fermentation patterns in IBS patients, can be 
understood when the utility of the products of bacterial fermentation are 
considered.  In the human colon a large quantity of unabsorbed carbohydrate 
is delivered to the large colon where it is fermented by the luminal bacteria to 
yield SCFAs. The SCFAs are utilised as the main source of energy for 
colonocytes and are absorbed by both non-ionic diffusion and by active 
transport, mediated through a sodium coupled transporter leading to active 
sodium and water influx.[207, 228] In addition the SCFAs provide the energy 
source for sodium absorption via the sodium-proton exchange. [207] 
Changes in the gut microbiota may lead to decreased production of SCFAs 
and loss of this stimulatory effect coupled with the osmotic effect of 
increased non-absorbed carbohydrate in the gut lumen can result in 
significant diarrhoea.[229] Patients with IBS-D have a different composition 
of colonic SCFAs, with relatively higher levels of n-butyrate and less acetate 
as a result of differing colonic bacteria.[207] Specific overgrowth of 
methanogenic bacteria in the colon is exclusively associated with IBS-C and 
it seems like the methane itself may have a direct effect on gut motility.[230] 




factor and reduced numbers of these bacteria in IBS patients may result in 
some of the observed abnormal gas handling.[225] 
 
 It is proposed that the pathogenesis of IBS may result from exposure 
to differing microbiotal pools in early childhood and in particular the relative 
lack of exposure to pathogenic gut bacteria. [45] The ‘hygiene hypothesis’ is 
certainly plausible given the complex interactions between the gut 
microbiome and the host.  
The development and employment of new gene sequencing techniques is  
rapidly expanding the available knowledge of the gut microbiota and will 
undoubtedly lead to a greater understanding of its role in the development, 
function and disease of the human GI tract. 
 
2.4 Probiotics in the treatment of IBS 
2.4.1 Mechanisms of action of probiotics 
 
 The importance of the gut microbiome in the development and 
maintenance of normal gut physiology, motility, immune-tolerance and 
competence has already been established. The probiotic concept differs in 
that it refers to the utilisation of specific strains of microorganism and their 




function, prevent or treat disease, alleviate symptoms or restore normal 
function.  
 It is widely accepted that the first observations of the positive health 
benefits of live microorganisms were made by Professor Élie Metchnikoff; a 
Russian scientist working at the Pasteur Institute who went to on to become 
the Nobel Laureate. He observed that the fermented milk products 
consumed in rural communities in Bulgaria contained lactic acid producing 
bacteria that may contribute to the extended life expectancy of those 
communities in which they were consumed. [231] This microorganism later 
became known as Bulgarian bacillus and ultimately lactobacillus bulgaricus 
sp. and is perhaps the first documented probiotic. In 1917, following an 
outbreak of shigella, German professor Alfred Nissle isolated the bacterial 
strain that later became known as “Eschericia coli” 1917 from the faeces of a 
soldier not affected by the outbreak. In a time when antibiotics were not 
readily available this bacterial strain became a common treatment for 
infective gastroenteritis. Despite the fact that the concept of probiotics has 
been around for more than a century, our understandings of the mechanisms 
of action are still limited and even the definition as to what constitutes a 
probiotic is not universally agreed upon. However, The World Health 
Organisation (WHO) definition of what constitutes a probiotic is now 
generally accepted it states that a probiotic is :  





 A principle problem of describing the mechanisms of actions of a 
probiotic, is that the individual mechanisms may be unique to a particular 
species and/or strain of micro-organism, as well as being relevant only to a 
particular host or disease state.  As such, this description will concentrate on 
mechanisms of action that are relevant only in the context of IBS and will 
also make the assumption that low grade inflammatory responses, altered 
mucosal permeability, antigenic hypersensitivity, visceral hypersensitivity and 
altered motility all contribute to the pathogenesis and symptoms of IBS.  
  
 Transient Trichella spiralis infection in murine models can lead to 
altered visceral perception and dysfunctional motility.[232] In a similar model, 
ingestion of Lactobacillus paracasei NCC2461  results in the reversal of 
muscle hypercontractility; visceral hypersensitivity and decreased  
cyclooxygenase 2 (COX-2) expression. [233] This result provides evidence 
of the potential for a probiotic to have an effect either directly or indirectly at 
the neuromuscular junction, resulting in a change in motility and also have 
anti-inflammatory and anti-nociceptive effects. In the same study several 
different probiotics were studies but L. paracasei NCC2461 was the only one 
to produce these results, supporting the idea that probiotic effects are strain 
specific. A further study by Bar et el. examined the effect of exposure to 
Escherichia Coli Nissle 1917 on isolated human colonic muscle fibres in an 
vitro organ bath and found increased fibre contractility, supporting the 




Indirect evidence of the clinical effects of probiotic on gut motility is provided 
by Johansson et al. in their study in which the probiotic Lactobacillus 
plantarum DSM 8943 (299v) was given to a group of normal human 
volunteers. The probiotic produced a change in luminal colonic pH and thus 
a change in the environmental conditions to favour the growth of particular 
bacteria. The outcome was an increase in the faecal quantity of 
bifidobacteria and lactobacilli as well as improved motility, increased stool 
volume and decreased flatus. [235] 
 
 In a rodent model of stress induced colonic dysfunction by Eutamene 
et al. the observed increased permeability and visceral hypersensitivity are 
both improved by L. paracasei NCC2461. [136] The ability of probiotics to 
improve visceral hypersensitivity is further supported by the observations of 
sustained increased expression of opioid and cannabinoid receptor mRNA, 
seen with ingestions of lactobacillus acidophilus NCFM [236] and a separate 
murine model of antibiotic induced visceral hypersensitivity alleviated by L. 
paracasei NCC 246. [237] Probiotics may also have the ability to moderate 
intestinal antigenic responses and thus reduce inappropriate inflammatory 
responses to intestinal luminal content.  Lactobacillus rhamnosis GG and 
Bifidobacteria animalis MB5 have both been shown to increase expansion of 
anti-inflammatory T-cell populations and increase IL-10 secretion and thus 





 The evidence for different mechanisms of action of probiotics within 
the intestinal lumen is extensive and much of it may be relevant to their 
efficacy in IBS.  As discussed these may include actions on the 
neuromuscular junctions and motility, visceral hypersensitivity, inflammatory 
and allergenic responses and mucosal permeability. In addition to their direct 
actions, probiotics also have an effect on the luminal environment and as 
such may also result in favourable growing conditions for certain groups of 
bacteria.  These bacteria themselves may have a probiotic effect and thus 
the original positive effect may be amplified or added to. Perhaps the only 
certainty that can be gleaned from the evidence is the likelihood that all 
mechanisms of actions may be specific to the species and perhaps even the 
strain of probiotic. 
 It is difficult to describe particular characteristics of individual probiotic 
species and strains that could be classified as ideal and/or required of a 
probiotic to be used to treated patients with IBS. However, clearly any such 
probiotic must be delivered to the recipient in such a way that the individual 
bacteria are live and viable (able to divide and colonise the gastrointestinal 
lumen of the recipient).  They must also be able to survive transit through the 
arguable hostile environment of the upper gastrointestinal tract and lastly be 
able to adhere to, and colonise, the colonic mucosa without resulting in an 
unfavourable immune/inflammatory responses.  Whether long term 
colonisation and/or persistence with the colon is desirable is debatable as 




therapy with a probiotic is to return the colonic microbiota to a favourable 
composition which doesn’t perpetuate the symptoms of IBS then long term 
colonisation may not be required or even desirable.   
Until the pathological mechanisms of IBS are fully understood it is 
difficult to specify more detailed characteristics that would be desirable in a 
probiotic IBS therapy. Whether the anti-inflammatory properties, anti or pro-
motility characteristics, local or distantly acting immunogenic or modulating 
characteristics that a variety of different bacterial strains have been 
demonstrated to poses are yet to be clearly established. 
 
The probiotic preparation Symprove is a multi-strain probiotic containing 4 
individual strains of bacteria (Lactobacillus plantarum NCIMB 30173, 
Lactobacillus rhamnosus NCIMB 30174, Lactobacillus acidophilus NCIMB 
30175, Enterococcus faecium/durans NCIMB 30176). Historically, the 
product was developed as a way of preserving germinated grain as a high 
quality agricultural feed. The bacterial strains were used in a cascade 
sequence to reduce the pH of germinated ‘wet’ grain from pH 7 to pH 4 and 
in so doing improved the shelf life of the ‘wet’ grain from 10 days to 4 
months.  Subsequent observations by breeders and veterinary professional 
of livestock fed with the treated grain demonstrated unexpected results.  
Whilst much of this information is from observational work by the developers 
and/or anecdotal evidence, these observations included, reduced 




rates and decreased mortality. Eventually realising that the observed benefits 
were as a result of the contents of the ‘pickling liquor’ and not the germinated 
grain itself the developers set about understanding the pickling process itself. 
 Ultimately, the process of grain pickling was reverse engineered so 
that the germinated grain was utilised to provide the growing substrate for 
the ‘probiotic’ bacteria. The resultant bacterial product was then used as a 
veterinary supplement in ‘small animals’ for numerous years to treat 
gastrointestinal disturbances before the final refinement of the product for 
use in humans.  
 Symprove been commercially available for several years as a ‘health 
food supplement’ used by consumers for a variety of indications.  However, 
until this time there has been no formal assessment of efficacy of the product 
in the treatment of any gastrointestinal conditions in the human population.  
Furthermore, no in-vitro studies have been undertaken to ascertain any of 
the individual characteristics and properties of the individual microbial strains 




2.4.2 Current evidence of the efficacy or probiotics in the treatment of 





 The evidence for the efficacy of probiotic therapy in the treatment of 
patients with irritable bowel syndrome suffers from the same limitations 
common to all IBS studies. As previously discussed these include the 
considerable heterogeneity of the disorder itself, differing sub-groups 
characteristics, changing classifications of the disorder and the lack of a 
positive diagnostic test. In addition, there is no clearly established definition 
of what constitutes a clinical response or how to define a patient responder in 
terms of the individual symptoms of IBS, as well as global symptom 
improvement.  Recent guidelines produced by both the Federal Drug 
Authority (FDA) in 2010 and earlier guidelines produced by the European 
Agency for the Evaluation of Medicines (EMEA) in 2003, have sought to 
address some of these problems and standardise both inclusion criteria and 
outcome measures for such trials. However, both sets of guidelines differ 
considerably in their recommendations and a recent statement from the 
EMEA working group highlighting the need for comprehensive international 
guidelines to facilitate international collaboration and comparisons with and 
between research groups. 
 
  A particular problem that appears endemic amongst trials of 
probiotics in IBS is the apparent poor quality and methodological limitations 
of the studies themselves. The vast majority of probiotic and live microbial 
products are considered as foods, food supplements and health foods and 




regulatory controls as medicines.  It is quite possible that this fact alone 
coupled with the evidence that larger, more robust trials are significantly 
more difficult and costly to undertake; has resulted in the prevalence of poor 
quality studies within this field. Whilst arguably there is no direct evidence to 
support this belief, it is one that is held by many within the academic and 
scientific community.  
 
 Of the hundreds of original studies looking at the safety and efficacy of 
probiotics in the treatment of IBS, there are in fact very few that conform to 
the standardised randomised placebo controlled trial format and of these 
even fewer could be considered of sufficiently high quality.  Recently there 
have been several meta-analyses and systematic reviews that have 
attempted to address these problems and answer the question of whether 
probiotics in general and/or specific probiotics, have sufficient evidence of 
efficacy in the treatment of IBS. The results of these meta-analyses will be 
considered collectively rather than as individual studies themselves. 
 
   Of the clinical studies analysed by the authors, very few were 
actually deemed of sufficient quality to include in the meta-analyses.  
McFarland et al, after assessing study quality using the Linde Internal 
Validity Scale (LIVS) identified a total of fourteen trials for inclusion in their 




Hoveyda et al. fourteen trials using similar trial quality rating tools. [239, 240] 
Table 4 summarises the study size, duration, disease sub-types probiotic 
strain(s), outcome measures and primary endpoints and other significant 
results from the trials included in all three meta-analyses.  Understandably 
the majority of the trials feature in all three meta-analyses, but the full papers 
of some could not be accessed using on-line sources and search engines 
and so these studies have not been included in the table. 
 
 Hoveyda et al. concluded that overall there was modest improvement 
in global symptoms after treatment with probiotics when compared to 
placebo. The overall OR for improvement in global symptoms reported as 
dichotomous data was 1.6 in favour of probiotics (95% CI 1.2 to 2.2); 
heterogeneity  I2 = 28% (figure 1); and for continuous data  the standardised 
mean difference  (SMD) was 0.23 (85%CI 0.07 to 0.38);heterogeneity I2 = 
0%. [239] (figure 2).  McFarland et al. reported a pooled RR of 0.77 (85% CI 
0.62 to 0.94). NNT 7.3; for less global symptoms after treatment with 
probiotics compared to placebo using a random effect model, heterogeneity 
X2 = 41.0 d.f. [32] (figure 3). Moayyedi et al. reported a reduction in global 
symptoms with probiotics over placebo in studies reporting a dichotomous 
outcome with a pooled RR 0.71 (95% CI 0.57 to 0.88), NNT 4, heterogeneity 
X2 28.3 d.f.  (figure 4) and in those using continuous data an SMD of -0.34 





 Abdominal pain scores were also shown to improve after treatment 
with probiotics over placebo. Moayyedi et al. reported an improvement in 
abdominal pain with an SMD of -0.51 (95 CI -0.91 to -0.09), heterogeneity X2 
= 61.08 d.f.,[240] Hoveyda et al. in studies using dichotomous data with an of 
OR 2.88 (95% CI 1.84 to 4.50), heterogeneity I2 = 1%; [239] (figure 6) but no 
benefit in those using continuous data, SMD 0.05 (95% CI - 0.09 to 0.19), 
heterogeneity I2 51%; and McFarland et al. a pooled RR of  0.78 (95% CI 
0.69 – 0.88), heterogeneity X2 = 36.6 d.f. (figure 7).  The number of studies 
reporting on other associated IBS symptoms were significantly fewer but 
Hoveyda et al. reported a significant improvement in bloating with studies 
using dichotomous data (four studies) OR 1.75 (95% CI 1.03 to 2.96), I2 = 
0%; but no difference in those reporting bloating using continuous data, SMD 
0.05 (95% CI -0.10 to 0.21) I2 = 8% (figure 8). [239]  
 
 All three meta-analyses reported similar significant heterogeneity 
between studies but a modestly beneficial effect of probiotics on global 
symptom and abdominal pain. The similar findings from the separate meta-
analyses are not surprising in that they all review a similar set of studies. 
Furthermore, it is also interesting to note that Mcfarland et al. found that 
larger studies reported a stronger positive effect of probiotics with Moayyedi 
et al. reporting similar effect in studies of higher methodological quality.[32, 
240] All three sets of authors rightly stress that the significant heterogeneity, 




studies seriously limit the validity of the meta-analyses. Even more 
importantly it must be considered that at least 60 individual probiotic strains 
and 19 different products were considered in the meta-analyses and 
therefore it is impossible to draw any unifying conclusions for probiotics as a 
whole.  Perhaps the only reasonable conclusions to make are that of the 
probiotics studies for the treatment of IBS, the majority seem to have some 
modest efficacy and good safety profiles and that the efficacy of each 
probiotic strain and preparation must be considered to apply only to that 
species and/or strain alone.  Finally, the results should not be extrapolated to 



























 weeks Escherichia coli DSM 17252 
and Enterococcus faecalis 
DSM16440 
No prior P-EP specified. 
Study a re-analysis of previous work to give P-
EP as improvement in abdominal pain and 
global symptom score (computed). Responder 
defined as at least 50% improvement. 
P =EP: Global symptom score, responders 68.5% probiotic vs. 
37.8% placebo (p < 0.001). 










6 weeks Bifidobacterium animalis 
DN1730101 + S. thermophiles 
and Lactobacillus bulgaricus  
Functional digestive disorders quality of life 
(FDDQL) P-EP – discomfort HRQoL (health 
related) at week 3, responder defined as 
improvement of >10% from baseline score 
S-EPs other HRQoL dimensions. Bloating 
abdominal pain stool characteristics and 
global digestive symptoms week 3 and 6 
(Likert scales). 
HRQoL discomfort responders higher 65.2 vs. 47.7%, p < 0.005  
(P-EP). 
 
Decrease bloating score 0.56 ± (s.d.)1.01 vs. 0.31 ± 0.87, p <0.03. 
 
No difference in HRQoL dimension actual score or symptom 









4 weeks Lactobacillus rhamnosus GG P-EP: no pain (a relaxed face on ‘faces pain 
score’). 
S-EPs: improvement of at least 2 ‘face scores’ 
from baseline, self-reported pain severity, 
frequency of self-reported pain and use of 
medication for abdominal pain. 
P-EP:  
Overall study population: 25% probiotic vs. 9.6% placebo (relative 
benefit RB 2.6, NNT 7). 






Rome II 4 weeks Bifidobacteria infantis 35624 
 
(Dose ranging study: 1 x 106, 
1 x 108 and 1 x 1010 vs. 
placebo) 
P-EP comparison of daily abdominal pain 
score at week 4. 
S-EPs comparison of bloating/distension, 
incomplete evacuation straining, passage of 
gas urgency and overall self-reported global 
symptom assessment (SGA). 
P-EP: improvement in abdominal pain vs. placebo, -0.89 vs. -0.58, 
p =0.023) for dose 1 x 108. 
Other dose ranges not superior to placebo. 
 
S-EPs: improvement in, incomplete evacuation, passage of gas, 
training and bowel habit satisfaction in 1 x 108 group only. 
SGA 20% greater improvment than placebo (p = 0.02) 1 x 108 
group only). 
 


























Lactobacillus delbrueckii ssp. 
bulgaricus, Lactobacillus 
plantarum, and Streptococcus 
salivarius ssp. thermophilus 
P-EP improvement in abdominal bloating 
score (VAS scores) 
S-EPs improvement  in VAS scores for 
flatulence, abdominal pain and urgency. 
Proportion of weeks with satisfactory relief 
from bloating. (those patients who document 
at least 50% weeks of satisfactory relief 
declared responders. 
P-EP: Satisfactory relief of bloating 46% vs. 33%  in the probiotic 
and placebo groups (p = 0.27 NS). 
 
S-EPs: Vas score for flatulence (39.5 ± 2.6 (SD) vs. 29.7 ± 2.6 







Rome II 8 weeks Lactobacillus salivarius ssp 
salivarius UCC4331 and 
Bifidobacterium infantis 35624 
No priori P-EP specified. 
Symptoms of abdominal pain, bloating and 
bowel movement difficulty assessed (Likert 
scale and VAS score) and a composite score 
of all 3 calculated.  IBS-QOL used to assess to 
quality of life. 
Significant difference in abdominal pain (7.78 (SE 1.36) vs. 12.21 
(SE 1.85)), (p < 0.05)  bloating (10.17 (SE 1.67) vs. 14.39 (SE 
2.18)) (0.05 < P < 0.1) in the B. infantis 35624 group over vs. 
placebo and composite scores (24.56 (SE 3.63) vs. 40.52 (SE 
4.68)). (p < 0.05 after adjustment for multiple comparisons). 
 No significant differences between the symptom or composite 






Rome II 4 weeks Lactobacillus plantarum LP01 
+ Bifidocterium breve BR0 
(group A) 
Lactobacillus plantarum LP01 
+ Lactobacillus acidophilus 
LA02 (group B) 
Overall pain score ( 4point Likert scale) 
Overall symptom severity score ( 4 point Likert 
scale). 
Overall Pain: 
45% group. A, 49% group B, 29.5% placebo 
Overall symptom score: 
46% group A, 55.6% group B, 14.4% placebo 













Lactobacillus delbrueckii ssp. 
bulgaricus, Lactobacillus 
plantarum, and Streptococcus 
salivarius ssp. thermophilus 
P-EP: satisfactory relief of symptoms. 
Responder defined as satisfactory relief. 
question (yes/no) of symptoms for 4 of 8 
weeks.  
 
S-EPs: comparison of mean scores for 
individual IBS symptoms and bowel function ( 
VAS scores). 
P-EP:  Responders 38% probiotic vs. 33% placebo (p = 1.00). 
 






Summary of previous RCTs of different probiotics in the treatment of IBS.  The studies included are those that are included in the previous meta-analyses of 
the subject.  Gives number of patints included in study, age range, diagnostic criteria utilised in inclusion criteria, brief description of trial and major 

















Manning 4 weeks Lactobacillus plantarum 299V P-EP: improvement in abdominal pain. 
S-EP: Improvement in overall symptoms 
score. 
 
Questionnaire of symptoms scores (rating 
scale) for  abdominal pain, stool frequency and 







Rome 20 weeks Lactobacillus casei GG P-EPs: Improvement in abdominal pain, 
bloating and bowel frequency 
S-EPs: Improvement in other symptom scores. 
 
Diary and questionnaires assessing abdominal 
pain, bloating, faecal urgency, diarrhoea, 
constipation, borborygmi, flatulence, belching, 
acid reflux, heartburn and nausea (Likert 
scales). 
P-EPs:  No significant difference between probiotic for abdominal 






Rome 4 weeks Lactobacillus plantarum DSM 
9843 
No priori P-EP specified. 
Symptoms of abdominal pain, flatulence, 
defecation function (number and stool type). 
Reduction in flatulence, 44% probiotic vs. 18% placebo reported a 
50% reduction in flatulence (p < 0.05). 
Reduction in abdominal pain and improvement in bowl function in 






None 4 weeks Streptococcus faecium 
 
 
No priori P-EP specified. 
Clinician assessment of global symptom 
improvement. VAS scores for pain, bowel 
function, flatulence and meteorism, and 
boroborygmi 
More patients ‘improved’ or ‘significantly improved’ in Clinician 




Figure 1: Forest plot of improvement in overall symptoms (dichotomous data) in 






A forest plot from the meta-analysis by Hoveyda et al. comparing the dichotomous data 
(adequate relief of symptoms) from studies with suitable data for analysis. Compares 
placebo to probiotic in each cohort. Figure 1 is reproduced with permission from the 
original article by Hoveyda et al. [239]
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Figure 2:  Forest plot of improvement in overall symptoms (continuous data) in 





Forest plot of 6 trials included in the Hoveyda meta-analysis, Shows the 
improvement of overall symptom severity score, when reported using a continuous 
variable to report the outcome. Figures 2 is reproduced with permission from the 
original article by Hoveyda et al. [239]  
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Figure 3: Forest plot of randomised controlled trials of 14 treatment arms from 
12 studies measuring the relative risk of IBS symptoms after probiotic treatment 






Forest plot of RCTs from 12 trials (14 treatment arms). Shows the relative risk (RR) of 
having IBS symptoms after treatment with a probiotic compared to placebo. Figure 3 is 
reproduced with permission from the original article by McFarland et al. [32]  
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Forest plot from meta-analysis by Moayyedi et al. Shows the relative risk (RR) of persisting IBS 
symptoms after treatment with a probiotic compared to placebo using dichotomous data.  The 
results are grouped according to probiotic species and/or if a combination product. Figure 4 is 
reproduced with permission from the original article by Moayyedi et al. [240]  
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Forest plot from meta-analysis by Moayyedi et al. Shows the relative risk (RR) of persisting IBS 
symptoms after treatment with a probiotic compared to placebo using continuous data.  The 
results are grouped according to probiotic species and/or if a combination product. Figure 5 is 
reproduced with permission from the original article by Moayyedi et al. [240]  
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Figure 6:  Forest plot of improvement of abdominal pain (dichotomous data) in 






Forest plot from meta-analysis by Hoveyda et al. Shows the odds ratio (OR) of improvement in 
the symptom of abdominal pain in the different RCTs after treatment with a probiotic compared 
to placebo (dichotomous data). Figures 6 is reproduced with permission from the original article 
by Hoveyda et al. [239]  
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Figure 7: Forest plot of randomised controlled trials of 12 treatment arms from 
10 studies measuring relative risk of abdominal pain after treatment with a 




Forest plot for meta-analysis by McFarland et al. showing the relative risk (RR) of abdominal 
pain in 10 RCTs (12 treatment arms) after treatment with probiotic compared to placebo. Figure 
7 is reproduced with permission from the original article by McFarland et al. [32]  
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Figure 8: Forest plot of improvement of bloating (dichotomous data) in patients 






Forest plot from meta-analysis by Hoveyda et al., showing the odds ratio (OR) of bloating from 
the included RCTs after treatment with probiotic compared to placebo (dichotomous data). 

















 The study was conducted in accordance with the guidelines for Good 
Clinical Practice (CPMP ICH 135 95), the principals of the Declaration of 
Helsinki and with all relevant local and national guidelines including the 
archiving of records. The study protocol was reviewed by the Bromley National 
Research Ethics Committee (NRES) and given a favourable ethical opinion. 
Later amendments to the study protocol were reviewed by the Outer London 
NRES committee following the dissolution and amalgamation of the former 
committee into this new body. Further review was undertaken locally by the 
Research and Development Committee of Kings College Hospital who acted as 
Sponsors for the study. The study was registered on the ISRCTN register 
(International Standard Randomised Controlled Trial Number) 
(ISRCTN77512412). 
 
 All participants were provided with a full verbal description of the trial and 
a booklet containing detailed written information about the study protocol 
(appendix 1). After having an opportunity to ask questions, all participants were 
required to give informed written consent prior to enrolment in the study 
(appendix 2).  Wherever possible data was stored in an anonymous format.  
All computerised data was stored in an encrypted and password protected 
format in accordance with Data protection legislation. Original written data is 




3.2 Study Design. 
 
 This study was a single centre, randomised, double blind, placebo 
controlled trial conducted in the gastroenterology outpatient department of 
Kings College Hospital, London. The study took place between October 2008 
and September 2011. A total of 186 participants were recruited and 
randomised. Study participants received either active treatment with the study 
probiotic suspension or placebo. The placebo was an inert liquid (water) 
containing natural citrus flavourings only. Participants were allocated to receive 
active treatment or placebo randomly, (section 4.2.3) in a 2:1 ratio giving 124 
patients on active treatment and 62 patients on placebo.  This study was 
designed as a ‘Phase II’ study, to examine both the efficacy and safety of the 
probiotic preparation in the target population. The probiotic suspension has 
been commercially available for human consumption for several years, 
however, the safety profile for the preparation has not been studied in a 
controlled format. Therefore, within the study design, it was decided to include a 
larger number of patients taking probiotic than placebo in order to potentially 
yield more information about its safety profile and any unwanted effects.  
 
 The study period was for a total of seventeen(sixteen plus  one) weeks, 
which included one week of pre-assessment, twelve weeks of treatment and 
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four weeks of follow up.  The full timetable of visits and interactions with 
participants is given in Table 5. 
 
3.2.1 Participant Selection and Screening. 
 
 Participants for the study were selected in two ways:  Direct from tertiary 
care at Kings College hospital and from Primary Care from a number of local 
GP clinics.  Participants with IBS, under the care of a gastroenterologist at 
Kings College Hospital, or patients newly referred directly to the 
gastroenterology service with a suspected diagnosis of IBS were informed 
about the study and given an information sheet during their routine outpatient 
appointment. Patients who then showed an interest in participation were offered 
a separate initial assessment appointment with a member of the research team.   
 
 Potential participants from Primary Care were identified from the 
computer databases of two local primary care facilities (General  Practice (GP)) 
that consented to participate in the study. Using these databases, patients with 
an established diagnosis (made by their GP) who had consulted with the GP 
within the preceding 12 months regarding their IBS symptoms, or had received 
a prescription for mebeverine during the same time period, were identified. 
Potential participants were then sent an open information letter from the GP , 
the study information booklet and a separate invitation letter from the research 
124 
 
group inviting the GP patients to take part in the research study. Patients who 
subsequently contacted the research team, were then offered an initial 
assessment appointment with a member of the research team in the outpatient 
department at Kings College Hospital.  
 
 Those respondents who consented, attended an initial screening 
outpatient assessment (visit 1) during which demographic data was collected, a 
detailed clinical history was obtained and participants underwent a full clinical 
review.  Participants who had not previously been diagnosed with IBS by an 
experienced gastroenterologist at Kings College hospital, underwent standard 
screening investigations to establish the diagnosis. Patients who were currently 
under the care of an experienced gastroenterologist at Kings College Hospital, 
had these investigations repeated if they had not been performed in the one 
month prior to screening. All patients underwent faecal calprotectin and those 
with diarrhoea also underwent a small bowel permeability study (SBPS) within 
the two weeks prior to study entry.  Small bowel permeability was assessed 
using the method describe by Menzies et al. that analyses urinary excretion of 
orally administered sugars ( D-xylose, 3-O-D-glucose lactulose and Rhamnose). 
[252] 
 
 Where the history, clinical examination or investigations indicated a 
diagnosis other than IBS, the investigator initiated appropriate investigations 
and the participant’s involvement in the study was suspended until these were 
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completed.  If these further investigations resulted in either a confirmed, or 
‘strongly’ suspected alternative diagnosis, then participants were reassessed as 
to their suitability to take part in the study and excluded if they no longer met the 
entry criteria. In cases where there was any doubt about the diagnosis, the final 
decision as to inclusion to the study was made by the Principle Investigator. Any 
patients in which an alternative diagnosis was reached as a result of the 
screening investigations, were referred for investigations and treatment with an 
appropriate clinician. 
 
3.2.2 Diagnostic Criteria for IBS. 
 
 Currently there are no specific investigations or panel of tests available to 
positively confirm a diagnosis of IBS. A diagnosis of IBS is therefore based on 
the detailed assessment of an individual’s history of symptoms and clinical 
findings by an experienced physician, as to whether they meet a set of 
established symptom criteria in the absence of an alternative explanation for the 
symptoms. For the purpose of this study, participants were only considered to 
have a confirmed diagnosis of IBS if they met the Rome III criteria.[5] The 
compliance of a patient’s symptoms with The Rome III criteria were assessed 
using a simple questionnaire adapted from the Rome III diagnostic criteria 
(Table 6). Once the diagnosis of IBS was confirmed it was then necessary to 
establish whether the patient was currently symptomatic.  For the purpose of 
this study patients were considered to have symptomatic IBS if they had an IBS 
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symptom severity score (IBS-SSS) of ≥150. The level of ≥150 was chosen 
based on information from the validation studies of the IBS-SSS; in which 
normal subjects or those with quiescent symptoms are considered as having an 
IBS-SSS of ≤75 and that a meaningful difference in the IBS-SSS score would 
be a change of ≥50 points.  A cut off point of ≥150 was therefore chosen for 
inclusion in the study, to reasonably allow demonstration of a meaningful 
change in the IBS-SSS in response to the study treatment. 
 
3.2.3 Inclusion and Exclusion Criteria. 
 
 The inclusion and exclusion criteria were chosen in order to ensure that 
only patients with a diagnosis of IBS were included in the study, and to minimise 
the effects of potential confounding of co-morbid conditions on the outcome 
from the study.  All sub groups of IBS were included within the study. 
Inclusion Criteria: 
 Age 18-65 years at screening visit. 
 Male or Female. 
 Diagnosis of IBS made by an experienced Gastroenterologist and 
Rome III diagnostic criteria met. (Rome III assessment performed 
by study physician). 
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 Commencement of symptoms at least six months prior to 
screening visit. 
 Current active disease (defined as IBS-SSS score of ≥150) 
 Willingness and ability to give informed written consent 
 Willingness and ability to complete questionnaires during the 
study. 
 Willingness to undergo pre- and post-study investigations as per 
the study protocol. 
 
Exclusion Criteria. 
 Age <16 or >65 at screening. 
 History of confirmed diagnosis (histological and/or endoscopic) of 
other gastro-intestinal diseases: 
o Crohn’s disease. 
o Ulcerative colitis. 
o Microscopic/Collagenous colitis. 
o Coeliac disease. 




 Gall stone disease (permitted if undergone cholecystectomy >1 
year previously and confirmation of absence of residual common 
bile duct stones). 
 Gastroparesis. 
 Previous or current significant psychiatric co-morbidity.  
(Mild anxiety and depressive symptoms were accepted at the 
discretion of the screening physician. Patients currently under 
investigation; suffering from a recent or on-going depressive 
episode, requiring a change in treatment during the preceding 
three months or treatment other than low dose anti-depressants 
were excluded). 
 Anti-depressant usage: low dose anti-depressants prescribed as 
part of IBS treatment were permitted, e.g. citalopram 10-20mg 
daily, amitriptyline 10-20mg daily. 
 Current alcohol misuse or dependency.* 
 Current drug misuse or dependency.* 
(* Previous misuse or dependency permitted at discretion of 





o Previous use of a probiotic preparation within one month of 
screening. 
o Previous adverse reaction to probiotic preparation. 
 (Patients were instructed to avoid all other probiotic    
 preparations during the study period). 
 IBS medications:  
(Patients already taking IBS medications including anti-spasmodics, 
peppermint preparations or low dose antidepressants, on regular or as 
required bases were permitted to continue using them in the same 
manner during the study. Increased dosages or new medications were 
not permitted during the study. 
 Dietary restrictions and elimination diets: 
(Patients who were already on an established wheat and/or  dairy 
elimination diet, or had self-imposed dietary restrictions for a period of 
not less than three months prior to the start of the study were permitted. 
Patients were instructed not to change diets during the study period. 
Patients were asked to refrain from major dietary changes  during the 
study period). Patients being treated using the FODMAP exclusion diet 





 The use of antibiotics was not restricted during the study   
 period. Antibiotic usage during the study period was recorded  




3.2.4 Study medication. 
 
 During the study patients received either placebo (or probiotic in a dose 
of 1ml per kg each day during the treatment phase. Patients were requested to 
take the medication each morning on an empty stomach and eat or drink 
nothing other than clear fluids for at least 10 minutes after taking the 
probiotic/placebo.  If patients forgot the morning dose they were instructed to 
take the medication later in the day when remembered, with a period of no food 
for at least two hours prior to consumption. 
  
3.2.5  Patient visits and assessment. 
 
 All clinical assessments, investigations and monitoring visits during the 
study were performed by the lead physician. At each assessment point during 
the ‘active treatment’ phase, all study participants had a separate meeting with 
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a non-clinical research assistant to receive their next supply of study  probiotic 
or placebo. The research assistant was not blinded and took no other part in 
any other clinical aspects of the study.  
 
 At ‘visit one’ the lead physician provided full verbal and written 
information regarding the study; then with consent, undertook a full review of 
the participants medical history and conducted a full physical examination. If the 
history was clearly not consistent with a diagnosis of IBS, appropriate 
alternative investigations and intervention were undertaken and the screening 
process stopped. These participants took no further part in the study. 
Participants whose history and physical examination was consistent with a likely 
diagnosis of IBS who had not been previously investigated had the following 
laboratory investigations arranged: 
 
 Full blood count. (FBC) 
 Erythrocyte sedimentation rate. (ESR) 
 C-reactive protein. (CRP) 
 Renal profile. (urea, creatinine, potassium and sodium). 
 Liver function tests (Albumin, globulin, bilirubin, alanine 
transaminase (ALT), gamma-glutamyl transpeptidase (G-GT) and 
alkaline phosphatase (ALP)). 
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 Coeliac serology (anti-tissue transglutaminase (tTG), anti-
endomysial, anti-gliadin antibodies and serum IgA level. 
 Small bowel permeability study. (if IBS-D or IBS-M) 
 Faecal calprotectin. 
 
 If participants already had an established diagnosis of IBS made by an 
experienced gastroenterologist and had undergone previous laboratory 
investigations, they were repeated as per the following protocol: 
 
 FBC, CRP, ESR, faecal calprotectin, small bowel permeability 
study – if not done within four weeks of entry into the study. 
 Coeliac serology – repeated if not done within six months. 
 
 Participants who were thought to be likely candidates to take part in the 
study and gave verbal consent, were asked to complete the IBS-SSS 
questionnaire to assess symptom severity and thus eligibility for inclusion in the 
study. 
 
 At ‘visit two’, the laboratory investigations were reviewed and if 
participants had abnormal laboratory investigations, or the lead investigator 
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suspected an alternative diagnosis, then further investigations were arranged 
and the participant was suspended from the trial assessment.. The participants 
requiring further investigations had a repeat ‘visit two’ arranged to review these 
and reassess study eligibility. Participants were excluded from the trial if further 
investigations confirmed or suggested an alternative diagnosis to IBS was likely. 
In unclear cases the final decision regarding diagnosis was made by the lead 
investigator and confirmed by the principal investigator prior to inclusion in the 
study.  
 
 Patients who had normal laboratory investigations, an IBS score of ≥150 
and met the Rome III criteria as assessed by the study questionnaire, (Table 6) 
were then invited to participate in the study. Written consent was completed at 
‘visit two’ and the participant enrolled. Each participant was assigned the next 
available sequential trial identification number and completed the appropriate 
questionnaires as required by the study protocol. (Table 5). All participants were 
given a study identity form that included the trial identification number and 
emergency contact details for the trial team. 
 
 During the study, participants were reviewed every four weeks by the 
lead investigator. At each visit, participants were asked about compliance with 
the study treatment, any unwanted side effects or adverse events and any 
variances from the study protocol; including any other medications used during 
this period. Compliance with study medication was assessed at each of the four 
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weekly visits during the treatment phase of the study.  Participants were asked 
specifically if they had taken each daily dose, missed one or less doses per 
week, missed one-three doses per week or missed greater than three doses per 
week, at each visit.  
 
 Study questionnaires were completed as per the study protocol. 
Participants who were experiencing significant side effects or adverse events or 
withdrew consent, were withdrawn from the study and the reason recorded. 
Those participants who failed to attend a follow up appointment were contacted 
and offered a further appointment one week later. Participants who did not 
attend two consecutive follow up appointments or could not be contacted were 
withdrawn from the trial. Every effort was made to contact participants who 
failed to attend. 
   
 At ‘visit five’, week twelve of the study, participants were asked to stop 
taking the study probiotic/placebo and underwent the end of study 
investigations. (FBC, Renal profile, liver function tests, CRP, ESR, small bowel 
permeability (if IBS-D or IBS-M) and faecal calprotectin) Study compliance, 
variances, side effects and adverse incidents were recorded.  
 
 A four week follow up period where patients took no further medication 
then followed before the final review (visit six). Final information was collected 
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as per the protocol and the participants involvement in the study concluded. A 
further appointment was also made for each participant to meet the Principal 
Investigator after ‘visit six’.  At this meeting the participant was ‘unblinded’ and 
as required further treatment and follow up was discussed. The Principle 
Investigator remained ‘blinded’ to the patients study identification number but 
was ‘unblinded’ to whether they received probiotic or placebo. This additional 
step in the blinding protocol was taken to ensure that informing the patient of 
their allocation to placebo or probiotic, did not comprise the ‘blinding’ of the 
Principle Investigator. 
 
3.2.6  Randomisation and Blinding. 
 
 The study protocol included a total of 186 patients with twice as many in 
the probiotic group compared to the placebo group. Participants were therefore 
randomised into three groups of equal size. Two active treatment groups and 
one placebo group giving an overall ratio of active treatment: placebo of 2:1. 
The decision to use three equal sized groups was to ensure investigator 
blinding.   The groups were compiled using a simple non-stratified two stage 
computer randomisation protocol, utilising the Mersenne twister algorithm, a 
pseudo-random number generator to randomise participants equally into each 
of the three groups. The full randomisation for all 186 patients was completed 
prior to the start of recruitment.  At the screening visit each participant was 
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assigned the next sequential trial number by the Lead Investigator. The 
randomisation protocol is illustrated in Appendix 3. 
 
 Two copies of the randomisation sequence were kept during the study. 
One  held by the research assistant, (non-clinical) who was responsible for 
allocation of the probiotic/placebo during the study, and a second ‘emergency’ 
copy that was held in a sealed security file during the study; to be accessed in 
the unlikely event that there was a need to ‘unblind’ for a study participant in 
case of a medical emergency.  The Lead Investigator remained blinded 
throughout the study and was responsible for all clinical contact with 
participants during the study period. At the end of their involvement in the study 
each participant was reviewed and ‘unblinded’ by the Principal Investigator, who 
also arranged and carried out all follow-up care required. The Lead Investigator 
had no further clinical contact with participants after completion of the study to 
ensure maintenance of blinding. 
 
 The placebo and probiotic were provided and distributed in identical 
bottles in sealed, identical cardboard boxes. The content of the boxes was 
identified by an eight digit numeric code assigned by the manufacturer and 
known to the research assistant only. The probiotic and placebo were, as far as 
possible, similar in taste, colour and consistency. The placebo was an inert 




 All data collected during the study was entered in to a secure, encrypted 
database in a pseudo-anonymised form. All data was collated into the three 
treatment groups and the database locked prior to ‘unblinding’ 
 
3.3 Laboratory investigations. 
 
 Haematological and biochemical tests were carried out using Adviva 
1200 and 2400 analyzers respectively, (Siemens, Frimley, UK) intestinal 
permeability assessment (differential urinary excretion of lactulose / L-
rhamnose) using mass spectrometry for marker analyses and faecal 
calprotectin (EK-Cal Calprotectin kit, Buhlmann, Switzerland). All laboratory 
investigations and measurements were carried out by the Department of 




3.4 Outcome measures 




 The main outcome measurements of the study were a change in the 
symptom severity of the participants in response to treatment with either the 
probiotic or placebo.  At the time the study commenced there was no universally 
accepted standard to assess response to treatment in IBS clinical trials.  For the 
purposes of this study, it was felt that the use of independently developed and 
validated symptom severity and QOL questionnaires should be utilised, to 
maximise the relevance and application of the study and to facilitate comparison 
with other IBS clinical trials.   
 
 Symptom severity was assessed using the IBS-SSS (IBS symptom 
severity score) developed by Francis et al. [255] The IBS-SSS utilises five 
simple questions to assess the severity of the principle symptoms of IBS 
namely: Abdominal pain, bloating, bowel habit dysfunction and satisfaction with 
bowel habit.  Each of the four symptom domains are assessed using a 100mm 
visual analogue scale (vas). Pain is further assessed for duration; by the 
number of days a patient has experienced pain over the preceding ten days, 
which when multiplied by ten gives a further score out of 100. This results is an 
increased weighting within the score for abdominal pain; as it includes scores 
for both duration and severity, which is line with the consensus opinion that pain 
is the single most important symptom for patients with IBS.  The IBS-SSS 
questionnaire thus yields an overall score range of 0 to 500. The original 
authors have validated the score for sensitivity to change and reproducibility, 
and from their study concluded that a score of ≤75 indicated no symptom 
activity and was comparable to scores obtained from the control group.  A score 
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of >75 to ≤175 was consistent with mild symptoms, >175 to <300 with moderate 
symptoms and ≥300 with severe symptoms. They also concluded that a change 
in the IBS-SSS score of ≥50, represented a meaningful change in symptoms 
with a sensitivity and specificity of 76% and 68% respectively. [255] The IBS-
SSS questionnaire is shown in Appendix 4. 
 
 The IBS-QOL score is a specific QOL score for IBS sufferers utilising a 
34 item questionnaire.  It was developed by Patrick et al. and based on a 
combination of outcomes from conceptual models of generic and gastro-
intestinal specific health related quality of life questionnaires, the 
bothersomeness of IBS symptoms as reported by organised focus groups, and 
specific qualitative interviews with patients. [256] The IBS-QOL score evaluates 
eight individual domains (dysphoria, interference with activity, body image, 
health worry, food avoidance, social interaction, and sexual relationships) and 
gives an overall QOL score out of 100. For the purpose of this study the scores 
for individual responses to each item were scored in a negative manner, (e.g. a 
response of ‘not at all’ would score four, whereas ‘extremely’ would score zero) 
This is not the conventional way of scoring this questionnaire and results in a 
higher score indicating a better quality of life, however it does not alter the 
quantitative values of the individual scores or scale. The IBS-QOL score was 
validated by the authors for internal consistency and reproducibility, as well as 
comparability with symptom severity and other established generic and gastro-
intestinal specific health related quality of life instruments. The IBS-QOL 




 The IBS-SSS questionnaire was completed at the beginning and end of 
the pre-study assessment week (week -1 and week 0). The IBS-QOL reports on 
quality of life over the preceding four weeks and was therefore only completed 
at week 0 to yield baseline data.  The questionnaires were completed at each 
time point according to the study protocol (Table 5) 
 
3.42  Primary and Secondary Outcome Measures. 
 
 In the original study protocol the primary outcome measure was a 
change in the IBS-QOL score.  However, a further review of other similar clinical 
studies of new treatments for IBS highlighted the fact that a change in QOL was 
difficult to demonstrate, even when a significant improvement in individual and 
global symptoms was observed. Moreover, it is also demonstrated that there 
may be a lack of congruity between improvement in symptoms and changes in 
QOL measurement. The original authors of the IBS-QOL have validated their 
questionnaire to demonstrate construct validity, internal consistency reliability 
and reproducibility. However, this has not been further validated externally.  
 
 After consideration of this information the IBS-SSS was used as the main 
outcome measure, and difference in the change in IBS-SSS from baseline to 
week twelve between the probiotic and placebo group was considered the 
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primary end point. The pre-study power calculation was therefore calculated on 
achieving a difference in the change in the IBS-SSS between the two groups. 
The IBS-QOL was still included but as a secondary end-point. 
 
 The secondary end-points for the study were; change in the IBS-QOL at 
12 weeks; change in either the IBS-SSS or IBS-QOL at other time points (4, 8, 
and 16 weeks); and a change in the IBS-SSS individual composite scores for 
pain, bowel habit, bloating and QOL. 
 
  
3.5 Study probiotic and placebo preparation. 
 
 This study was desired to assess the safety and tolerability efficacy of a 
multi-strain liquid probiotic. The probiotic used is a liquid preparation prepared 
for the study by the Symprove Ltd., The Sands Business Centre, Farnham, 
Surrey. GU10 1PX.  The preparation method utilises a fermentation process 
with germinated barley as a substrate/growing media to culture the specific 
probiotic strains.  The product contains the following four bacterial strains: 
 
 Lactobacillus plantarum NCIMB 30173  
 Lactobacillus rhamnosus NCIMB 30174 
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 Lactobacillus acidophilus NCIMB 30175 
 Enterococcus faecium/durans NCIMB 30176 
 
 A 50ml dose of the probiotic contains approximately 109 colony forming 
units (CFUs) i.e. individual bacteria that are live and capable of replication.  The 
probiotic is maintained in a liquid form, with live activated bacteria or CFUs in a 
suspension of an extract of the fermentation liquid to maintain the bacterial 
viability. The probiotic is gluten and dairy free. The probiotic preparation has 
been shown, in an independent study commissioned by the manufacturers, to 
remain stable and biologically active (continues to replicate) after exposure to a 
solution of acidity comparable to that of the ‘resting’ human stomach, (pH 3) for 
thirty minutes. 
 The placebo consisted of sterile water with the following additions (of 
water 130g of ascorbic acid and 3g of beta carotene per 25 l water). The 
additions were included to give the placebo a taste and appearance similar to 
the probiotic preparation.  The final placebo contained (0.26g ascorbic acid and 
0.006g beta carotene per 50ml measure). Quality assurance for the probiotic 






3.6 Statistical analysis. 
 
 Statistical analysis was conducted using STATA 12.1 and SPSS 21 
statistical software. The statistical analysis for the primary end point and related 
analysis was performed by and/or under the supervision of Dr Salma Ayis, 
lecturer in Statistics, Kings College London. 
 
 The original power calculation to discern the total number of patients for 
inclusion in the study was derived from the assumption that 40% of patients in 
the placebo arm would show an improvement in the IBS-SSS, whilst the 
probiotic group would show a similar reduction in IBS-SSS score in 65% of 
patients, detected with a power of 90%.  A change in the base-line score of 50 
points was considered as the minimal clinically important difference (MCID) 
 
 The statistical analysis was performed using both a per-protocol (PP) 
and intention to treat (ITT) approach.  All patients that received study 
medication were included in the ITT population and all patients that completed 
the twelve weeks active treatment phase were included in the PP population. 
For the ITT analysis. the missing data from patients who were lost to follow up, 
withdrew before completion of the study or data lost due to administrative error 
was generated using the last observation carried forward principle. (LOCF) 
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[257] A comparison of the PP and ITT (LOCF) analyses was used as a basic 
sensitivity analysis when comparing the data. 
 
 Frequency tables and cross-tabulations were derived to explore any 
differences or associations between different variables and/or baseline 
characteristics. Modelling with ordinary linear regression was used to further 
analyse the primary end point. Residual plots were used to test the regression 
models. 
The primary and secondary efficacy measures were analysed for the per-
protocol (PP) and an ITT basis using independent sample t-test. Where 
repeated analyses were conducted on multiple secondary endpoints within the 
same data, one-way ANOVA was used.  Adjustment for potential confounding 
baseline variables was conducted using analysis of covariance (ANCOVA). 
Pearson-Chi-squared analysis was used to compare the proportions of subjects 
achieving mild or no symptoms within the two groups in a post-hoc analysis. A p 














Table 5 : Visit and Investigation and Questionnaire Protocol. 
 
 
Schedule of visits for study, includes description of individual elements and purpose of each 
visit. 
*At visit 2 further investigations will be initiated if clinically indicated and a further ‘visit 2’ review 
arranged   
** Monitoring visits – include recording of variances, compliance, side effects, adverse events 
and serious adverse events. 
+ Faecal calprotectin, CRP, ESR, FBC, renal/liver/bone profiles and small bowel permeability 
study. 
++ Visit 6(b): Study participants will be reviewed by the Principal Investigator to be unblinded 





































































Patient unblinding ++ 
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Table 6:  Rome III Criteria Questionnaire. 
 
Question Answer 
1  Do you currently experience recurrent abdominal pain or discomfort* 
(if yes then go to question 2) 
YES/NO 
2  Over the last 3 months at this pain/discomfort occurred for at least 3 
days per month 
YES/NO 
3 a Does the abdominal pain/discomfort improve with defecation  
(passage of stool/faeces) 
YES/NO 
b Is the onset of this abdominal pain/discomfort associated with a 
change in the form of stool 
(appearance e.g. – change from hard stool to runny or soft stool) 
YES/NO 
c Is the onset of this abdominal pain associated with a change in the 
frequency of stool 
(eg. having a bowel movement, more or less often than usual for you) 
YES/NO 
4  Did your current symptoms original start at least 6 months ago. 
 
YES/NO 
5  Over the last one month have these symptoms occurred on at least 2 
days each week ** 
YES/NO 
 
Description of individual questions used for study inclusion to ensure participants diagnosis of 
IBS is concordant with the Rome III criteria. 
*    Discomfort – is an uncomfortable sensation that is not described as pain 
 
** Question 5 – this is not a requirement of the Rome III criteria but is suggested as additional 
measure by the Rome III consensus working group when considering patients for entry into 
clinical trials. 
The Rome III diagnostic criteria for IBS are met if the answers to questions 1, 2, 4,and at least 















4.1  Cohort demographics. 
   
4.1.1 Recruitment. 
  Study recruitment commenced in October 2008 and was 
completed by July 2011.  A total of 392 patients were screened for eligibility to 
take part in the study.  Of these 191 were recruited and took part in the study. A 
total of 201 patients that were screened were not included in the study. The 
reasons for exclusion from the study are; 52 patients did not give consent to 
take part; 39 did not attend their next appointment and were not randomised; 
and 41 patients had a diagnosis of IBS but were not symptomatic as defined by 
the study protocol (IBS-SSS of ≥150). 50 patients with a previous diagnosis of 
IBS were confirmed to have a diagnosis other than IBS (simple constipation, 
other functional gastro-intestinal disorders (not IBS) diverticular disease, 
inflammatory bowel disease, gynaecological disorders, drug related diarrhoea, 
coeliac disease, HIV related diarrhoea, post infective gastroenteritis diarrhoea 
(<4 weeks duration) and small intestinal bacterial overgrowth). Seven of the 
remaining patients were excluded as a result of significant psychiatric co-
morbidity and 12 were excluded for not meeting one or more of the other 
inclusion criteria (pregnancy, age >65, long-term antibiotics, severe liver 




 A total of 191 patients were recruited to the study. Five patients were 
recruited and allocated a trial participant number at ‘visit 1’. However, they did 
not attend their next appointment (visit 2) at the end of the screening period to 
receive the first allocation of study medication.  It was decided that as these 
patients did not receive any probiotic or placebo and investigator blinding would 
be unaffected it would be reasonable to reallocate these trial identification 
numbers.  The CONSORT flow chart of study recruitment and withdrawal is 
represented in figure 10. 
 
 
4.1.2 Baseline Demographics and Investigations. 
4.1.2.1 Age and Gender. 
 
 The overall age range of participants in the study was 18-65 with a mean 
age of 38.3 years (SD ± 10.6). In the probiotic group the mean age was 39.1 
(SD ± 10.5) and placebo group 36.8 (SD ± 10.7) and there was no significant 
difference between the groups (p = 0.162). The mean age did not very 
according to gender with mean ages of 39.8 (SD ± 10.5) and 37.7 (SD ± 10.7) 




 Significantly more females (129) than males (57) were recruited to the 
study.  The female to male ratio within the study was 2.26:1 which reflects the 
known female predominance of IBS prevalence in the UK. There was no 
significant difference in the ratio of males to females between the active (2.1:1) 
and placebo (2.6:1) treatment groups (p = 0.50), (Pearson Chi-square method). 
(table 7) 
 
4.1.2.3 Disease sub-group and duration. 
 
 The allocation and randomisation of patients to the study groups was not 
stratified by disease duration of sub-group. Disease duration has been sub-
divided into 3 categories, (< 1 year, 1 to 5 years and greater than 5 years). 
There are no significant differences between the proportions of each category in 
the active and placebo groups (table 7). Similarly there are no significant 
differences between the proportions of disease sub-type, based on stool 
characteristics, between the groups (table 7).  It is of note that 136 (73.1%) of 
the patients recruited to the study had either IBS-M or IBS-D, with only 40 
patients having IBS-C and 10 patients IBS (unclassified). The low proportion of 
patients with IBS-C and IBS means than meaningful sub-group analysis of 





4.1.2.4. Medications and miscellaneous characteristics. 
 
  Details of the number of patients taking individual medications is given in 
table 8 (some patients were taking more than one medication). The use of 
medication between the group did not differ significantly other than in the use of 
SSRIs. Whilst low dose SSRI were permitted in the inclusion/exclusion criteria it 
is noted that there are substantial more patients (13 vs. 2) in the probiotic group 
compared to placebo. Table 8 contains other additional information on baseline 
demographic information but no significant differences occurred between the 
treatment and placebo groups. 
 
4.2 Baseline IBS-SSS 
 
 The IBS-SSS was measured at week -1 and week 0 in all subjects.  The 
reason for measuring it at two time point was to give an indication of the degree 
of variability of this measure at study entry.  There was no significant difference 
between the mean IBS-SSS score at week -1  (307.5, sd ± 71.7) or week 0 
(300.9, sd ± 78.5) score for the whole cohort (p = 0.067, CI: -0.460 – 13.685) or 
in the active treatment group; week -1 (305.3 sd ± 69.1) and week 0 (302.1, sd 
± 74.8)(p = 0.479, CI: -5.599 – 11.860). In the placebo group there was a 
significant difference between the IBS-SSS scores between week -1 (312.5, sd 
± 76.9) and week 0 (298.5, sd 85.9)(p = 0.031, CI: 1.288 – 25.746). There were  
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no significant differences in the week -1 or week 0 scores between the probiotic 
and placebo group (table 9). The apparent difference in the placebo group 
between week -1 and week 0 is suggestive of a small improvement in symptom 
severity prior to the commencement of the treatment phase of the study. In light 
of the observed difference in the scores in the placebo group an average score 
of the week -1 and week 0 scores was calculated. The mean ‘average IBS-SSS’ 
score for the whole cohort was 304.4 (SD ± 71.4). The mean in the probiotic 
group was 303.6 (SD ± 68.0) and the placebo group 306.0 (SD ± 78.2) (table 9).   
 
 Subsequent analysis shows that there was no difference between the 
mean ‘average IBS-SSS score at baseline in the probiotic group (303.6, SD ± 
68.0) and the placebo group (306.0, SD ± 78.2)(p = 0.832, CI: - 24.940 – 
20.090). The calculated ‘average baseline IBS-SSS was therefore used as the 
reference point for statistical analysis. The overall distribution of the IBS-SSS at 
baseline conforms to the normal distribution and is similar across both the 
active and placebo group. Figures 11 – 13  show the distribution of the IBS-SSS 
score at baseline. 
 
 As discussed, it was noted that there was an excess number of patients 
in the probiotic group taking low dose SSRIs or amitriptyline at the start of the 
study.  A further analysis of the IBS-SSS at baseline excluding those patients 
taking this medication showed no significant difference between the groups with 
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the probiotic group having a mean baseline IBS-SSS of 303.5 and the placebo 
group 304.9. (CI: -25.12 – 22.23)(p = 0.90).   
 
 A model using ordinary linear regression was performed to explore 
whether the IBS-SSS score at baseline was affected by age, gender, duration of 
disease or disease subtype. The results are shown in table 10, none of the 
potential confounding baseline variables had any significant effect on the IBS-
SSS. A graph illustrating the relationship between age and baseline IBS-SSS is 
included in results figure 14. 
 
4.3 Baseline IBS-QOL. 
 
 The IBS-QOL actual score is used to calculate the ‘scale score 
converting it to a score out of 100. All the IBS-QOL scores quoted in this thesis 
and used in the analysis will refer to the scale score. The overall mean IBS-
QOL score at baseline was 52.4, SD ± 20.1.  There was no significant 
difference in the mean IBS-QOL scale score the probiotic group the mean was 
53.2 (SD ± 20.2) and in the placebo group 50.7 (SD ± 19.9) (p = 0.43), (table 
11). The distribution of baseline IBS-QOL score conforms to the normal 
distribution and is similar across both the probiotic and placebo group is shown 
in figures 15 to 17. A model using ordinary linear regression was performed to 
explore the effects on the baseline IBS-QOL of age, gender, disease subtype 
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and duration on.  None of these factors appear to have any effect (table 12) the 
linear regression effect of age and the distribution of IBS-QOL are shown in 
figure 18 
 
  A linear regression analysis was performed to explore the relationship 
between the IBS-QOL and IBS-SSS at baseline. There is a clear relationship 
between the IBS-SSS and IBS-QOL at baseline with a higher IBS-SSS score 
(worse symptoms) correlating with a lower IBS-QOL (worse quality of life).  
 
The unstandardised correlation coefficient of the regression is -0.13 (95% CI: -
0.151 to -0.10) (p < 0.001) (figure 19). 
 
4.4 Laboratory investigations. 
 
 At enrolment in the study all patients underwent screening as per the 
study protocol. Patients with abnormal baseline laboratory parameters and 
biomarkers were excluded from the study as per the protocol.   There were no 
significant differences between the probiotic and placebo group in any other 
investigations including liver and renal function tests, thyroid function tests or 
any of the other investigations. The specific results of these investigations were 
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not considered to be relevant to the subjects of this thesis and have therefore 
not been included.  
 
 Those patients with an elevated level of the faecal biomarker calprotectin 
underwent further investigations including colonoscopy and/or wireless capsule 
endoscopy to establish IBS as the correct diagnosis. Patients in which these 
investigations yielded alternative diagnoses or reasonable doubt over the 
diagnosis of IBS were excluded.  
 
 The baseline haemoglobin, CRP and faecal calprotectin can be found in 
table 13  There were no significant differences between the baseline laboratory 
parameters. These parameters were repeated at the end of the study the values 
for which are also given in table 13 There were no significant changes in the 
any of the laboratory parameters measure between baseline and the end of the 
study or between the probiotic and placebo groups at the end of the study. The 
results of the small bowel permeability tests found that all but one study 
participant had normal small bowel permeability at study entry. The overall 
mean urinary excretion of lactulose/ L-rhamnonose was 0.025 (SD ± 0.020) and 
did not differ between the probiotic and placebo groups (p > 0.9).  Only one 
patient in each group and small bowel permeability test value that was higher 
than the normal range of 0.06. In view of this result no further analysis of the 




 The mean faecal calprotectin in the study cohort at baseline and end of 
study was 33.1 (SD ± 75.3 µg/g) and 30.1 (SD ± 51.1) which did not differ 
significantly from each other.  The mean faecal calprotectin for the probiotic and 
placebo groups at baseline were 35.2 µg/g (SD ± 89.3) and 29.1 µg/g (SD ± 
38.6); and study completion 29.8 µg/g (SD ± 35.6) and 32.5 µg/g (SD ± 72.1) 
respectively which also did not differ from one another significantly (table 14). 
 
 Twenty two patients had faecal calprotectin levels that were higher than 
the normal range at study entry (normal ≤50µg/g), mean 113.9 µg/g (SD ± 
56.1). The mean IBS-SSS at baseline in patients with a faecal calprotectin of 
≥50 was 302.98 and 312.59 in those with a faecal calprotectin of ≤50 which did 
not differ between the two groups. In this group the post-study calprotectin was 
80.9 µg/g (SD ±116.4) also did not differ significantly from the baselines level.  
In the probiotic group there appears to be a trend in reduction of the faecal 
calprotectin from 111.4 µg/g (SD ± 62.5) at baseline to 66.6 µg/g (SD ± 49.8) (p 
= 0.18) compared to the placebo group calprotectin as baseline 118.4 µg/g (SD 
± 48.7) and post-study 106.8 µg/g (SD ± 194.4) (p = 0.88). However, the 
number of cases at 22 is small and the standard deviation of the results is large 





4.5 Safety and tolerability. 
4.5.1 Side effects, adverse events and study withdrawals. 
 
 No adverse events or serious adverse events were documented during 
the study.  The numbers of reported side effects in the study were relatively few 
and most were short lived lasting only a few days up to a week.  The reported 
side effects are shown in Table 15.  In the probiotic group there were more 
reported events of nausea and bloating compared to placebo. The probiotic 
studied is previously known to cause short term nausea and bloating in a small 
number of patients which is consistent with the findings in this study. 
 
 A total of 34 (18.3%) patients withdrew from the trial during the active 
treatment phase, of these 24 (19.4%) were in the probiotic arm and 10 (16%) in 
the placebo. 28 (15.1%), (19 (15.3%) probiotic and 9 (14.5%) placebo) of the 
patients who withdrew did so because of social or personal reasons not related 
to the study (work commitments, moving away from study area, personal 
bereavement etc.) or did not attend study appointments and could not be 
contacted.  Of remaining 6 withdrawals, 5 in the probiotic group were due to 
side effects (diarrhoea and abdominal pain, taste of the product, nausea, flatus, 
bloating) and 1 in the placebo group (constipation). A further 14 patients, 7 from 
each group withdrew during the follow up period. This gives a total of 152 




4.5.2 Compliance and tolerability. 
 
 The patient compliance with study medication was assessed at regular 
intervals during the treatment phase of the study as per the study protocol. 
Compliance with taking study medication was very high throughout the study 
with >97% of participants in both probiotic and placebo groups missing either 
none or less than one dose of medication per week (table 16). Of those patients 
that did not report specific side effects as discussed in section 5.21 the probiotic 
and placebo were well tolerated. 
 
4.6 Primary and secondary outcomes: Result and analysis of changes 
in IBS-SSS  and IBS-QOL. 
 
 All 186 patients were included in the ITT analysis using the LOCF 
principle for missing data as described.  152 patients were included in the PP 






4.6.1  Change in IBS-SSS 
 
 The mean IBS-SSS scores at week 12 differed significantly between the 
two groups at 230.07 (SD ± 108.87) in the probiotic and 270.88 (SD ± 103.52) 
in the placebo group (p = 0.027) in the PP analysis; and 243.18 (SD ± 107.15) 
probiotic and 277.18 (SD ± 104.47) placebo group (p = 0.044) in the ITT 
analysis (tables 17 and 18). The primary end-point for the study was the 
difference in the change in IBS-SSS scores at week 12. The change in IBS-SSS 
at week 12 in the probiotic group was -70.97 (SD ± 88.25) and -32.02 (SD ± 
80.88) in the placebo group in the PP analysis (p = 0.010) and -63.25 (SD ± 
85.95) and -28.30 (SD ± 79.89) respectively in the ITT analysis (p = 0.012).  
The difference in change between the intervention group (probiotic) and 
placebo group  at week 12 was -38.95 (p = 0.01; CI: -68.24 to -9.66) for the PP 
analysis and -34.95 (p = 0.01; CI: -62.03 to -7.87) in the ITT analysis. The 
primary end-point analysis is based on one-way ANOVA of the IBS-SSS at 
week 12 and is significant at the 5% level. There is a small observed difference 
in magnitude of effect between the PP and ITT analysis but the results remains 
significant at the 5% level. The LOCF method does not shown any major 
difference form the per-protocol analysis and can be considered as a crude 
sensitivity analysis of the imputed values of the LOCF method. 
 
 Adjustment of the primary end-point for variance in IBS-SSS at baseline 
using  ANCOVA analysis results in  only a very small difference in magnitude of 
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effect but no difference in the significance. Adjusted mean difference in change 
of IBS-SSS at week 12 was -39.18 (p = 0.009, CI: -68.24 to – 9.94) and -34.85 
(p = 0.012, CI: -61.88 to -7.83) for the PP and ITT analyses respectively.  
 
 An ordinary linear regression model was fitted to the IBS-SSS total score 
at week 12 for both the PP and ITT analysis. The resultant estimated regression 
coefficient for the PP and ITT analyses showed a mean difference in score 
between the placebo and treatment of 40.81 (p = 0.027, CI: 9.94 – 68.42) and 
34.12 (p = 0.048, CI: 0.36 – 67.87) respectively. This is a basic estimate without 
adjustments for any potential confounding factors, the magnitude of effect is 
smaller in the ITT analysis but both are significant and the 5% level. An 
adjustment for baseline SSS score was made to the regression models.  For the 
PP  analysis the estimated coefficient after adjustment for baseline IBS-SSS 
was 39.18 (p = 0.009, CI: 9.94 – 68.42) and for the ITT 34.85 (p = 0.012, CI: 
7.83 – 61.88). In both cases this adjustment for baseline results in a slightly 
smaller magnitude of effect but the confidence intervals are slightly narrower 
and there is no observed difference in the significance of the result. A further 
model adjusting for age was also explored but the effect was not significant and 
so was removed from the model. 
  
 There was no observed difference in the mean IBS-SSS scores at weeks 
4 and 8 or at the end of the 4 week follow up period (week 16) in either the PP 
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or the ITT analysis between the probiotic and placebo groups (tables 19 and 
20).  The IBS-SSS mean scores for the ITT analysis are illustrated in figure 20.  
 
 Secondary end points included changes in the individual IBS-SSS 
component scores at week 12 and 16.  The mean change in pain scores at 
week 12 were -27.54 (SD ± 47.65) and -11.38 (SD ± 46.22) in the probiotic and 
placebo groups respectively (p = 0.048) for the PP analysis; and -23.40 (SD ± 
45.41) and -9.05 (SD ± 46.09), (p = 0.48) in the ITT analysis.  The mean change 
in the ‘bowel habit satisfaction scores at week 12 were -17.44 (SD 23.31) and -
6.78 (SD ± 22.74) in the probiotic and placebo groups respectively (p < 0.01) for 
the PP analysis ; and  -14.18 (SD ± 22.73) and -4.86 (SD ± 21.98), (p = 0.010) 
in the ITT analysis. There were no differences in any of the other IBS-SSS 
components scores at week 12 and no difference in any of the component 
scores at week 16.The mean values for the component scores and mean 
change in scores for pain, bloating bowel habit satisfaction and QOL at weeks 
12 and 16  are shown in tables 21 to 24. The component scores  for the ITT 
analysis at week 12 are illustrated in figure 21. 
 
4.6.2 Change in IBS-QOL. 
 
 A Change in the IBS-QOL was one of the secondary end-points for the 
study.  There were no significant differences in the IBS-QOL score at any time 
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points in the study. Particularly there was no significant difference in the IBS-
QOL at weeks 12 or 16 in either the PP or LOCF analysis (table 25 and 26) as 
there were no significant changes in the IBS-QOL observed then no further 
analysis was undertaken. 
 
4.6.3 Sub group and post-hoc analyses. 
4.6.3.1 IBS disease sub-type analysis. 
  
 The study protocol did not stratify patient inclusion by disease sub-type 
at study entry.  Patients were divided into sub-type according to the Rome III 
classification of type by predominant stool type. There were no significant 
differences in the numbers or patients of each sub-type between the probiotic 
and placebo group (table 6).  Sub-group analyses of the primary end point were 
undertaken on the individual disease sub types but no significant differences 
were found but the size of the groups were notably small.  
 
4.6.3.2  Analysis of primary end-point based for males and females.   
 
 As previously reported there were significantly more females (129) than 
males (57) in the study cohort but the proportions of each gender are similar 
within the placebo and probiotic group and consistent with the known 
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predominance of female patients with IBS in the UK population.  A sub group 
analysis was performed based on gender which shows that the mean change in 
the IBS-SSS at week 12 (the primary end-point)  in the probiotic arm is similar 
at -71.24 (SD ± 88.24) and -71.65 (SD ± 89.64) in males and females 
respectively in the PP analysis (p = 0.98) The change in IBS-SSS at week 12 in 
the placebo arm in both groups is also similar at  -31.52 (SD ± 88.24) and -
36.84 (SD ± 63.67) respectively (p = 0.83).  In the ITT analysis the changes in 
the IBS-SSS at week 12 are -60.65 (SD ± 84.76) and -59.88 (SD ± 89.48) in the 
probiotic group (p = 0.96) and; -25.58 (SD ± 86.48) and -37.00 (SD ± 61.65) in 
the placebo group (p = 0.62) for females and males respectively. The ITT 
analysis yields similar results to the PP analysis  with a smaller magnitude of 
difference as with previous analyses.  
 
 The above analyses demonstrate that there are no significant differences 
in the magnitude of changes in the primary end-point between the females and 
male sub groups in either the PP or ITT analyses. When taken as separate 
subgroups the primary end point of difference in the change in IBS-SSS at week 
12 remains significant in the female cohort at -39.71 (p = 0.32, CI: -75.88 to -
3.54) in the PP analysis and -35.07 (p = 0.31, CI: -66.95 to -3.18) for the ITT 
analysis. However, in the sub group of male patients no significant difference is 
demonstrated in the primary end point is -34.81 (p = 0.17, CI: -85.21 to – 15.60) 





4.6.3.3 Post-hoc analysis or subjects with mild to moderate symptom  
severity. 
 
  It was noted that the mean IBS-SSS score at baseline was considerable 
higher than expected with a mean value across the whole cohort of 304.4 (SD ± 
71.4).  Given this finding a post-hoc analysis was conducted to see whether 
there was a difference in the number of patients achieving mild or no symptoms 
(as defined by an IBS-SSS of ≤150 at week 12.   A total of 24 (21.05%) patients 
in the probiotic group compared to 8 (13.79%) in the placebo group achieved 
IBS-SSS scores of ≤150 at week 12.  Whilst this shows that a larger proportion 
of patients in the probiotic group achieved mild or no symptoms by week 12 this 






Figure 10: Study Flow Chart. 
 
 
Screening (n = 392) 
Diagnosis IBS not 
confirmed (n = 50) 
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Asymptomatic (IBS-SSS < 
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Week 12 end of treatment 
phase 





















Study consort flow chart showing numbers of patients in included/excluded 
and in the study cohort at each stage of the study protocol 
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Table 7: Patient demographics 
 




range 18-65 18-65 19-63 
ns 
mean(SD) 38.3 (10.6) 39.1 (10.5) 36.8 (10.7) 
Gender  n(%) 
male  57 40 (32.3) 17 (27.4) 
ns 
female 129 84 (67.7) 45 (72.6) 
Disease duration n(%) 
< 1 yr 13 10 (8.1) 3 (4.8) 
ns 1 – 5 yrs 96 62 (50) 34 (54.8) 
>5 yrs 77 52 (41.9) 25 (40.3) 
Disease sub-type n(%) 
IBS-M 66 38 (30.7) 28 (45.2) 
ns 
IBS-D 70 48 (38.7) 22 (35.5) 
IBS-C 40 31 (25.0) 9 (14.5) 
IBS 10 7 (5.6) 3 (4.8) 
Ethinicity n(%) 
White(British) 104 68 (54.8) 36 (58.1) 
ns 
White (Irish) 2 1 (0.8) 1 (1.6) 
White (other) 22 15 (12.1) 7 (11.3) 
Asian (British) 4 4 (3.2) 0 (0) 
Asian (other) 4 2 (1.6) 2 (3.2) 
Black (British) 11 8 (6.5) 3 (4.8) 
Black (African) 7 5 (4.0) 2 (8.1) 
Black(other) 6 3 (2.4) 3 (4.8) 
Mixed Race 9 6 (4.8) 3 (4.8) 
Other 5 4 (3.2) 1 (1.6) 
unknown 12 8 (6.5) 4 (6.5) 
Smokers n(%) 
 25 17 (13.7) 8 (12.9) ns 
Demographics of patient cohort including age, gender, duration of disease, IBS subtype (IMBS-
M (mixed), IBS-D (diarrhoea), IBS-C (constipation), IBS (unclassified by predominant stool type) 




Table 8:  Baseline medications. 
 
Number and type of medications being used by participants at study entry. 
Selective serotonin reuptake inhibitor (SSRI), proton pump inhibitor (PPI), non-
steroidal anti  
 
  
 Total Probiotic Placebo 
SSRIs (low dose) 15 13 2 
Amitriptyline 7 4 3 
PPI 18 11 7 
Mebeverine 7 6 1 
Colpermin 0 1 0 
Buscopan 7 5 2 
Paracetamol 8 7 1 
Codeine 6 5 1 
Gabapentin 1 1 0 
NSAIDs 4 2 2 
Tramadol 4 3 1 
Loperamide 7 5 2 
Doperidone 1 1 0 
Cyclizine 1 1 0 
Ranitidine 4 3 1 
Laxatives 3 3 0 
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Table 9 : Mean IBS-SSS scores at baseline 
 
 
Comparison of IBS-SSS between the probiotic and placebo group at baseline. 
* p = 0.067 (CI =  -0.460 – 13.685) paired sample t test 
† p = 0.479 (CI =  -5.599 – 11.860) paired sample t test 
‡ p = 0.031 (CI = 1.288 – 25.746) paired sample t test 
** p = 0.515 (CI =  -30.04 – 15.125) independent sample t test 
*† p = 0.776 (CI = -21.408 – 28.618) independent sample t test 




IBS-SSS Total Probiotic Placebo 
Average of week -1 and 0) 
Mean 304.4 303.6 ‡‡ 306.0 ‡‡ 
SD (±) 71.4  68.0 78.2 
Range 152 - 456 165 – 456 325.8 
Week -1 
Mean 307.6*  305.1 †  ** 312.5‡ ** 
SD (±) 71.7 69.1 76.9 
Range 152 - 460 152 – 456 152 – 460 
Week 0 
Mean 300.9* 302.1† *† 298.5‡ *† 
SD (±) 78.5 74.8 85.9 
Range 139 – 478 139 - 478 144 - 454 
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Comparison of frequency distribution of IBS-SSS at baseline between the probiotic groups.  The 





















Scatter plot of the IBS-SSS at baseline in both the placebo and probiotic groups.  The 
solid horizontal line depicts the mean IBS-SSS for the entire cohort. Each circle 














P-P plot (probability-probability) of the baseline IBS-SSS. Demonstrates that the 
observed and expected (calculated) cumulative probability of the IBS-SSS in 









Table 10:  IBS-SSS at baseline: Model of ordinary linear regression adjusting 








Mean IBS-SSS (constant) 301.15  238.27 364.02 
Age at study -0.37 0.47 -1.37 0.64 
Gender 7.09 0.55 -16.21 30.39 
Disease duration -5.92 0.50 -23.04 11.20 
Disease sub-type 7.45 0.19 3.80 18.71 
 
Ordinary linear regression modelling of the base-line IBS-SSS score.  The 
effects of age, gender, disease duration and disease sub-type are 




















Illustration of  the effect of Age on the linear regression model for the IBS-SSS 
at base-line. Each circle represents and individual patient and the solid line the 




Table 11:  Mean IBS-QOL  scale score at baseline (week 0) 
 
IBS-QOL Total Probiotic Placebo 
Week 0 
Mean 52.4 53.2 * 50.7 * 
SD (±) 20.1 20.2 19.9 
Range 1 - 93 1 – 93 15 - 87 
Comparison of the mean IBS-QOL at baseline in the probiotic and placebo groups. * No 
significant difference in the means p = 0.43 
 
Figure 15:  Distribution of IBS-QOL at baseline. 
 
Comparison of frequency distribution of IBS-QOL at baseline between the probiotic groups.  














Scatter plot of the IBS-QOL at baseline in both the placebo and probiotic groups.  The 
solid horizontal line depicts the mean IBS-QOL for the entire cohort. Each circle 













P-P plot (probability-probability) of the baseline IBS-QOL. Demonstrates that 
the observed and expected (calculated) cumulative probability of the IBS-SSS 







Table 12:  IBS-QOL at baseline: Model of ordinary linear regression adjusting 










61.00  43.15 78.84 
Age at study -0.04 0.98 -0.29 0.29 
Gender -1.43 0.67 -8.04 5.18 
Disease duration -2.34 0.35 -7.19 2.54 
Disease sub-type -1.46 0.37 -4.63 1.74 
 
Ordinary linear regression modelling of the base-line IBS-AOL score.  The 
effects of age, gender, disease duration and disease sub-type are 


















Figure 18:  IBS-QOL: linear regression model for age at baseline 
 
 Scatter plot of linear regression of effect of Age on IBS-QOL at baseline.  
Each circle represents and individual participant. The horizontal line demonstrate the 













Linear regression of relationship between the baseline IBS-SSS and IBS-QOL. The solid line 
demonstrates the linear regression with the interrupted lines showing the 95% confidence 
interval. A clear linear relationship is demonstrated with worse symptoms (high IBS-SSS)  being 



















Pre-study 13.6 (±1.2) P = 
0.65 
13.5 (±1.1) 13.6 (±1.4) 0.70 
Post-study 13.5 (±1.2) 13.5 (±1.2) 13.5 (±1.2) 0.96 
CRP (ng/l) 
Pre-study 33.1 (±75.3) P = 
0.76 
6.0 (±4.4) 7.0 (±9.4) 0.42 
Post-study 30.1 (±51.1) 6.9 (±12.4) 5.9 (±4.9) 0.52 
Faecal calprotectin (µg/g) 
Pre-study 33.1 (±75.3) P = 
0.87 
35.2 (±89.3) 29.1 (±38.6) 0.57 
Post-study 30.1 (±51.1) 29.8 (±35.6) 32.5 (±72.1) 0.48 
 
Table 14:  Change in faecal calprotectin in participants who had abnormal 













Faecal calprotectin (µg/g) 
Pre-study 
113.9 (± 56.1) 
P = 
0.32 
111.4 (± 62.5) 118.4 (±  
48.7) 
p  = 0.66 
Post-study 
80.9 (± 116.4) 66.6 (± 49.8) 106.8 (± 
194.4) 
P = 0.56 
   P = 0.18 P = 0.88  
 
Tables 13 shows the pre- and post-study  laboratory parameters (Hb, CRP and 
Faecal calprotectin). 






Table 15: Reported Side effects. 
 
Side effect Total Active Placebo 
Nausea 5 5 0 
Weight gain 1 1 0 
Change in bowel 
habit 
12 6 6 
Bloating 12 10 2 
Heartburn/dyspepsia 4 3 1 
Pain 7 3 4 
Vomiting 3 2 1 
Acne 2 1 1 
Headache 2 1 1 
Vaginal candida 1 1 0 
Flatulence 3 2 1 
Halitosis 1 0 1 
Fatigue 1 0 1 
Total 54 35 19 
 
Individual side effects reported by participants during the study period.  Each side effect is 
reported separately (by episode). Some individuals reported multiple side effects which are 





Table 16:  Medication compliance 
 
Doses missed Total (%) Probiotic (%) Placebo (%) 
Week 4 
Never missed 120 (67.4) 81 (68.6) 39 (65.0) 
Missed <1/week 55 (30.9) 34 (28.8) 21 (35.0) 
Missed 1-3/week 3 (1.68) 3 (2.5) 0 (0) 
Missed >3/week 0 (0) 0 (0) 0 (0) 
Week 8 
Never missed 100 (61.1) 64 (58.7) 36 (66.7) 
Missed <1/week 60(36.8) 42 (38.5) 18 (33.3) 
Missed 1-3/week 3 (1.84 3 (2.8) 0 (0) 
Missed >3/week 0 (0) 0 (0) 0 (0) 
Week 12 
Never missed 97 (63.8) 63 (63) 34 (65.4) 
Missed <1/week 52 (34.2) 35 (35) 17 (32.7) 
Missed 1-3/week 3 (2.0) 2 (2) 1 (1.9) 
Missed >3/week 0 (0) 0 (0) 0 (0) 
 
Table showing the reported compliance during the study. Compliance with medication was 
reported by asking individuals at each visit schedule whether they have been compliant with 












Table 17: Mean IBS-SSS scores at weeks 4,8,12, and 16 (PP analysis) 
 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Week 4 260.42 93.29 263.23 101.42 0.859 
Week 8 240.42 111.68 259.94 96.94 0.283 
Week 12 230.07 108.87 270.88 103.52 0.027 
Week 16 246.60 114.74 238.93 104.96 0.706 
 
 
Table 18: Mean IBS-SSS scores at weeks 4,8,12, and 16 (ITT analysis) 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Week 4 263.53 91.67 272.45 106.82 0.561 
Week 8 248.70 108.87 266.72 98.18 0.281 
Week 12 243.18 107.15 277.18 104.47 0.044 
Week 16 259.73 110.61 262.57 111.37 0.872 
 
Table 17 and 18 show the mean IBS-SSS at each recorded time point during 
the study for both the PP and ITT analysis 





Table 19: Change in mean IBS-SSS scores from baseline at weeks 4,8,12, and 
16 (PP analysis) 
 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Week 4 -42.83 74.39 -35.25 80.35 0.548 
Week 8 -63.00 92.02 -43.05 84.49 0.191 
Week 12 -70.97 88.25 -32.02 80.88 0.010 
Week 16 -52.25 96.89 -57.23 86.26 0.861 
 
 
Table 20: Change in mean IBS-SSS scores from baseline at weeks 4,8,12, and 
16 (ITT analysis) 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Week 4 -40.02 71.1 -33.55 78.64 0.578 
Week 8 -54.88 88.51 -39.28 85.41 0.261 
Week 12 -63.25 85.95 -28.30 79.89 0.012 
Week 16 -43.84 92.54 -43.43 82.81 0.977 
 
Tables 19 and 20 show the mean (and standard deviation) changes in the IBS-











Illustration of the change in the mean IBS-SSS score at each recorded time point in 
the study. The squares represent the placebo and the diamonds the probiotic 




























Table 21:  Mean IBS-SSS symptom component scores at weeks 12 and 
16 (PP analysis) 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Pain component score  
Week 12 77.72 56.58 102.48 54.09 0.010 
Week 16 89.45 87.15 89.78 56.15 0.975 
Bloating component score  
Week 12 42.59 29.02 46.81 28.39 0.393 
Week 16 44.11 32.76 38.60  0.354 
Bowel habit satisfaction component score  
Week 12 55.92 23.76 61.78 17.93 0.120 
Week 16 57.22 25.01 55.53 20.24 0.695 
QOL component score  
Week 12 53.84 23.58 59.81 20.50 0.124 
Week 16 55.83 24.09 55.02 22.02 0.850 
 
Mean individual component scores of the pain, bloating, bowel habit satisfaction 
and the QOL component of the IBS-SSS at the week 12 (end of treatment) and 







Table 22:  Mean IBS-SSS symptom component scores at weeks 12 and 
16 (ITT analysis) 
 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Pain component score  
Week 12 82.48 55.06 103.20 54.49 0.18 
Week 16 92.83 55.35 97.78 58.12 0.58 
Bloating component score  
Week 12 44.74 29.36 49.93 29.27 0.26 
Week 16 46.82 31.76 45.77 33.10 0.84 
Bowel habit satisfaction component score  
Week 12 59.42 23.80 63.87 18.75 0.21 
Week 16 61.02 24.53 60.62 21.15 0.91 
QOL component score  
Week 12 56.09 23.25 61.67 21.39 0.12 
Week 16 58.15 23.50 59.37 22.80 0.74 
 
Mean individual component scores of the pain, bloating, bowel habit satisfaction 
and the QOL component of the IBS-SSS at the week 12 (end of treatment) and 
week 16 (end of follow up) for the ITT analysis. P values calculated using one 





Table 23:  Change in mean IBS-SSS symptom component scores from 
baseline at weeks 12 and 16 (PP analysis) 
 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Pain component score  
Week 12 -27.54 47.65 -11.38 46.22 0.48 
Week 16 -15.89 55.81 -18.92 56.10 0.77 
Bloating component score  
Week 12 -10.38 23.59 -11.27 24.04 0.33 
Week 16 -8.68 24.72 -6.38 24.75 0.57 
Bowel habit satisfaction component score  
Week 12 -17.44 23.31 -6.78 22.74 <0.01 
Week 16 -15.89 25.02 -12.69 23.96 0.48 
QOL component score  
Week 12 -16.03 20.55 -11.42 15.80 0.16 
Week 16 -13.78 20.64 -14.36 18.11 0.87 
 
Change in the individual IBS-SSS component scores for Pain, bloating, bowel 
habit satisfaction and the QOL component for baseline at week12 (end of 
treatment) and week 16 (end of follow up), PP analysis. P values calculated 





Table 24:  Change in mean IBS-SSS symptom component scores from 
baseline at weeks 12 and 16 (ITT analysis) 
 
 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Pain component score  
Week 12 -23.40 45.41 -9.05 46.09 0.048 
      
Week 16 -13.05 51.88 -14.47 52.09 0.86 
Bloating component score  
Week 12 -9.01 22.99 -4.96 23.11 0.27 
Week 16 -6.94 24.33 -9.13 22.27 0.56 
Bowel habit satisfaction component score  
Week 12 -14.18 22.73 -4.86 21.98 0.10 
Week 16 -12.58 24.09 -8.11 23.30 0.24 
QOL component score  
Week 12 -14.03 20.00 -8.97 18.49 0.10 
Week 16 -11.97 19.94 -11.27 19.13 0.82 
 
Change in the individual IBS-SSS component scores for Pain, bloating, bowel 
habit satisfaction and the QOL component for baseline at week12 (end of 
treatment) and week 16 (end of follow up), ITT analysis. P values calculated 












Graph showing a comparison of the change in the overall IBS-SSS and 
individual component scores (pain, bloating bowel habit satisfaction and 
QOL component) between the probiotic and placebo group at week 12 
for the ITT analysis.  The overall change in the IBS-SSS at week 12 was 
the primary end point for the study.  P values calculated using one way 





















Table 25:  Mean IBS-QOL and change in IBS-QOL at weeks 12 and 16 
(PP analysis). 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Mean IBS-QOL Score  
Week 12 60.45 21.56 54.68 20.53 0.114 
Week 16 63.12 22.90 58.23 22.33 0.233 
Mean change in IBS-QOL score  
Week 12 9.06 18.24 7.67 19.13 0.662 
Week 16 13.34 19.27 12.52 19.49 0.815 
 
Table 26:  Mean IBS-QOL and change in IBS-QOL at weeks 12 and 16 
(ITT analysis). 
 Probiotic Placebo 
P 
value 
 Mean SD Mean SD  
Mean IBS-QOL Score  
Week 12 59.85 21.12 55.95 20.65 0.245 
Week 16 61.92 22.13 57.73 22.21 0.237 
Mean change in IBS-QOL score  
Week 12 6.62 13.22 4.58 13.67 0.343 
Week 16 9.69 14.55 6.36 14.39 0.317 
 
Table 25 (PP) and 26 (ITT)  show the mean IBS-QOL scores at week 12 (end of 
treatment) and week 16 (end of follow up); and the mean change in the IBS-QOL at the 



















  The aim of this research study was to undertake a robust and 
rigorous  single centre, randomised, double blind placebo controlled trial to 
establish the efficacy and safety of a novel multi-strain probiotic in the treatment 
of patients with symptomatic IBS which has essential been achieved. 
  
 Recruitment of patients to the study was slower than initially anticipated 
and the total study period was therefore extended from 24 to 36 months.  It was 
the initial intention in the study protocol to recruit patients that were directly 
known to, or referred to the gastroenterology outpatient department at Kings 
College Hospital. However, the recruitment protocol was amended, after 
appropriate submission and ethical approval of the new protocol. This alteration 
allowed for direct recruitment of patients with symptomatic IBS from primary 
care physicians.  This alteration not only supported recruitment to the study but 
also helped ensure that the cohort of patients gave a broader reflection of the 
overall local population of patients with symptomatic IBS by  including patients 
from primary healthcare providers that otherwise may not have been able to 
access the study.  
The impact of including patients from both primary and secondary care 
on the observed efficacy of the probiotic/placebo was not considered as part of 
the original study design.  It is probably reasonable to assume that those 
patients with IBS who are referred to secondary care may have more severe 
symptoms. However, it has also been previously established by other authors 
that significant differences in psychological profiles exist between consulting 
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and non-consulting patients, [57] and that psychological co-morbidities are more 
prevalent in patient who report more numerous or more severe symptoms. [7] In 
considering the impact of inclusion of both sub-populations it’s difficult to 
theorise whether those participants included from a primary care background 
have symptoms that are less severe and so are more likely to be responders.  It 
is equally difficult to surmise whether the differing psychological profiles in either 
sub-populations make it more or less likely that they will be actual responders or 
be likely to report a placebo effect. 
The inclusion of the participants from  both sub-populations arguable 
makes the results relevant and applicable across both populations, however, 
given that the study design was not powered to demonstrate efficacy in the sub-
populations is not possible to prove or refute this assumption. 
  
 Overall, nearly four hundred patients were screened for inclusion in the 
study in order to achieve the required cohort of 186 patients specified by the 
study power calculation.  Initially, the exclusion of greater than 50% of patients 
in the screening process may lead to suspicion that the exclusion criteria for the 
study were too specific resulting in a study cohort that is too narrowly defined 
and not representative of the intended target population. However, more careful 
inspection of the excluded patients clearly demonstrates that only 19 patients 
with a diagnosis of IBS were excluded from the study because of ineligibility.  
The remaining exclusions can be seen in the CONSORT flow chart (figure 10) 
were as a result of a combination of reasons that included the patient not 
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currently having any active symptoms; not having a diagnosis of IBS; declining 
to give consent; and failing to attend the second screening visit. 
 
 The screening process described in the protocol consisted of 2 visits one 
week apart. Whilst not formally described as a ‘run in period’ this allowed for 
two separate measurements of the IBS-SSS to ensure some stability of the 
baseline data for study analysis. However, as a result of this screening protocol 
five patients who were allocated a trial identification number after being 
screened at ‘visit one’ subsequently did not attend ‘visit 2’ to complete the.  
Despite repeated attempts to contact these patients they were essential lost to 
follow up and took no further part in the study.  Blinding of the allocation of 
these 5 patients and their associated trial ID number was maintained and none 
received any study medication. It was therefore decided that reallocation of 
these trial numbers would preserve the size of the study cohort without 
undermining the integrity of blinding of the ITT principle. There were no 
breaches of the randomisation and/or blinding protocol during the study period. 
  
 It is well established and accepted that IBS symptoms in individual 
patients show a high degree of temporal variability. It has also been suggested 
that inclusion of a period of baseline observation in clinical trials of IBS 
populations is an important consideration in study design[258]  and this 
approach has been adopted by multiple research groups two of which are cited 
as examples. [29, 30]  During the screening period of our study some variability 
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in the IBS-SSS score at baseline was identified. In the probiotic group no 
significant temporal variability was noted but in the placebo group the variability 
was statistically significant.   There were no differences in the mean IBS-SSS 
score between the probiotic and placebo group at either time. However, after 
consideration it was decided that the most appropriate action was to average 
the IBS-SSS scores from week -1 and week 0 to mitigate this variability in the 
placebo group.  The averaging of baseline was conducted in both probiotic and 
placebo groups for continuity which remained similar after averaging.   
  
 The decision to include twice the number of patients in the active 
treatment group compared to placebo may result in some criticism of the study 
design.  This decision was pre-specified in the protocol and considered in the 
power calculation and therefore does not affect the statistical validity of the 
study’s findings.  Prior to the commencement of this study there was no formal 
evidence or previous clinical trial to demonstrate the safety and/or tolerability of 
the probiotic being studied. This is despite it being used, albeit, in relatively 
small numbers in ‘consumers’ and volunteers with a variety of 
gastroenterological conditions including IBS. When designing the study it was 
therefore considered essential that this study yield sufficient information 
regarding side effects, adverse events and overall safety and tolerability of the 
study and hence the decision to increase the size of  the probiotic cohort. This 
also increases the recruitment as patients have a more than average chance of 




 The pre-study power calculation indicated that a study cohort of 186 
patients would be adequate to demonstrate a difference in the primary end point 
with 90% power. However, when conducting the study analysis it was identified 
that the original power calculation was performed using a one-sided or 
directional test to calculate power.  Utilising a one sided tests makes the 
incorrect assumption that the change in the primary end-point is directional. 
Furthermore, the original power calculation utilised an MCID of ≥50 points in the 
IBS-SSS to define a responder whereas the study primary end-point was the 
difference in the mean change in score rather than utilising a categorically 
defined end point. The decision to amend the study protocol and change the 
primary end-point to a comparison of means was undertaken prior to starting 
recruitment and was felt to be more appropriate primary given the exploratory 
nature of the study.  As a result of this methodological error the power was 
recalculated using a comparison of the means and a non-directional or two-
sided test resulting in a calculated study power of the actual study of 80% which 
remains adequate. The latter power calculation dose not utilise the 50 point 
MCID.  This methodological correction has not had a significant adverse effect 
on the power of the study or the validity of the outcome but should still be noted. 
  
 We have already demonstrated that there were no significant differences 
in the baseline demographics between the probiotic and placebo arms of the 
study.  The study cohort does include significantly more females than males but 
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the gender ratio of 2.26:1 (female: male) is reflective of the known female 
predominance in the study population and is similar in both arms of the study.  
This gender imbalance could have been addressed by stratification of 
recruitment by gender but this was not included in the study design.  Whilst the 
lack of stratification has resulted in a cohort that is reflective of the gender 
characteristics of the IBS population it has led to the inclusion of only a 
relatively small cohort of men (57) in this study.  It was never the intention to 
power the study sufficiently to demonstrate efficacy in each gender separately 
but this lack of power if more keenly seen in the male cohort due to its size. The 
impact of this is discussed in further details later. 
 
 There were no adverse events or serious adverse events recorded 
during the study period and the side effects reported were mild and transient in 
nature.  It is noted that in the first few days of taking the probiotic there was a 
higher number of patients who reported an increase in bloating but this settled 
after a few days in all but a few cases.  It has been previously noted by the 
developers/manufacturers of the studied probiotic that some bloating does 
occur during the first few initial days of treatment.  There is evidence that 
bacterial fermentation by luminal bacteria may contribute to bloating both 
through a methanogenic process [225] and changes in colonic motility. [229] It 
is therefore possible that this transient bloating may be as a result of changes to 
the luminal microbiome that occur as a result of the introduction of the probiotic. 
The underlying physiological mechanisms that lead to this transient bloating for 
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this particular probiotic preparation has not been established and would require 
further research that is not the subject of this thesis.   
 
 Withdrawals from the study were less than predicted at 18.3% during the 
treatment phase with a further 5.6 % withdrawing during the follow up period. Of 
the withdrawals from the study only 5 (4%) of patients in the active treatment 
group can be directly attributed to side effects of the probiotic. Compliance with 
study medication was very high with the vast majority of patients missing none, 
or less than one dose per week on average.  The method of assessing 
compliance was to simply ask each patient directly at each study visit.  
Alternative methods of assessing compliance by measuring the amount of 
remaining probiotic at each visit were considered too difficult and equally 
unreliable for this study. It is accepted that relying on patient reporting of 
compliance may not give a true reflecting of the actual compliance. It is of note 
that compliance in both the probiotic and placebo arms of the study was similar. 
  
 Overall, the number and nature of side effects and the tolerability of the 
probiotic observed in this study is reassuring. The apparent lack of significant of 
severe side effects observed in the active treatment arm of this study is 
important. Many currently available, conventional medications for the treatment 
of IBS are reported to have a variety of sometimes quite significant side effects 
which can limit their usefulness in clinical practice.  Whilst the observed safety 
202 
 
profile in this study indicates that the probiotic can be used without any 
significant concerns this should be corroborated by further studies.  
   
 The primary end point of this study; a difference in the change in IBS-
SSS score between the placebo groups at week 12  was achieved with a highly 
significant result (p = 0.012) and an 80% power suggesting that this probiotic 
preparation is efficacious at improving symptoms in patients with IBS. In 
addition, there was a significant difference in the actual IBS-SSS score between 
the 2 groups at week 12 (p = 0.027 (PP) and p = 0.044 (ITT)). Changes in the 
IBS-SSS at earlier time points during the study were not significantly different 
between the probiotic and placebo groups. The trend in IBS-SSS shows a 
continuous reduction in global symptom severity throughout the study in the 
probiotic group with a static response in the placebo group. Previous empirical 
information from the probiotic manufacturer had indicated that a 12 week 
treatment period would be appropriate to demonstrate efficacy which appears to 
be supported by our study. 
 
 The changes observed in the IBS-SSS component scores are only 
significant for pain and bowel habit satisfaction. It is acknowledged that this 
study was not powered to detect changes in the individual component scores. 
Furthermore, the design of the IBS-SSS instrument includes a pain score that is 
weighted higher than the other component scores. Our study was therefore 
perhaps more likely to show a significant difference in the pain component 
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score given as the magnitude of change is also likely to be larger as a result of 
this weighting.  Regardless of this, in our study the observed change in IBS-
SSS score appears in principle to be due to changes in the component scores 
for pain and satisfaction with bowel habit. The significant change in the pain 
component score is worthy of note as pain is perhaps considered to be the 
singularly most important symptom of IBS,[255] and is the only absolute 
symptom required by the Rome III criteria.  A further larger study, with adequate 
power may clarify whether improvement in each individual component 
symptoms scores contributes to the overall improvement in global symptom 
severity. 
 
 Only 3 RCTs of probiotics in IBS have been identified that utilise the IBS-
SSS instrument as an outcome measure, two of which are only available as 
abstracts.   The first of these studies by Simren et al. compared a dairy 
preparation containing Lactobacillus paracasei, Lactobacillus acidophilus and 
bifidobacterium lactic 299v in 67 patients.  In this study both the treatment group 
and placebo group showed a significant reduction in the IBS-SSS score from 
baseline  (p = 0.006 and p = 0.0001) respectively but there was no difference 
between the probiotic and placebo groups.[259] A further study by the same 
group in  58 patients, used a non-dairy liquid preparation containing the same 
strain of bifidobacteria; showed a significant change in IBS-SSS from baseline 
in the placebo group (p = 0.0001) but not in the probiotic group P = 0.08).[31] 
Niv et al. also used the IBS-SSS for the primary end-point in a study of 
lactobacillus reuteri ATCC 55730 in a study of 57 patients but whilst they 
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demonstrated an improvement in the overall IBS-SSS across the cohort there 
was no observed difference between the probiotic and placebo groups.[33] All 
three of these studies had relatively small study cohorts and do not report 
whether a power calculation was performed prior to commencement of the 
study.  Both of these factors may explain the apparent lack of efficacy 
demonstrated although it is equally conceivable that the probiotics used were 
actually ineffective.  
 
 In the meta-analysis by McFarland et al. the pooled relative risk (RR) 
was 0.77 (85% CI 0.62 to 0.94). NNT 7.3;  for reduction in global symptoms 
after treatment with probiotic compared to placebo using a random effect model, 
heterogeneity X2 = 41.0 d.f. [32] This meta-analysis indicates that in the studies 
that included a measure of global symptom severity in their design there is an 
apparent reduction in global symptoms after treatment with probiotic compared 
to placebo. However, out of the 14 studies that reported changes in global 
symptom severity only 4 studies used specific, independently validated 
symptom severity scores. One of the largest studies of probiotics in IBS by 
Whorwell et al. assessed the efficacy of Bifidobacterium infantis 35624 in 362 
females with IBS in a dose ranging study.  They reported a significant difference 
in global symptom severity as measured by their own composite score at the 
end of treatment (p = 0.013)[243] which is comparable to our results. It should 
be noted though that this study did not include male patients and excluded 




 A further secondary end-point was the maintenance of a difference in the 
change in the IBS-SSS scores at week 16 but the study did not demonstrate a 
significant difference between the placebo and probiotic for this outcome.  The 
purpose of this end-point was to explore whether the therapeutic effect of 
treatment with the probiotic preparation was maintained four weeks after 
stopping treatment.  Whilst the study did not demonstrate this the actual results 
for the probiotic and placebo groups at this time point are interesting and are 
worthy of further consideration.  The results from the probiotic group show a 
mean change in IBS-SSS at week 12 of -70.97 (SD ± 88.25) at week 12 and -
52.25 (SD ± 96.89) at week 16 in the PP analysis.  At the same time points in 
the placebo group the mean change is -32.02 (SD ± 80.88) and -57.23 (SD ± 
86.26) respectively.  The PP analysis is chosen specifically as the ITT analysis 
utilises the LOCF principle to generate missing data which may result in a false 
elevation of the ‘end of follow up’ value.   When considered individually it would 
appear that the therapeutic effect in the probiotic group is maintained after four 
weeks albeit with some reduction in magnitude of effect.  In the placebo group 
something different occurs and there is a considerable increase in the reduction 
in the IBS-SSS score four weeks after stopping the placebo.  The reason for 
this change in the IBS-SSS in the placebo group is not clear. One possible 
explanation is that the placebo itself led to a reduction in the change in IBS-SSS 
which, whence the placebo was withdrawn then reversed. The placebo 
consisted of sterile water with inert natural flavourings and colourings as 
described in the method. Given that it contains only very small amounts of 
206 
 
ascorbic acid and beta carotene at it is highly unlikely for this to be the case.  
Furthermore, an improvement in the IBS-SSS score during the treatment phase 
was observed in the placebo group and it therefore cannot be concluded that 
the placebo led to a worsening of symptoms. The reason for this behaviour in 
the placebo response is not apparent. Therefore, it would be reasonable to 
conclude that whilst no significant difference is demonstrated in the change in 
IBS-SSS between the 2 groups at week 16 there does appear to be at least 
some maintenance of the therapeutic effect of the probiotic. Further research is 
needed to examine the potential maintenance of the therapeutic effect. 
  
 The final secondary end-points that need some discussion are the 
change in the IBS-QOL at weeks 12 and week 16.  The IBS-QOL was 
specifically included in this study as an end-point to explore whether an 
improvement in the IBS-SSS corresponded to an improvement in the perceived 
quality of life of patients.  This study did not demonstrate any difference 
between probiotic and placebo at any time point for the IBS-QOL score.   At 
baseline the IBS-QOL is similar between the 2 groups and perhaps even more 
importantly there is a clear relationship between the IBS-QOL and IBS-SSS, 
unstandardised regression coefficient of -0.13 (p = 0.001). As expected, this 
demonstrates that worse symptoms are associated with a poor quality of life 
score. This relationship, which would seem to be a logical, it is not continued at 
the end of the intervention. One explanation could be that a change in symptom 
severity occurs quicker in response to treatment than a subsequent subjective 
change in QOL and therefore this study was not long enough to detect the 
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latter.  However, whilst this may appear possible there is no evidence to 
currently support this theory.  It is also possible that as this study was not 
powered to show a specific change in the IBS-QOL score the lack of apparent 
efficacy to change QOL occurs simply as a result of a type II error. 
 
 The IBS-QOL itself was constructed to be a reliable tool to evaluate 
disease specific QOL in patients with IBS and was validated for internal validity 
and reproducibility by the original authors.[17] However, whilst addressing 
whether changes in the IBS-QOL were representative of changes in response 
to treatment the authors did not address whether such changes corresponded 
with global symptom change.  The construct of the IBS-QOL questionnaire and 
the separate domains within it deal primarily with ideas that could be considered 
to be of a psychological nature (dysphoria, sexual dysfunction, body image, 
social interaction and relationships).  Moreover, in a later article, one of the 
leading authors from the original article concludes that changes in the IBS-QOL 
are demonstrated primarily in the psychosocial rather than physical 
domains.[260] It is therefore possible to theorise that changes in the IBS-QOL 
may not correspond to changes in physical symptoms although this would need 
to be tested further and is not part of the remit of this study. It one possible 
implication is that  the psychological factors need to be treated and addressed 




 It is of note that perhaps the largest probiotic trial to date by Whorwell et 
al., whilst showing a significant improvement in Global symptom severity also 
did not detect any difference in IBS-QOL. [243] Infact, the author of this thesis 
has been unable to identify any, well designed, probiotic RCT in a western 
population that utilises the IBS-QOL (English version) that has demonstrated a 
significant change in this score in the treatment group over placebo.  
 
 The use of SSRIs as additional medication at low does was permitted in 
the study cohort provided that they were started more than 3 months before 
inclusion in the study and that usage and dose remained constant through the 
study period.  On analysing the data it became apparent that there were 
considerably more patients taking SSRIs in the probiotic group (13 (10%)) 
compared to placebo (2 (3%). These patients were not excluded from the 
analysis but it is possible that the disparity between the number of participants 
taking SSRIs between the two cohorts may have an influence on the results. 
Whether taking an SSRI has on affect the likelihood of a placebo response or 
mute the efficacy of the actual probiotic is not clear. However this difference in 
the probiotic and placebo cohorts should be noted. 
 The probiotic bacteria used in this study are presented in the 
fermentation liquor in which it is produced. This fermentation liquor contains 
various nutrients and extracts from the germinated barley grain used in the 
production process of the product. Its reported purpose is to maintain the 
viability of the bacterial strains within the delivery medium.  However, it is 
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conceivable that as these nutrients act as a growth substrate for the bacterial 
strains that may also exert a prebiotic effect to other bacterial strains.  No 
previous studies have been conducted to establish whether the probiotic 
delivery medium itself may be efficacious as a prebiotic in the treatment of IBS 
but this may warrant further study. 
 
 The final point to consider is the observed difference in outcome between 
males and females in the primary end-point. It has already been discussed that 
there were significantly more females than males recruited into the study. As 
this study was only powered to show a change in the overall cohort it would be 
expected that the gender sub-groups are underpowered. However, this is likely 
to be more keenly seen in the male sub-group as a result of its considerably 
smaller size.  However, careful inspection of the results from these sub-groups 
shows that the magnitude of change in the treatment group is similar at -71.24 
(SD ± 88.24) and -71.65 (SD ± 89.64) for males and females respectively in the 
PP analysis and similarly -60.65 (SD ± 84.76) and -59.88 (SD ± 89.48) in the 
ITT analysis.  As can be seen the therapeutic effect is almost identical in the 
probiotic group for both males and females (p = 0.98 (PP) and p = 0.96 (ITT)).  
However, there is a difference in the placebo group with a change of -25.58 (SD 
± 86.48) and -37.00 (SD ± 61.65) for females and males in the PP analysis.   
This observed difference between males and females in the placebo group 
does not quite reach significance (p = 0.063) at the 5% level but a clear trend is 
seen.  It would therefore be reasonable to conclude that the therapeutic effect of 
the probiotic is observed to be similar in both males and females.  Nevertheless, 
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the smaller sub-group size and apparent increased placebo effect in the male 
sub-group have resulted in no difference between probiotic and placebo being 
demonstrated. Based on these observations it is reasonable to suggest that a 
further study that is sufficiently power may demonstrate a difference between 
the probiotic and placebo in male patients. 
 
 It is important to consider the outcome in this study in the context of 
comparative studies but, as already discussed, such comparison of IBS clinical 
trials can be difficult due to a lack of defined end points and considerable 
heterogeneity of both the condition itself and study methodology.  It is perhaps 
even more important when comparing trials of probiotics as the vast majority of 
clinical trials and preparations contain different species and strains of probiotic; 
can contain one or several different probiotic strains; and are presented in 
different formats (freeze dried capsules, dairy substrates etc). As such, any 
such comparisons whilst perhaps necessary are likely to be significantly 
compromised as a direct result of these factors. It is this very conclusion that is 
reached by the three recent meta-analyses in this subject.[32, 239, 240] Our 
study is exciting in that it joins one of very few randomised controlled trials into 
the treatment of IBS with a probiotic preparation that have been conducted 
using strict and robust research standards, complies to the CONSORT 




 There has been much discussion and consideration recently of what 
constitutes a minimal clinically important difference (MCID) in the context of IBS 
symptoms in clinical trials. For example the creators of the IBS-SSS suggested 
in their original validation studies that a change of ≥50 points would be clinically 
significant.[255] In our study the mean change in IBS-SSS in the treatment 
group was –70.97 (SD ± 88.25) and -63.25 (SD ± 85.95) in the PP and ITT 
analysis respectively which would indicate an MCID has been observed. 
However, a later study  has suggested that a change of ≥95 points in the IBS-
SSS score would represent a MCID.[261] The finding of this later study have 
not been further corroborated by other research groups and is at odds with the 
original article. Whilst it is important to comment on this latter article it was not 
available before the commencement of our study and therefore was not 
considered its design. As a result our study was not powered to show a change 
of this magnitude in the IBS-SSS. 
 
 In addition, changes in European and American legislation have further 
tried to clarify MCIDs and specific end-points for clinical trials in the 
development of new treatments for IBS. The effects of these changes and an 
apparent increased desired to improve the robustness of IBS clinical trial 
research is yet to be seen. Our study has demonstrated that this liquid multi-
strain probiotic preparation is well tolerated, has a good safety profile and 
suggests that it is efficacious in the treatment of IBS patients including those 
with the moderately severe symptoms.  Whilst it is of reasonable size and larger 
that all but a few clinical studies of probiotics in IBS; employs a robust 
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methodological design and complies with the CONSORT guidelines it remains 
limited in that it is a single centre study.  Furthermore, since its inception, the 
described changes in opinions and legislation mean that our findings are 
perhaps already limited in their application.  It is therefore essential that further 
research is undertaken in a large, multicentre randomised controlled trial to not 
only confirm out original findings but also to update them to meet the latest 
standards required of research into new therapies for IBS patients. 
 
 The findings of our study are exciting and interesting but in many way 
pose more questions than answers.  The efficacy of the studied probiotic in the 
treatment of IBS is suggested by the results but need be confirmed by a further 
study.  In addition the role of the potential pre-biotic component of the probiotic 
product should also be considered and further clinical studies may benefit from 
including a study arm that contains only the delivery medium without the 
bacterial component. However, given the manufacturing method this may not be 
achievable.  Any further clinical studies should also be adequately powered to 
allow for sup-group analysis to establish or refute efficacy in both male and 
female cohorts as well as within IBS disease sub-categories. Finally, and 
perhaps most importantly, whilst our work proposes the efficacy of the study 
probiotic in the treatment of IBS it does not give any indication as to the 
individual characteristics and mechanisms of the included bacterial strains that 
result in this efficacy.  The author considers that further ‘basic science’ research 
into the mechanisms of actions of the individual strains of bacteria included in 
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Assessment of Symprove in IBS patients 
We would like to invite you to participate in a research trial that we are conducting. Before you 
decide it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with friends, 
relatives and your GP if you wish. Ask us about anything that  
is not clear or if you would like more information. Take your time to decide whether you wish 
to take part before signing the consent form. Thank you for reading this. 
 
What is the purpose of this study?  
The reason for the trial is that some patients such as yourself require specialist treatment for 
the Irritable Bowel Syndrome (IBS). You have been diagnosed with IBS by your 
Gastroenterologist. It is likely that you have or are experiencing some of the following 
symptoms; abdominal bloating and/or pain, intermittent constipation and/or diarrhoea, 
excessive wind and an alteration in your bowel openings. Some patients also feel tired, 
experience musclepains (fibromyalgia) or headaches and some women may have symptoms of 
endometriosis (abdominal pain and irregular periods, etc). 
Many treatments are currently available for IBS. Mostly these are dietary (high or low fibre 
diet, avoidance of dietary products, wheat free diet) or involve medicines such as anti-
spasmodic drugs (buscopan, mebeverine, etc.), peppermint preparations and sometimes anti-
depressants. The effectiveness of these measures varies greatly and it  
is likely that you have tried one or more of these without success. A new approach to the 
treatment of IBS is increasingly being assessed by Gastroenterologists. This involves giving a 
mixture of bacteria that are thought to be helpful in maintaining/restoring normal gut 
function.  These bacteria are called pro-biotics but are also commonly referred to as ‘friendly 
bacteria’ because of their beneficial effects. 
The idea is that the symptoms of IBS may be caused by an interaction between 
the bacteria that are found in the intestine and the internal immune system. If, for some 
reason the normal balance of bacteria changes and there are too many of the “bad” bacteria 
the symptoms of IBS are  thought to emerge. The probiotics are given with a view that they 
will  grow within the gut and restore the normal balance of bacteria, killing off the ‘bad’ 
bacteria, reliving symptoms and restoring normal bowel function. As yet  
the scientific basis of pro-biotic treatment in IBS has not been tested extensively. 
 
’Symprove’ is a liquid containing 3 different “friendly” bacteria. It has been tested in a few 
patients with IBS and the results are sufficiently promising as for us to conduct a double blind 
trial on the product to assess how effective it is as compared with placebo treatment (where 
patients ingest a compound that resembles the Symprove liquid but without the bacteria). 
These trials are called ‘double blind’ because neither the researchers or the patient/participant 
knows who is getting the active product and who is receiving the placebo 
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Why have I been chosen?  
You have been chosen because your Gastroenterologist or General Physician has made the 
diagnosis of IBS and that you are still symptomatic. 
 
Do I have to take part?  
When you are contacted we will describe the study and go through this information sheet 
answering any questions you have. You will be given a consent form, which should only be 
signed when you have had time to think about the study and you are sure you want to take 
part.  
You are under no obligation to participate. If you decide to take part you may withdraw from 
the study at any time and withdrawal will not affect your future treatment in any way. 
 
What will happen if I take part?  
We will be contacting persons that have IBS and require treatment. All those that are willing 
(about 200) to participate will be enrolled into the study. You will be asked to consent to the 
investigation and the study and your General Physician will be informed about your 
participation. You will be seen by an experienced research doctor who will document your 
details and explain the study in detail to you. There will be some extra visits to the hospital and 
additional blood and faecal samples. You will be asked to rate your symptoms so that we can 
follow up how these change with the treatment.  
When you have consented to participate in the study you will be randomized to having the 
Symprove or the ”dummy”/placebo preparation. This means that neither you nor your doctor 
know in which treatment group you are in (although, if your doctor needs to find out he can do 
so). Two people will receive the active preparation to each on the “dummy”. All the study 
medication has similar appearance and taste and you will be asked to store the study 
medication in a fridge and drink (according to your body weight) a fixed amount every day for 
3 months. When the study is finished you may want to know the results of the study and if so 
we will send you a report if you so wish. 
 
What do I need to do?  
There is no lifestyle restrictions imposed by this trial and you should go about your life as 
usual. It is important that you take the study medication regularly as directed and you should 
continue taking your other regular medication. 
 
What is the preparation that is being tested? 
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 Symprove is a liquid preparation that contains three types of intestinal “friendly” bacteria. 
These are present in their billions per each millilitre or teaspoon. Symprove and the “dummy” 
are given on a kilogram basis. For instance if you weigh 60 kg you should take 60 mls of the 
liquid preparation daily orally. 
 
What alternatives are there for treatment?  
This is a study that assesses a new pro-biotic treatment for IBS. Although your consultant 
Gastroenterologist has requested the treatment there are many treatments  
for IBS (see above). However many of these are unproven and/or of limited benefit, but you 
may want to try these rather than the trial medication. Either way you are free to have the 
conventional treatments and not enter the trial. Patients enrolled in the trial will not be able to 
use other IBS treatment for the duration of the trial. This will not alter your management in 
any way in the future. 
 
What are the potential disadvantages and risks of taking part?  
There are no disadvantages of participating that we are aware of. The preparation  
may cause some softening of stools for a few days. 
 
What are the side effects of any treatment when taking part? 
 Pro-biotics have been shown to be very safe and without major side effects especially in IBS 
where there is no major damage to the intestine. Symprove is a pro-biotic and we have not 
come upon any major side effect. A few patients have had loosening of stools for 2-3 days 
when starting the treatment. Other potential side effects include diarrhoea and excessive 
wind, but these are infrequent and mild. 
 
What are the possible benefits of taking part?  
We cannot promise the study will help you but the information we get from this study will help 
the treatment of people with IBS. 
What if new information becomes available? 
 Sometimes during the course of research projects, new information becomes available about 
the condition that is being studied. If this happens, your doctor will tell you about it and 
discuss with you whether you want to continue in the study. If you decide to withdraw your 
research doctor will make arrangements for your care to continue. If you decide to continue in 
the study you will be asked to sign an updated consent form. 
What happens when the research study stops?  
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In the unlikely event that the study stops before we have recruited all the patients that we 
require you will be informed that your participation is not required 
 
What if something goes wrong? 
 Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. Compensation for any injury caused by taking part of this 
study will be in accordance with the guidelines of the Association of the British Pharmaceutical 
Industry (ABPI). Broadly speaking the ABPI guidelines recommend that "the sponsor", without 
legal commitment, should compensate you without you having to prove that it is at fault.  
This applies in cases where it is likely that such injury results from giving any new drug or any 
other procedure carried out in accordance with the protocol for the study. "The sponsor" will 
not compensate you where such injury results from any procedure carried out which is not in 
accordance with the protocol for the study. Your right at law to claim  
compensation for injury where you can prove negligence is not affected.  
Copies of these guidelines are available on request. 
Complaints about the study.  
If you have concerns about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (Dr Guy Sisson 07958342353). If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital. 
 
Will my taking part in this study be kept confidential?  
Yes. Data about this research will be secured against unauthorised access and no individual will 
be identifiable from published results without their prior consent. If, exceptionally, we wish to 
retain confidential information beyond completion of the research project, we will undertake 
to let you know the reasons for retaining the information and the circumstances in which this 
might be disclosed. In view of this, we need your consent to these arrangements. 
 
What will happen to the results of the research study? 
The results will be analysed and published in a scientific journal. If you so wish we can send 
you a copy when available. 
 
 
Who is organising and funding the research?  
This research has been instigated by Professor Bjarnason and is supported by the inventors of 




Who has reviewed this study?  
The Bromley Research Ethics Committee has reviewed these studies (not “approved”). 
 
You will be given a copy of the information sheet and a signed consent  
form to keep. 
We do hope you will be able to participate. If you have any further questions please contact 
Professor Ingvar Bjarnason on 020-3299-3417 or 07784589003. If you do take part of this 
study and need immediate advise you can contact Dr Guy Sisson during daytime and 





Professor Ingvar Bjarnason 
Professor of Digestive Diseases 























Centre number:   …………………. 
Study number:   …………………. 
Patient Identification number 
for this trial:    …………………. 
 
 
Title of Project: Assessment of Symprove in IBS patients 
 
Name of Researcher: Prof. I Bjarnason (telephone 07784589003 at any time) 
 
                    Please initialise box 
I confirm that I have read and understood the information sheet dated  
June 2008for the above study and have had the opportunity                     
to ask questions 
I understand that my participation is voluntary and that I am free                      
to withdraw at any time, without giving any reason, without my                
medical care or legal rights being affected 
I understand that sections of any of my medical notes may be                   
looked at by responsible individuals from Symprove Ltd 
      or from regulatory authorities were it relevant to my taking part in                      
      research. I give permission for these individuals to have access                       
      to my records 
 
 I agree to take part in the above study 
 
_________________  _______  _________ 
Name of Patient   Date   Signature 
_____________________  _______   
Name of Person taking consent Date   Signature 
_________________  _______   
Researcher    Date   Signature 
 






















Randomisation protocol illustration 














































































































































































1 2  1 13  2 13  2 1 
1 1  2 6  1 6  3 2 
1 1  3 11  1 11  3 3 
1 3  4 18  3 18  2 4 
1 2  5 4  2 4  2 5 
1 2  6 5  2 5  1 6 
1 3  7 21  3 21  1 7 
2 1  8 17  1 17  1 8 
2 3  9 2  3 2  1 9 
2 1  10 8  1 8  3 9 
2 2  11 12  2 12  1 11 
2 3  12 3  3 3  2 12 
2 2  13 16  2 16  2 13 
2 3  14 20  3 20  2 14 
3 2  15 14  2 14  3 15 
3 2  16 1  2 1  2 16 
3 1  17 9  1 9  1 17 
3 1  18 19  1 19  3 18 
3 1  18 7  1 7  1 19 
3 3  20 9  3 9  3 20 
3 3  21 15  3 15  3 21 
 
Illustrations of Randomisation using the Mersenne twister algorithm 
A: Randomisation of group number (column 2) (Stage 1 randomisation) 
B: Randomisation of trial ID number (column 4) (stage 2 randomisation) 
C: Combining of randomisations of group number and ID number (columns 
 2+4) 























WEEK:  ____________________   (Date____/____/20____) 
PATIENT DETAILS:         
NAME:  ___________________    
dob   ____/____/19____ 
STUDY ID No: ___________________   Hospital No: ________________ 
 
INSTRUCTIONS 
1. For questions where a number of different responses are a possibility then please circle the 
response most appropriate to you. 
2. Some Questions ask you to write a response. 
3. Some questions require you to put a cross on a line which enables us to judge the severity of 
a particular problem. 
For example: 
 
How severe is your pain? 
 Please indicate with a (X) anywhere on the line between 0-100% in order to indicate as 
accurately a possible the severity of your symptoms. 
 





ALL INFORMATION OBTAINED DURING THE STUDY, INCLUDING YOUR RESPONSES TO THE 












Please fill in the date you completed the Questionnaire:_______________________ 
PART 2: SYMPTOM SEVERITY SCORE 
 1, a) Do you currently suffer from abdominal (tummy) pain?  
       b) If yes, how severe is your abdominal (tummy) pain?  
 
          0%                 
          
          
      100% 
 
 
    c) Please enter the number of days that you have had pain over the last 10 
days. 
  For example if you enter 4 days it means you had pain 4 out of the last 10 
days. If  
  you get pain every day enter 10. 
  Number of days with pain      
           
           
 x10 
2, a) Do you currently suffer from abdominal distension?* 
  (bloating/swollen or tight tummy) 
  (*women, please ignore distension related to your periods) 
  b) If yes, how severe is your abdominal distension/tightness 
  0%            100% 
  
 
 3, How satisfied are you with your bowel habit? 













circle appropriate box 
YES NO 
circle appropriate box 














 4,  Please indicate with a cross on the line below how much your irritable bowel  
  syndrome is affecting or interfering with your quality of life in general 
 




















      IBS QUESTIONNAIRE 
PART 2: OTHER IBS DATA BOWEL HABIT 
 
 5, a) What is the most number of times you open your bowels per 
/day/week/month? 
  Number of times       
   per day/week/month (circle appropriate) 
  Note: For some people the answers to part a and b could be the same 
    b) What is the least number of times you open your bowels per   
   day/week/month 
  Number of times       
   per day/week/month (circle appropriate) 
 
6. In the following questions you may circle more than one answer: 
  Are your motions ever: 
a) normal   often/occasionally/never (circle 
appropriately) 
b) hard      often/occasionally/never (circle 
appropriately) 
c) very thin (like string)  often/occasionally/never (circle 
appropriately) 
d) In small pieces   often/occasionally/never (circle 
appropriately) 
(like rabbit pellets) 
e) mushy (like porridge) often/occasionally/never (circle 
appropriately) 
f) watery   often/occasionally/never (circle 
appropriately) 
 
 7. In the following questions you may circle more than one answer: 
   Do you ever: 
a) pass mucus (or slime or jelly) with your motions 
 
b) pass blood with your motions 
 








Circle box appropriately 
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b) strain to open your bowels 
 
c) feel you haven’t emptied your bowel completely  













SITE OF PAIN 
 
Please mark with a cross (x) on the diagram below where you get your pain 
(use more than one cross if necessary) 
 
 8.  Do you ever: 
  a) Notice your stools are more frequent of loose  
   when you get pain 
  b) notice whether your pain is frequently eased by  
   opening your bowels 
 9. In the last year on approximately how many weeks were you: 
  a) absent from work due to IBS 
   (enter 52 if you have given up work completely due to IBS) 
  b) at work suffering from IBS 
YES NO 
YES NO 
Circle box appropriately 
























PLEASE WRITE IN 
TODAY'S DATE: _____ ______  _____ 






PLEASE READ THIS CAREFULLY 
 
ON THE FOLLOWING PAGES YOU WILL FIND STATEMENTS CONCERNING BOWEL PROBLEMS 
(IRRITABLE BOWEL SYNDROME) AND HOW THEY AFFECT YOU. 
 
FOR EACH STATEMENT, PLEASE CHOOSE THE RESPONSE THAT BEST APPLIES TO YOU  
AND CIRCLE THE NUMBER OF YOUR RESPONSE. 
 
IF YOU ARE UNSURE ABOUT HOW TO RESPOND TO A STATEMENT, PLEASE GIVE THE BEST 
RESPONSE YOU CAN. THERE ARE NO RIGHT OR WRONG RESPONSES. 
 


















The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL) was developed by Donald L. Patrick, Ph.D. at The 
University of Washington, Douglas A. Drossman, MD at The University of North Carolina, Novartis Pharmaceuticals Corporation, 




About Your Feelings 
 
Please think about your life over the past month (last 30 days) and look at the statements 
below.  Each statement has five possible responses. For each statement, please circle the one 
response that best describes your feelings. 
 
 1. I feel helpless because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 2. I am embarrassed by the smell caused by my bowel problems. (Please circle 
 one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 3. I am bothered by how much time I spend on the toilet. (Please circle one 
 number) 
  
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 4. I feel vulnerable to other illnesses because of my bowel problems. (Please 
 circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 5. I feel fat or bloated because of my bowel problems. (Please circle one 
 number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL     
IBS-QOL English/The UK 2002 
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 6. I feel as though I am losing control of my life because of my bowel problems. 
 (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 7. I feel that my life is less enjoyable because of my bowel problems. (Please 
 circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 8. I feel uncomfortable when I talk about my bowel problems. (Please circle one 
 number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 9. I feel depressed about my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 10. I feel isolated from other people because of my bowel problems. (Please circle 
 one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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 11. I have to be careful about the amount of food I eat because of my bowel 




  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
12.  Because of my bowel problems sexual activity is difficult for me. (Please circle 
 one number) 
  (If not applicable, please circle “NOT AT ALL”) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 13. I feel angry that I have bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 14. I feel as though I irritate others because of my bowel problems. (Please circle 
 one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 15. I worry that my bowel problems will get worse. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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 16. I feel irritable because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 17. I worry that people think I exaggerate my bowel problems. (Please circle one 
 number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 18. I feel that I get less done because of my bowel problems. (Please circle one 
 number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 19. I have to avoid stressful situations because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 20. My bowel problems reduce my sexual desire. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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 21. My bowel problems limit what I can wear. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 22. I have to avoid strenuous activity because of my bowel problems. (Please 
 circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 23. I have to be careful about the kind of food I eat because of my bowel 
 problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 24. Because of my bowel problems I have difficulty being with unfamiliar people. 
 (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
 25. I feel sluggish because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
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 26. I feel “unclean” because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 27. Long trips are difficult for me because of my bowel problems. (Please circle 
 one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 28. I feel frustrated that I cannot eat when I want to because of my bowel 
 problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
 29. It is important to be near a toilet because of my bowel problems. (Please circle 
 one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 




 30. My life revolves around my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
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31. I worry about losing control of my bowels. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
32. I am afraid that I won't be able to have a bowel movement. (Please circle 
one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
33. My bowel problems are affecting my closest relationships. (Please circle 
one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT  
  5 A GREAT DEAL 
 
 
34. I feel that no one understands my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 






       IBS-QOL English/The UK 2002 
 
